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ABSTRACT
The aromatic prenyltransferase SirD in Leptosphaeria maculans shares sequence 
homology with fungal indole prenyltransferases and is hypothesized to catalyze the 
normal O-prenylation of tyrosine in the first committed step in the biosynthesis of the 
phytotoxin sirodesmin PL. We cloned, expressed, and biochemically characterized SirD 
and discovered that it was a dimethylallyltyrosine synthase. We synthesized tyrosine and 
tryptophan derivatives and tested SirD for aromatic substrate promiscuity. NMR studies 
revealed that SirD catalyzes normal O-, N-, and £-prenylations on tyrosine derivatives 
and N- and C-prenylations on tryptophan derivatives with normal prenylation at C6 and 
C7 and reverse prenylation at N1 and C7 of the indole ring, depending on the substituent.
The aromatic prenyltransferase dimethylallyltryptophan synthase in Claviceps 
purpurea catalyzes the normal prenylation of tryptophan at C4 of the indole nucleus in 
the first committed step of ergot alkaloid biosynthesis. 4-Methyltryptophan is a 
competitive inhibitor of the enzyme that has been used in kinetic studies. We found that 
4-methyltryptophan is an alternate substrate, which gave four products. Similarly, 4- 
methoxytryptophan and 4-aminotryptophan are alternate substrates. NMR studies 
revealed that dimethylallyltryptophan synthase catalyzed normal prenylation at N1, C3, 
C5, and C7 and reverse prenylation at C3 of the indole ring, depending on the substituent. 
Synthesized aromatic amino acid analogues were also tested with dimethylallyl- 
tryptophan synthase.
The ability of dimethylallyltyrosine synthase and dimethylallyltryptophan 
synthase to prenylate six different sites on the indole nucleus, with normal and reverse 
prenylation at two of the sites, is consistent with a dissociative electrophilic alkylation of 
the indole ring where orientation of the substrates within the active site and substituent 
















2. SYNTHESIS OF ENZYMATIC SUBSTRATES AND




3. SIRD: BIOCHEMICAL CHARACTERIZATION AND












A. HRMS DATA............................................................................................................... 145





3.1. Crystallization conditions resulting in SirD crystal formation..................................74
3.2. 1H and 13C NMR data and structures of isolated enzymatic products from L-tyrosine 
and 4-mercapto-L-phenylalanine......................................................................................... 80
3.3. Kinetic parameters for SirD substrates at 30 °C .........................................................85
3.4. Aromatic substrate analogues tested for turnover with SirD and corresponding 
product ratios.........................................................................................................................90
3.5. 1H and 13C NMR data and structures of isolated enzymatic products from L- 
tryptophan and 4-methyl-L-tryptophan................................................................................95
3.6. 1H and 13C NMR data and structures of isolated enzymatic products from 4-methoxy 
and 7-methyl-L-tryptophan.................................................................................................102
4.1. Aromatic substrate analogues tested for turnover with 4-DMATS and the 
corresponding product ratios...............................................................................................123
4.2. Kinetic parameters for 4-DMATS substrates at 30 °C ............................................ 124
4.3. 1H and 13C NMR data and structures of isolated enzymatic products from 4-methyl 
and 4-methoxy-L-tryptophan..............................................................................................127
4.4. 1H and 13C NMR data and structures of isolated enzymatic products from 4-amino 
and 2-oxo-L-tryptophan......................................................................................................134
S.1. HRMS data of synthesized compounds.................................................................... 146
LIST OF FIGURES
Figure Page
1.1. Chemical structures of representative examaples of ETPs and prenylated alkaloids. 7
1.2. Chemical structures of representative prenyltransferase products highlighting the 
different types of prenyl acceptors....................................................................................... 10
1.3. Cartoon representation of the 4-DMATS (FgaPT2) crystal structure...................... 19
1.4. 4-DMATS proposed mechanisms.................................................................................21
2 .1 . Amino acid analogues synthesized............................................................. ................ 49
3.1. The engineered sirD gene constructs synthesized by Genscript............... ................ 54
3.2. L. maculans sirD engineered gene and encoded amino acid sequence ................ 69
3.3. S. diversum sirD engineered gene and encoded amino acid sequence. ................ 70
3.4. SDS-PAGE of pLmSirD expression in BL21 (DE3)................................. ................ 71
3.5. SDS-PAGE of pSdSirD expression in BL21 (DE3).................................. ................ 73
3.6. Diffraction pattern obtained from the ~ 8  A SirD JENA D3 crystal........ ................ 74
3.7. A sequence alignment of L. maculans SirD and A. fumigatus FgaPT2 (4-DMATS)
containing the predicted secondary structure of SirD and the secondary structure 
determined by FgaPT2’s crystal structure...........................................................................76
3.8. Homology structure of SirD......................................................................................... 77
3.9. Active site of SirD........................................................................................................ 77
3.10. Radioautography TLC of the assay for the determination SirD’s natural 
substrates................................................................................................................................  79
3.11. Thermal stability of SirD 82
3.12. Michaelis-Menten kinetic plots for select SirD substrates.......................................84
3.13. Radioautography TLCs of substrate promiscuity assays for SirD.......................... 86
3.14. Radioautography TLCs of substrate promiscuity assays for SirD.......................... 88
3.15. HPLC chromatogram of 4-mercapto-L-phenylalanine and DMAPP incubation with 
SirD 92
3.16. HPLC chromatogram of 4-methyl-L-tryptophan and DMAPP incubation with
SirD.........................................................................................................................................93
3.17. HPLC chromatogram of L-tryptophan and DMAPP incubation with SirD............ 97
3.18. Timecourse of L-tryptophan or 4-methyl-L-tryptophan incubations with DMAPP 
and SirD................................................................................................................................. 98
3.19. HPLC chromatogram of prenylated 4-methyl-L-tryptophan and DMAPP incubation 
with SirD................................................................................................................................ 99
3.20. HPLC chromatogram of 7-methyl-L-tryptophan and DMAPP incubation with 
SirD 101
3.21. HPLC chromatogram of 4-methoxy-L-tryptophan and DMAPP incubation with 
SirD 104
3.22. Tryptophan prenylation sites and orientations catalyzed by SirD.........................106
3.23. HPLC chromatogram of 4-vinyl-L-tryptophan and DMAPP incubation
with SirD.............................................................................................................................. 107
3.24. HPLC chromatogram of DIT and DMAPP incubation with SirD......................... 108
4.1. SDS-PAGE of pHDMAT/pGroESL co-expression in BL21 (DE3)....................... 120
4.2. Radioautography TLCs of substrate promiscuity assays for 4-DMATS.................121
4.3. Michaelis-Menten kinetic plots for select 4-DMATS substrates............................. 124
4.4. HPLC chromatogram of 4-methyl-L-tryptophan and DMAPP incubation with 
4-DMATS............................................................................................................................ 126
4.5. HPLC chromatograms of prenylated 4-methyltryptophan product co-injection....130
ix
4.6. HPLC chromatogram of 4-methoxy-L-tryptophan and DMAPP incubation with 4- 
DM ATS............................................................................................................................... 131
4.7. HPLC chromatogram of 4-amino-L-tryptophan and DMAPP incubation with 4- 
DM ATS............................................................................................................................... 133
4.8. Prenylation sites and orientations catalyzed by 4-DMATS..................................... 136
4.9. HPLC chromatogram of 4-hydroxy-L-tryptophan and DMAPP incubation with 4- 
DM ATS............................................................................................................................... 137
4.10. HPLC chromatogram of dihydroiso-L-tryptophan and DMAPP incubation with 4- 
DM ATS............................................................................................................................... 139
4.11. HPLC chromatograms of prenylated 2-oxo-L-tryptophan incubations with 4- 
DM ATS............................................................................................................................... 140






















HMBC heteronuclear multiple-bond correlation spectroscopy
HMQC heteronuclear multiple-quantum correlation spectroscopy
HPLC high performace liquid chromatography
HRMS high-resolution mass spectrometry
HSQC heteronuclear single-quantum correlation spectroscopy





NMR nuclear magnetic resonance
PLP pyridoxal-5’ -phosphate




TLC thin layer chromatography
TOCSY total correlation spectroscopy
xii
ACKNOWLEDGMENTS
First and foremost, thanks to Dr. C. Dale Poulter for his mentorship, advice, 
support, patience and trust throughout my time in his lab. Thanks to all the past and 
present members of the Poulter group for their helpful discussions, enlightened ideas, and 
friendship. Special thanks to my extremely patient and loving wife, Becky, who tolerated 
my extended hours, weekdays and weekends, in the lab.




Isoprenoids, commonly called terpenoids, constitute the largest known family of 
natural products. According to The Dictionary of Natural Products, over 58,000 
compounds of this class are reported.1 The structural diversity necessary to create this 
vast array of distinct compounds originates from the use of the five-carbon building block 
isoprene. It is a fascinating example of nature’s creativity; using a simple five-carbon 
chain to build larger, structurally more complex carbon backbones, which are further 
tailored by the organism.
Synthesized and exploited by all three domains of life (Eukaryota, Bacteria, and 
Archaea), isoprenoids serve as an assortment of functional tools.2-5 Functional roles are 
classified into two categories -  essential roles (primary metabolism) and nonessential 
roles (secondary metabolism). Examples of essential roles include: membrane integrity 
(cholesterol, diphytanyldiglycerol tetraether lipids in archaea2), hormones (testosterone, 
estrogen, gibberellins), electron carriers (ubiquinone, heme A), cellular localization and 
lipid anchoring (protein prenylation), and photosynthetic pigments (carotenoids). 
Examples of secondary metabolism roles include: attractants for pollinators or seed 
dispersers (flavonoids) ,6 defense mechanisms (ergot alkaloids) ,6,7 and virulence 
(sirodesmin PL) .8 Isoprenoids are also useful as renewable resources and commercial 
commodities, including polymers, flavorings and fragrances, adhesives and solvents, as 
well as agricultural chemicals (pyrethrins) and pharmaceuticals (taxol, artemisinin) .3
Isoprenoid Biosynthesis
In Nature, isoprenoids are derived from the five-carbon building block isoprene, 
but organisms do not use isoprene directly. Instead, two isoprene derivatives, isopentenyl
2
diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), are utilized as activated 
forms of the five-carbon building block. Organisms use one of two pathways, and 
sometimes both, to synthesize the universal precursors IPP and DMAPP (Scheme 1.1) .9 
The mevalonate (MVA) pathway is present in higher eukaryotes, archaea, and some 
bacteria; 10 the nonmevalonate pathway, or 2C-methyl-D-erythritol-4-phosphate (MEP) 
pathway, is an alternative pathway used in bacteria, plant chloroplasts, and algae.11,12
The MVA pathway condenses three molecules of acetyl-CoA to form 3-hydroxy-
3-methylglutaryl-CoA (HMG-CoA) before reduction to mevalonate. Two subsequent 
phosphorylations and a decarboxylation yields IPP.10 In the final step, isopentenyl 
diphosphate isomerase (IDI) converts IPP to DMAPP.13 In the MEP pathway, pyruvate 
and glyceraldehyde 3-phosphate are condensed and reduced to form 2C-methyl-D- 
erythritol 4-phosphate. MEP then reacts with CTP to form CDP-ME, which is 
phosphorylated and cyclized to form a methylerythritol cyclodiphosphate. Subsequent 
reduction and water elimination yields IPP and some DMAPP. To control the titer of IPP 
and DMAPP, IDI is also utilized in the MEP pathway.11 The presence of DMAPP, as 
well as other allylic isoprenoids, is essential for isoprenoid chemistry as the allylic double 
bond stabilizes the positive charge formed by diphosphate dissociation.
To create structural diversity from IPP and DMAPP, the five-carbon units are 
connected via prenyltransferase reactions to produce longer, linear isoprenoids. The 
principal chain elongation reaction is a 1’-4 condensation between IPP (prenyl acceptor) 
and DMAPP (prenyl donor) to form the C10 isoprenoid geranyl diphosphate (GPP) .13 
Successive additions of IPP form farnesyl diphosphate (FPP, C15), geranylgeranyl 
diphosphate (GGPP, C20), and so on.14 These longer isoprenoids are then used as branch
3
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points for the diverse array of biosynthetic pathways found in all domains of life (Scheme
1 .2 ).
Secondary Metabolites
Isoprenoids are categorized into essential roles (primary metabolism) or non­
essential roles (secondary metabolism). Primary metabolism provides metabolites 
necessary for an organism’s survival. Secondary metabolites, while typically produced 
from primary metabolism intermediates, are compounds superfluous for an organism’s 
survival. They may, however, provide a selective advantage to the producing organism 
to facilitate survival in an ecological niche.15 Secondary metabolism is common in 
bacteria, plants, and fungi. Examples of secondary metabolite classes include 
polyketides, nonribosomal peptides (dioxopiperazines), and terpenes (ergot alkaloids) .16
Epipolythiodioxopiperazines (ETPs) are fungal secondary metabolites 
characterized by a sulfur-bridged dioxopiperazine ring formed from the condensation of 
two amino acids (Figure 1.1) .17 Although this core moiety is found to carry various 
modifications, the molecular mechanism of toxicity originates from the sulfur atoms in 
the bridged ring. Two mechanisms are hypothesized to confer this toxicity -  ETP-protein 
cross-linking through cysteine residues causing enzyme inactivation and reactive oxygen 
species production through redox cycling.18 Although the exact function of ETPs is 
unknown, their toxicity suggests they are chemical agents used for defense or virulence. 
This toxicity also makes ETPs attractive pharmaceutical options.
Gliotoxin, the first reported ETP, 19 is produced from many different fungal 
species including Gliocladium fimbriatum and Aspergillus fumigatus. It causes both 





'O -P -O -P -O '
IDI
O ' O '
0 0
II II








0 0  
i i  ii







0  OII II -—k





0  OII II






















- S N '' '








lysergic acid diethylam ide
HO X - N  
H O - X  H W p ,
■ N < r
'C H .
ergotamine
Figure 1.1. Chemical structures of representative examaples of ETPs and 
prenylated alkaloids.
species and mitochondrial membrane disruption.17 Gliotoxin was also shown to inhibit 
the protein farnesyltransferase and protein geranylgeranyltransferase enzymes, 
introducing ETPs as potential anti-cancer therapeutics.20 Leptosphaeria maculans, the 
causal agent of blackleg disease in canola,21 produces sirodesmin PL, a phytotoxin that 
causes host nonspecific necrosis.8,21 Interestingly, sirodesmin PL is an ETP-terpene 
hybrid compound. Sirodesmin diversum produces chiral isomers of sirodesmin PL .17 
Other ETPs include sporidesmin A, the O-prenylated dithiosilvatin, and bis-ETPs such as 
leptosin.18
Prenylated indole alkaloids constitute a large family of chemically diverse 
biologically active secondary metabolites (Figure 1.1) .22-24 Biosynthetically, the carbon 
skeletons of these compounds are constructed from prenyl diphosphates and tryptophan 
or derivatives of tryptophan. The electronic nature of tryptophans, facilitating 
electrophilic attack at seven positions on the indole nucleus, allows Nature a plethora of 
opportunities to create structural diversity.25 Prenylated tryptophans can be further 
divided into categories based on prenylation site and/or prenyl acceptor. The 
brevianamides (C2 of Trp-Pro dipeptides), the amauromines (C3 of Trp-Trp dipeptides), 
the asterriquinones (various sites of bis(indolyl)benzoquinones), and the ergot alkaloids 
(C4 of Trp) are examples of prenylated tryptophan secondary metabolites.22
Ergot alkaloids, secondary metabolites derived from 4-dimethylallyltryptophan 
(DMAT), are sorted into two categories -  amide derivatives of lysergic acid and clavine 
alkaloids. Although both categories contain a tetracyclic ergoline ring system, the clavine 
alkaloids contain neither a carboxylic acid or amide derivative.22 Lysergic acid 
diethylamide (LSD), a psychedelic drug, is unarguably the most well-known ergot
8
alkaloid. The structurally similar ergotamine is a lysergic acid derivative containing an 
amide-bonded peptide moiety. Given their structural similarities to the neurotransmitters 
noradrenaline, dopamine, and serotonin, ergot alkaloids are of great pharmaceutical 
interest as evidenced by the use of ergotamine as a medication for the treatment of acute 
migraines.7 Therefore, much synthetic25 and biosynthetic22 effort has been devoted to 
understanding the chemistry, biology, and genetics of ergot alkaloids.
Prenyltransferases
Prenyltransferases are a family of enzymes that catalyze the alkylation of prenyl 
acceptors by allylic isoprenoid diphosphates. A variety of electron-rich nucleophiles are 
able to accept prenyl donation including alkenes (farnesyl diphosphate synthase14), thiols 
(protein farnesyltransferase and protein geranylgeranyltransferase26), amines (tRNA- 
dimethylallyl diphosphate transferase27,28), hydroxyl groups (geranylgeranylglyceryl 
phosphate synthase29), and aromatic rings (dimethylallyltrypotphan synthase30) (Figure
1 .2 ).
Farnesyl diphosphate (FPP) synthase, perhaps the most studied prenyltransferase, 
is a member of the isoprenyl diphosphate synthase family.31 FPP synthase catalyzes the 
synthesis of £,£-farnesyl diphosphate, a vital intermediate in the biosynthetic pathway of 
compounds such as cholesterol32 and farnesylated and geranylgeranylated proteins.33 To 
synthesize FPP, the enzyme catalyzes two 1’-4 couplings between a homoallylic acceptor 
and an allylic donor.14,34 In the dissociative electrophilic alkylation mechanism, the 
dissociation of the diphosphate moiety from the allylic substrate DMAPP creates a 
resonance-stabilized carbocation that is electrophilically attacked by the 3,4-double bond 
of the homoallylic substrate IPP. Formation of a tertiary carbocation and subsequent
9
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Figure 1.2. Chemical structures of representative prenyltransferase products 
highlighting the different types of prenyl acceptors.
elimination of a proton forms the C10 isoprenoid GPP. The newly formed GPP then acts 
as the allylic substrate for a second 1’-4 coupling with another molecule of IPP to form 
the C15 isoprenoid FPP. The crystal structures of avian35 and E. coli36 FPP synthases 
revealed a novel tertiary structure now known as the “isoprenoid synthase fold.” The 
core is composed of 10 a-helices that surround a large active site cavity. This binding 
pocket includes two well-conserved DDXXD motifs, which coordinate the divalent 
cations needed for diphosphate stabilization and are important for catalysis.37
Protein prenyltransferases are another well-studied subgroup of 
prenyltransferases.31 Many eukaryotic cellular proteins are post-translationally modified
with isoprenoid chains, thereby increasing their affinity for the membrane. These 
modified proteins include the Ras superfamily (Ras, Rab, Ral, Rac, and Rap), nuclear
33 38 39lamins, heterotrimeric G-proteins, and phosphodiesterases. Protein
farnesyltransferase (FTase) and protein geranylgeranyltransferase (GGTase) catalyze the 
divalent cation-dependent alkylation of sulfhydryls on C-terminal cysteines with FPP and 
GGPP, respectively. The conserved C-terminal CaaX motif is the site of prenylation, 
where “a” is typically an aliphatic amino acid and X is the amino acid that specifies 
whether farnesylation or geranylgeranylation occurs.40
Aromatic prenyltransferases are vital enzymes in the biosynthesis of secondary 
metabolites in plants, fungi, and bacteria.41-44 Typically, they catalyze C-C bond 
formation between an aromatic carbon of the prenyl acceptor and C1’ (“normal” 
prenylation) or C3’ (“reverse” prenylation) of the prenyl donor. In some cases, bond 
formation can also occur between a heteroatom on an aromatic ring and C1’ or C3’ of the 
prenyl donor. Currently, aromatic prenyltransferases are grouped into four different 
categories -  lipoquinone biosynthesis, plant secondary metabolism, “ABBA” 
prenyltransferases, and fungal indole prenyltransferases.
Aromatic prenyltransferases in lipoquinone biosynthesis catalyze the addition of 
long chain prenyl moieties to aromatic acceptors such as 1,4-dihydroxy-2-naphthoate 
(DHNA), homogentisate (HGA), or 4-hydroxybenzoate (4-HB). The DHNA 
octaprenyltransferase MenA from E. coll catalyzes simultaneous decarboxylation and C40 
prenylation at C2 of DHNA.45 HGA prenyltransferases also catalyze simultaneous 
decarboxylation and prenylation (C20, C45, or phytyl) of HGA, however, at different 
positions of the diphenol ring.46,47 4HB octaprenyltransferases, UbiA from E. coli48 and
11
COQ2 from yeast,49 catalyze the C40 prenylation at C3 of 4HB; these prenyltransferases 
do not catalyze decarboxylations. The UbiA family of prenyltransferases, found in 
humans, plants, bacteria, and yeast, are known for their isoprenoid substrate promiscuity, 
accepting short chain isoprenoids such as GPP and FPP.48 The lipoquinone biosynthetic 
aromatic prenyltransferases include a conserved aspartate-rich motif, similar to FPP 
synthase.41 Correspondingly, their activity is dependent on Mg2+ or other divalent cations. 
Being integral membrane proteins, no experimentally determined structures are available 
yet; a structural model of UbiA, however, was recently constructed.50 Based on the 
soluble sesquiterpene cyclase 5-epi-aristolochene synthase from Nicotiana tabacum,51 
UbiA corresponded well to an all a-helical terpenoid synthase.50
One method to create structural diversity in plant secondary metabolism is the 
prenylation of aromatic compounds.52 4HB geranyltransferase and naringenin 8 - 
dimethylallyltransferase (N8DT) are examples of flavonoid prenyltransferases.53 The 
biosynthesis of shikonin, a plant naphthoquinone, requires the prenylation of 4HB. 4HB 
geranyltransferase, the first secondary metabolite prenyltransferase cloned from plants, 
catalyzes the geranylation at C3 of 4HB.54 This reaction is identical to the UbiA family of 
enzymes, except 4HB geranyltransferase is specific for GPP. In the sophoraflavanone G 
biosynthetic pathway, N 8DT catalyzes the condensation of naringenin and DMAPP. 
Both 4HB geranyltransferase and N 8DT contain aspartate-rich motifs and are Mg2+ 
dependent.41
The ABBA42,43 and fungal indole prenyltransferases44 are distinctly different from 
the prenyltransferases described above. These enzymes are soluble, do not contain 
aspartate-rich regions, and are independent of divalent cations for activity (except for
12
NphB). CloQ from Streptomyces, the first identified ABBA prenyltransferase, catalyzes 
the C3-prenylation of 4-hydroxyphenylpyruvate using DMAPP in the chlorobiocin 
biosynthetic pathway.55 The subsequent crystallization of a sequence-related enzyme, 
NphB (formerly Orf2), revealed a previously unidentified antiparallel a-helix-P-sheet 
fold, later termed ABBA due to the a-P-P-a architecture.42,56 Although the natural 
substrate is unknown, NphB catalyzes C-geranylations of phenolic substrates including 
1,6-dihydroxynaphthalene.56 CloQ was later crystallized and its structure was confirmed 
to be an ABBA fold.57 Fnq26 from Streptomyces cinnamonensis DSM1042 was 
determined to catalyze both normal and reverse C-prenylations of flaviolin and normal O- 
prenylations of 4HB and 1,3-dihydroxynaphthalene.58 Fnq26 was the first ABBA 
prenyltransferase seen to catalyze prenylations at C3’ of the prenyl donor.
Fungal indole prenyltransferases catalyze alkylation of the indole ring in 
tryptophan, tryptophan-containing dipeptides, or indole-containing compounds with 
DMAPP to give the different naturally occurring carbon skeletons.44 The dimethylallyl 
moiety can be attached at C1’ or C3’, further increasing structural diversity. Although 
fungal indole prenyltransferases contain little sequence similarity with bacterial ABBA 
prenyltransferases, biochemically, they are very similar. Fungal indole prenyltransferases 
are soluble, do not possess aspartate-rich motifs, are catalytically active in the absence of 
divalent cations, and are known to fold in the a-P-P-a pattern.41,44,59-61 4- 
Dimethylallyltryptophan synthase (4-DMATS) from C. purpurea, the first indole 
prenyltransferase purified, characterized, and cloned, catalyzes the normal prenylation of 
tryptophan at C4 by DMAPP.62,63
13
Dimethylallyltyrosine Synthase
The first known genes responsible for the biosynthesis of sirodesmin PL were 
reported in 2004.64 Eighteen genes, spanning a 6 8 -kilobase region, were found to encode 
the necessary enzymes for the production, regulation and self-resistance of sirodesmin PL 
in Leptosphaeria maculans. As known from early labeling experiments and intermediate 
analysis,65-67 the biosynthesis of sirodesmin PL requires a nonribosomal peptide 
synthetase for the condensation of tyrosine and serine, a dimethylallyl transferase, and 
enzymes catalyzing a Claisen rearrangement, a sulfurization, an acetylation, a 
methylation, a reduction, and a number of oxidations (Scheme 1.3). Analysis of the 
eighteen genes revealed 16 potential ETP biosynthetic enzymes, one transcriptional 
regulator, and one ABC transporter assumed to control sirodesmin PL efflux and thus 
resistance.64 The sixteen proposed biosynthetic enzymes include SirP, a two-module 
nonribomsomal peptide synthetase; SirT, a thioredoxin reductase for disulfide bond 
formation; SirH, an acetyl transferase; SirM and SirN, methyl transferases; SirB, SirC, 
and SirE, cytochrome P450 monooxygenases; SirO, an oxidoreductase; and SirD, a 
prenyltransferase.
The prenyltransferase gene, sirD, was found to be a homologue of a fungal 
DMATS from Neotyphodium coenophialum. Given the other members of the gene 
cluster and sirodesmin PL’s structure, the SirD enzyme was hypothesized to prenylate the 
tyrosyl group of either free L-tyrosine or the cyclic dipeptide cyclo-L-Ser-L-Tyr (c-SY) .64 
Pedras and Yu recently completed an isotopic feeding experiment, utilizing tritium- 
labeled biosynthetic intermediates to determine incorporation into sirodesmin PL .68 L- 
tyrosine and O-dimethylallyl-L-tyrosine were efficiently incorporated into phomamide
14
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and sirodesmin PL, while c-SY was not. This suggested that the SirD-mediated 
prenylation of L-tyrosine is the first committed step in sirodesmin PL biosynthesis. Thus, 
SirD is a dimethylallyltyrosine synthase.
A BLAST69 search reveals that SirD is a member of the aromatic 
prenyltransferase/DMATS superfamily. 7-DMATS from A. fumigatus is the closest 
relative studied to-date. SirD shares 35% identity and 52% similarity with 7-DMATS. 
Other relevant comparisons to sequence identity are: 31% with FgaPT2 from A. 
fumigatus, 27% with 4-DMATS from C. purpurea, and 27% with CTrpPT from A. 
oryzae DSM1147. A putative dimethylallyltyrosine synthase from Sirodesmium 
diversum is the nearest known relative of L. maculans SirD (87% identity), however the 
C-terminus is truncated by 165 residues compared to L. maculans SirD.
Dimethylallyltryptophan Synthase
Prenylated indole alkaloids constitute a large family of chemically diverse 
biologically active natural products.22-24 Biosynthetically, the carbon skeletons of these 
compounds are constructed from prenyl diphosphates and tryptophan or derivatives of 
tryptophan. Collectively a family of enzymes, the dimethylallyltryptophan synthases 
(DMATS) catalyze alkylation of the indole ring in tryptophan or tryptophan-containing 
dipeptides at positions N1, C2, C3, C4, C5, C6 , or C7 by DMAPP to give the different
63 70 76naturally occurring carbon skeletons. , ' The dimethylallyl moiety can be attached at 
C1’ (“normal” prenylation) or C3’ (“reverse” prenylation), further increasing structural 
diversity. For wild type DMATSs both normal and reverse prenylation is seen at N170,77 
and C2.71,78 Only reverse prenylation is seen at C3 in either the a- or P-configuration by 
the DMATSs AnaPT72 or CdpC3PT,73 respectively. Only normal prenylation is seen at
16
C4,63,78 C5,74 and C6 .75 7-DMATS catalyzes normal prenylation at C7 of L-tryptophan76 
and MpnD catalyzes reverse prenylation at C7 of an indolactam.79
4-DMATS catalyzes the normal prenylation of tryptophan at C4 by DMAPP as 
the first committed step in ergot alkaloid biosynthesis.30 The enzyme was the first indole 
prenyltransferase to be purified, characterized, and later available from expression clones 
and has been studied from Clavicepspurpurea62,63,80 and Aspergillusfumigatus.59,78,81,82 
BLAST alignments with 4-DMATS from C. purpurea and other DMATSs report the 
following sequence identities: 56% with FgaPT2 from A. fumigatus, 35% with FtmPT1 
from A. fumigatus, 35% with CdpC3PT from Neosartorya fischeri, 31% with CdpNPT 
from A. fumigatus, 47% with 5-DMATS from A. clavatus, 23% with IptA from 
Streptomyces sp. SN-593, and 28% with 7-DMATS from A. fumigatus69
Extensive work has been performed to understand the binding of substrates and 
the chemical mechanism of 4-DMATS. Initially, a random sequential binding
2+ 30 83mechanism was proposed for 4-DMATS in the presence of 20 mM Ca . ’ A random 
sequential binding mechanism would allow either substrate, tryptophan or DMAPP, to 
bind first, followed by the binding of the second substrate to form an active complex. 
Subsequent studies including substrate binding, isotope trapping, and rapid quench 
experiments revealed the inability of DMAPP to bind in the absence of a divalent metal 
while tryptophan binds equally well in the presence or absence of metal.84 It was also 
determined that very little DMAPP binds in the presence of metal. Since it is known that
30,63,83,844-DMATS is catalytically independent of divalent metal ions,30,63,83,84 it is suggested a 4- 
DMATS:DMAPP complex is catalytically unproductive. Therefore, an ordered
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sequential mechanism where tryptophan binds first, followed by DMAPP is proposed for 
prenylation to occur.84
The prenylation of indole rings has been of great interest to chemists and 
enzymologists alike. The delocalization of the lone electron pair on the nitrogen atom 
facilitates electrophilic substitution at positions 2-7 of the indole ring. However, the C4 
position is normally understood to be an unfavorable position for substitution.85 
Consequently, the study of the C4 prenylation of tryptophan by 4-DMATS is of 
exceptional interest. Two mechanisms have been proposed for the chemical reaction 
performed by 4-DMATS: a direct electrophilic aromatic substitution at C4 or an 
electrophilic substitution at another position followed by a prenyl migration to C4.
Two labeled substrate studies support a dissociative electrophilic alkylation 
mechanism. Shibuya and coworkers verified an inversion of configuration at C1’ of the 
dimethylallyl moiety while the allylic double bond geometry is preserved.86 The authors 
proposed dissociation of the diphosphate moiety from C1’ followed by subsequent C4 
attack of C1’ on the face opposite the pyrophosphate ion. Luk and Tanner observed 
scrambling of an 18O-isotope label in [1-18O]-DMAPP in a positional isotope exchange 
(PIX) experiment.82 The scrambling of the 18O label from the bridging position to a 
nonbridging position provides strong evidence for a dissociative mechanism where 
DMAPP dissociates into a stabilized allylic carbocation/pyrophosphate ion pair before 
electrophilic attack occurs.
Substrate analogue studies, specifically linear free energy relationships using 7- 
substituted tryptophan analogues and fluorinated DMAPP analogues, also support direct 
electrophilic aromatic substitution at the C4 position.80 A Hammett plot of 7-substituted
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tryptophan analogues generated a good linear correlation with p = -2.0. The authors 
concluded that although the value of -2 .0  is at the low end for benzene derivatives, it is 
consistent with an electrophilic aromatic substitution mechanism.
Recently crystallized, 4-DMATS (FgaPT2) from A. fumigatus consists of a 10- 
stranded antiparallel P-barrel surrounded by a-helices (Figure 1.3) .59 To date, this 
“ABBA PT” fold is only seen for five other prenyltransferases - FtmPTl,61 CdpNPT,60 
NphB,56 CloQ,57 and EpzP.87 The crystal structure of FgaPT2 from A. fumigatus in 
complex with tryptophan and dimethylallyl £-thiolodiphosphate (DMASPP), a non- 
hydrolyzable DMAPP analogue,88 revealed two active site amino acids thought to be 
important for catalysis.59 A hydrogen bond between Glu89 and the indole N-H likely 
increases the electron density in the indole ring. Lys174 is situated near C4 and is a 
likely candidate for removing the C4 proton during rearomatization.
The mechanism currently proposed for prenylation by DMATSs is a dissociative 
electrophilic alkylation of the indole ring by DMAPP where cleavage of the carbon- 
oxygen bond in DMAPP gives a dimethylallyl cation-PPi ion pair, with subsequent
19
Figure 1.3. Cartoon representation of the 4-DMATS (FgaPT2) crystal structure 
depicting a side view (left) and top-down view (right). PDB: 3I4Z.
alkylation of the indole moiety, followed by loss of a proton to give the prenylated 
product. In the case of 4-DMATS, regiospecific alkylation of C4 of the indole ring by 
C1’ of the allylic cation generates an arenium intermediate, which rearomatizes by 
deprotonation at C4 to produce dimethylallyltryptophan (DMAT) (Figure 1.4A). 
Recently, a K174A mutant of FgaPT2 gave a C3 reverse-prenylated 
hexahydropyrroloindole as the major product in addition to a small amount of DMAT.89 
The authors suggested a new mechanism where the initial alkylation is a reverse 
prenylation at C3 of the indole ring, followed by a Cope rearrangement to give the 
normal C4 prenylated arenium intermediate and deprotonation facilitated by Lys174 to 
produce DMAT (Figure 1.4B).
Dissertation Overview
The work presented in this dissertation describes the cloning and characterization 
of SirD, a dimethylallyltyrosine synthase, the synthesis of aromatic amino acid substrate 
analogues, and the aromatic substrate promiscuity of SirD and the 
dimethylallyltryptophan synthase 4-DMATS. Chapter 2 describes the chemical and 
enzymatic syntheses of substrates and substrate analogues for the tyrosine and tryptophan 
prenyltransferases. Chapter 3 describes the cloning and biochemical characterization of 
SirD, including the promiscuity studies involving tyrosine and tryptophan derivatives. 
Finally, Chapter 4 focuses on 4-DMATS and its ability to prenylate tryptophan 
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Figure 1.4. 4-DMATS proposed mechanisms. A, direct dissociative electrophilic 
alkylation; B, dissociative electrophilic alkylation and rearrangement.
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CHAPTER 2
SYNTHESIS OF ENZYMATIC SUBSTRATES AND 
AROMATIC AMINO ACID ANALOGUES
Introduction
Vital to the study of promiscuous enzymes is the possession of a substrate library. 
Because SirD and DMATS prenylate aromatic amino acids, we were most interested in 
analogues of tyrosine, tryptophan, and phenylalanine. Certain analogues of interest, such 
as O-methyl-L-tyrosine and 4-amino-L-phenylalanine, are available commercially, while 
other analogues, such as 4-mercapto-L-phenylalanine and 4-vinyl-L-phenylalanine, must 
be synthesized.
A literature search for the synthesis of 4-mercapto-L-phenylalanine or L- 
thiotyrosine produces a two-step synthesis featuring the chlorosulfonation of L- 
phenylalanine followed by a Sn/HCl reduction.90,91 The synthesis of a protected form of 
4-vinyl-L-phenylalanine was also reported, however as an intermediate in the synthesis of 
4-(phosphonomethyl)phenylalanine, an unnatural amino acid valuable for mimetic 
studies of protein-tyrosine kinases.92 These two approaches were used as starting points 
for the synthesis of the 4-mercapto- and 4-vinyl-L-phenylalanine analogues.
The synthesis of indoles, which can be incorporated into tryptophans, has been 
extensively studied for well over 100 years. The most well known procedure is the 
Fischer indole synthesis, a condensation of phenylhydrazine with an aldehyde or ketone 
under acidic conditions to form indoles.93 Other synthetic routes to indoles are also well 
documented: Reissert’s condensation of nitrotoluene and diethyl oxalate followed by 
reductive cyclization;94 Leimgruber’s enamine formation from nitrotoluene and N,N- 
dimethylformamide dimethyl acetal and pyrrolidine followed by reductive cyclization;95 
and Sugasawa’s chloroacetylation of anilines followed by reductive cyclization.96 Once 
the desired indole is obtained, the amino acid moiety is built through the synthesis of
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gramine.97 Previously in the Poulter group, substituted tryptophans were synthesized 
using these established procedures.98
As noted above, the organic syntheses of indoles and tryptophans are well 
documented. However, not only are these synthetic pathways both step- and time­
intensive, they also produce a racemic mixture of DL-tryptophans. Isolation of the pure 
L-tryptophans requires an additional step, such as an enzyme-catalyzed selective 
hydrolysis reaction99 or purification by chiral chromatography. Alternatively, tryptophan 
synthase can be utilized, either as a cell extract or cell-free, to produce enantiomerically 
pure L-tryptophan analogues from a variety of indoles in one simple and convenient 
step.100-102
Tryptophan synthase is an a 2p2 tetramer that catalyzes the two final steps of 
tryptophan biosynthesis. The a-subunit catalyzes the formation of indole and 
glyceraldehyde-3-phosphate from indole-3-glycerol phosphate. The P-subunit then 
catalyzes the condensation of indole and L-serine to form L-tryptophan through a 
pyridoxal-5’-phosphate (PLP) dependent mechanism.103 Conveniently, the P-subunit is 
active in the absence of the a-subunit allowing simple heterologous expression and 
purification of active tryptophan synthase P-subunit.
In this chapter, we report the chemical and enzymatic syntheses of substrates and 
substrate analogues for the tyrosine and tryptophan prenyltransferases.
Experimental Procedures 
General
NMR spectra were recorded on a Varian Unity 300 MHz or Varian VXR 500 
MHz and spectra were processed with MestReNova 7.1. All chemical shifts and
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coupling constants are reported in parts per million (ppm) and hertz (Hz), respectively. 
1H chemical shifts are referenced relative to the following peaks: CDCl3 at 6 7.24 ppm, 
DMSO-d6 at 2.50 ppm (center peak), or DSS at 0.00 ppm. 13C chemical shifts are 
referenced relative to the following peaks: CDCl3 at 6 77.23 ppm (center peak), DMSO- 
d6 at 39.51 (center peak), or DSS at 0.00 ppm. 19F chemical shifts are referenced relative 
to trifluoroacetic acid at 6 -76.55 ppm. 31P chemical shifts are referenced relative to 
phosphoric acid in D2O at 6 0 ppm. HPLC was conducted on a Water 2690 Separation 
Module equipped with a Microsorb MVtm C18 5 ^m column and a Waters 996 
photodiode array detector. Silica gel flash chromatrography was performed using 
ZEOprep 60 ECO silica gel (Zeochem). Thin layer chromatography was carried out on 
silica gel 60 glass-backed plates (Merck). Silica TLC plates were visualized under UV 
light or by staining with 10% w/v phosphomolybdic acid (Sigma) in ethanol or 1.5% w/v 
ninhydrin (Sigma) in n-butanol with 3% v/v acetic acid. Mass spectrometry was 
performed by Dr. James Muller at the Chemistry Department Mass Spectrometry 
Laboratory, University of Utah. Stock solutions of all diphosphates were prepared in 25 
mM NH4HCO3. All diphosphate concentrations were determined using the phosphate 
analysis assay described by Lanzetta, et al.104
Materials
All compounds were obtained from Sigma-Aldrich unless otherwise noted. The 
following compounds were purchased from the companies indicated: triflic anhydride 
(Alfa Aesar); N-t-Boc-4-iodo-L-phenylalanine, 4-hydroxyindole, 7-hydroxyindole, 4- 
methoxyindole, 4-methylindole, 2-methylindole, and 4-azaindole (Chem-Impex 
International, Inc.); isopropyl P-D-1-thiogalactopyranoside (IPTG, Gold Biotechnology);
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thionyl chloride and lithium chloride (Mallinckrodt/JT Baker); chloramphenicol (MP 
Biomedicals); Fmoc-OSu (Novabiochem); and cellulose (Whatman). Sodium 2,2- 
dimethyl-2-silapentane-5-sulfonate (DSS) and deuterated solvents were purchased from 
Cambridge Isotope Laboratories, Inc. except sodium deuteroxide (NaOD) in D2O, which 
was purchased from Aldrich.
Synthesis of Diphosphates
The isoprenoid diphosphates DMAPP and IPP were prepared according to 
literature procedures.105,106
Tris(tetra-n-butylammonium) Hydrogen Pyrophosphate (1)
J. Scott Lee generously supplied 10.06 g (11.16 mmol) of 1.
3-Methyl-3-buten-1-yl ^ -Toluenesulfonate (Isopentenyl Tosylate, 2)
In a nitrogen atmosphere, 3-methyl-3-buten-1-ol (0.252 mL, 0.215 g, 2.50 mmol) 
was added to a solution of p-toluenesulfonyl chloride (0.55 g, 2 .8 8  mmol) and 4-(N, N- 
dimethylamino)pyridine (0.36 g, 2.96 mmol) in DCM (12.5 mL). After allowing the 
reaction to stir at rt for 2.5 h, a 100 x volume excess of hexanes was added and the 
resulting precipitate was removed by gravity filtration. The filtrate was concentrated by 
rotary evaporation, diluted with diethyl ether, then filtered and concentrated to yield 2 
(0.49 g, 2.04 mmol, 82%) as a colorless oil, which was used without further purification.
3-Methyl-3-buten-1-yl Diphosphate (Isopentenyl Diphosphate, 3)
In a nitrogen atmosphere, tosylate 2 (0.49 g, 2.04 mmol) in ACN (6 .8  mL) was 
treated with 1 (5.53 g, 6.13 mmol) dissolved in ACN (6  mL). The reaction mixture was
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allowed to stir at rt for 2 h. After removing the solvent by rotary evaporation, the residue 
was dissolved in a minimal amount of 1:49 IPA/25 mM NH4HCO3. The product was 
converted into its ammonium form by passing it through a DOWEX AG 50W-X8 (100 -  
200 mesh) cation-exchange resin column (30 equiv.) and lyophilizing to dryness. The 
resulting white powder was dissolved in 0.1 M NH4HCO3, diluted with a mixture of ACN 
and IPA, vortexed until a white precipitate formed, and clarified by centrifugation (2000 
rpm, 5 min). This process was repeated with the supernatant twice. The combined 
supernatants were concentrated in vacuo and lyophilized to yield a white powder. The 
white powder was then dissolved in a minimal amount of chromatography buffer and 
purified by cellulose flash chromatography using an elution system of 4.5:2.5:3 (v/v/v) 
IPA/ACN/0.1 M NH4HCO3 to yield 3 (0.11 g, 0.45 mmol, 22%) as a white solid; 1H 
NMR (300 MHz, D2O) 5 1.76 (s, 3H), 2.38 (t, J  = 6 .6  Hz, 2H), 4.04 (dd, J  = 6 .6 , 13.2 Hz, 
2H), ~4.8 (s, 2H, shielded by D2O); 31P NMR (121 MHz, D2O) 5 -7.19 (d, J  = 17.8 Hz, 
1P), -2.34 (d, J  = 17.7 Hz, 1P). Except for the shielded C4 singlet, the NMR data 
matched the published data.106
1-Bromo-3-methyl-2-butene (Dimethylallyl Bromide, 4)
In a nitrogen atmosphere, phosphorus tribromide (0.43 mL, 1.23 g, 4.53 mmol) 
was added dropwise to an ice-cold solution of 3-methyl-2-buten-1-ol (1.05 mL, 0.90 g,
10.5 mmol) in pentane (15 mL). The reaction was stirred at 0 °C for 25 min before 
MeOH (1.4 mL, 3.3 x mol excess) was added. The solution was allowed to stir for 
another 5 min at 0 °C. After removal of the aqueous layer, the organic layer was filtered 
through a celite/MgSO4 plug. The organic layer was then concentrated by rotary
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evaporation in a 0 °C water bath to yield 4 (0.69 g, 4.63 mmol, 102%) as a brown oil, 
which was used without further purification.
3-Methyl-2-buten-1-yl Diphosphate (Dimethylallyl 
Diphosphate, 5)
In a nitrogen atmosphere, bromide 4 (0.69 g, 4.63 mmol) in ice-cold ACN (15.4 
mL) was treated with 1 (8.7 g, 9.66 mmol) dissolved in ACN (19 mL). The reaction 
mixture was allowed to warm to rt and stirred for 2 h. After removing the solvent by 
rotary evaporation, the residue was converted into its ammonium form and purified 
according to the procedure described above for under the synthesis of 5 (IPP). 5 (0.52 g,
2.11 mmol, 46%) was obtained as a white solid; 1H NMR (300 MHz, D2O) 5 1.71 (s, 
3H), 1.75 (s, 3H), 4.44 (t, J  = 6.9 Hz, 2H), 5.44 (t, J  = 6.9 Hz, 1H); 31P NMR (121 MHz, 
D2O) 5 -11.74 (d, J  = 17.8 Hz, 1P), -6.87 (d, J  = 18.5 Hz, 1P). The NMR data matched 
the published data.106
Synthesis of O-Dimethylallyl-L-tyrosine 
N-(terf-Butoxycarbonyl)-O-dimethylallyl-L-tyrosine (6 )
NaH (60% in mineral oil, 152 mg, 6.33 mmol) was washed with hexanes (3 x 5 
mL) and added to a solution of t-Boc-L-tyrosine (613 mg, 2.18 mmol) in anhydrous THF 
(17.5 mL). After stirring at rt for 15 min, dimethylallyl bromide (4, 390 mg, 2.62 mmol) 
was added to the cloudy white mixture and stirred for 20 h. The resulting mixture was 
concentrated to a white foamy solid, diluted with 0.5 N NaOH (25 mL), and extracted 
with diethyl ether (3 x 20 mL). The aqueous layer was acidified to pH <2 and re­
extracted with EtOAc (3 x 20 mL). The combined organic layer was dried with Na2SO4,
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filtered, and concentrated to yield 6  (820 mg, 2.35 mmol, 108%). Compound 6 was used 
directly in the next step without any further purification.
O-Dimethylallyl-L-tyrosine (7)
Compound 6 (820 mg, 2.35 mmol) was heated to 150 °C under nitrogen for 60 
min. The orange solid was washed with ice-cold MeOH to give 7 (151 mg, 0.612 mmol, 
26%) as a white solid. Compound 7 was further purified by silica gel chromatography 
with gradient elution using 0 -  20% H2O in ACN; Rf 0.45 (ACN:H2O 4:1); 1H NMR (500 
MHz, D2O/NaOD, DSS) 5 1.68 (s, 3H), 1.73 (s, 3H), 2.68 (dd, J  = 13.5, 23.0 Hz, 1H), 
2.97 (dd, J  = 8.5, 23.0 Hz, 1H), 3.42 (dd, J  = 8.5, 13.0 Hz, 1H), 4.45 (d, J  = 11.0 Hz, 2H),
5.43 (t, J  = 10.5 Hz, 1H), 6.85 (d, J  = 14.0 Hz, 2H), 7.14 (d, J  = 14.0 Hz, 2H); 13C NMR 
(125 MHz, D2O/NaOD, DSS) 5 17.5, 25.1, 40.3, 57.5, 64.9, 114.9, 119.0, 130.5, 131.0,
139.6, 156.6, 182.2; UV (ACN:H2O 1:3) Xmax 223.8, 273.6 nm; MS-ESI m/z 272.1 [M + 
Na]+. The 1H and 13C NMR data matched the published data.68
Synthesis of 4-Mercapto-L-phenylalanine 
N-(terf-Butoxycarbonyl)-4-(»S-terf-butylthio)-L-phenylalanine (8 )
The tris(dibenzylideneacetone)dipalladium(0 )-chloroform adduct (Pd2dba3-CHCl3, 
0.045 g, 0.044 mmol, 1.5 mol%) was added to DMF (15 mL) under nitrogen, followed by 
1,1’-Bis(diphenylphosphino)ferrocene (DPPF, 0.111 g, 0.200 mmol, 6 .6  mol %). The 
mixture was allowed to stir at rt for 10 min. A mixture of triethylamine (0.92 mL, 6.60 
mmol) and N-t-Boc-4-iodo-L-phenylalanine (1.17 g, 3.00 mmol) in DMF (15 mL) was 
added dropwise and allowed to stir at rt for 10 min before the addition of 2 -methyl-2 - 
propanethiol (0.37 mL, 3.30 mmol). After stirring at 75 °C for 3 h, the reaction mixture
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was concentrated in vacuo, diluted with ethyl acetate (40 mL) and water (10 mL), cooled 
in an ice bath and acidified to pH 2-3 with 50 mM citric acid. The aqueous phase was 
extracted with EtOAc (25 mL) and the combined organic layers were washed with brine 
(2 x 20 mL) and dried over Na2SO4. The concentrated crude product was purified by 
silica gel flash chromatography with gradient elution using 0 -  100% EtOAc in hexanes. 
The resulting yellow oil was re-dissolved in hexanes/EtOAc and filtered to remove a 
small amount of purple solid. The filtrate was concentrated to yield a thick, yellow oil of
8 (0.75 g, 2.12 mmol, 71%); Rf 0.41 (DCM:MeOH 9:1); 1H NMR (300 MHz, CDCh) 5 
1.19 (s, 9H), 1.33 (s, 9H), 2.98 (dd, J  = 6.9, 13.8 Hz, 1H), 3.16 (dd, J  = 5.1, 13.8 Hz, 1H), 
4.55 (q, J  = 7.2, 13.2 Hz, 1H), 5.09 (d, J  = 8.1 Hz, 1H), 7.09 (d, J  = 7.8 Hz, 2H), 7.38 (d, 
J  = 7.8 Hz, 2H); 13C NMR (75 MHz, CDCh) 5 28.1, 28.3, 31.0, 37.7, 45.9, 54.2, 80.2,
129.6, 131.2, 137.1, 137.6, 155.4, 175.1. The 1H NMR matched the literature in DMSO- 
d6, however no 13C NMR was previously reported.107
Bis-(4-mercapto-L-phenylalanine) Disulfide (9)
Concentrated HCl (8  mL) was added to 8 (220 mg, 0.62 mmol) and was heated at 
reflux overnight. After cooling to rt, the solution was diluted with H2O (20 mL) and 
washed with EtOAc (3 x 20 mL). The resulting aqueous layer was lyophilized to yield a 
brown solid of 9 (87 mg, 0.22 mmol, 71%); Rf 0.24 (ACN:H2O 4:1), 0.34 (thiol) and 0.48 
(disulfide) (n-BuOH:AcOH:H2O:pyridine 15:3:10:6); 1H NMR (500 MHz, DMSO-d6) 5
3.12 (d, 6.5 Hz, 4H), 4.15 (t, 6.5 Hz, 2H), 7.31 (d, 8.5 Hz, 4H), 7.49 (d, 8.0 Hz, 4H), 8.44 
(br, 4H); 13C NMR (125 MHz, DMSO-d6 ) 5 35.1, 53.0, 127.4, 130.7, 134.6, 134.7, 
170.2; UV (ACN:H2O 1:3) Xmax 206.2, 242.8 nm; MS-ESI m/z 198.0 [Monomer + H]+,
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393.2 [M + H]+, 415.3 [M + Na]+; HRMS-ESI TOF m/z [M + H]+ calcd for 
C18H21N2O4S2 393.0943, found 393.0945.
Synthesis of 4-Vinyl-L-phenylalanine 
L-Tyrosine Methyl Ester (10)
Thionyl chloride (4 mL, 55.0 mmol) was added dropwise to a suspension of L- 
tyrosine (5.45 g, 30.1 mmol) in MeOH (100 mL, 247 mmol) at 0 °C. The mixture was 
allowed to warm to rt and stirred overnight. After removing the solvent by rotary 
evaporation, the residue was washed with diethyl ether (2x50 mL). Compound 10 was 
obtained as a white solid (5.7 g, 29.2 mmol, 97%); 1H NMR (300 MHz, D2O) 5 3.13 (dd, 
J  = 7.2, 14.7 Hz, 1H), 3.24 (dd, J  = 5.7, 14.7 Hz, 1H), 3.82 (s, 3H), 4.36 (dd, J  = 5.7, 7.2 
Hz, 1H), 6.87 (d, J  = 8.7 Hz, 2H), 7.13 (d, J  = 8.7 Hz, 2H). The 1H NMR data matched 
the published data, 108 except in my spectrum the a proton (4.36) is resolved from the 
methyl group (3.82).
N-(9-Fluorenylmethoxycarbonyl)-L-tyrosine Methyl Ester (11)
A solution of N-(9-fluorenylmethoxycarbonyl)succinimide (4.89 g, 14.5 mmol) in 
1,4-dioxane (30 mL) was added to a mixture of 10  (2.50 g, 12.8  mmol) and NaHCO3 
(3.11 g, 37.0 mmol) in H2O (30 mL). After stirring for 23 h at rt, the mixture was 
acidified to pH 2-3 with 1 N HCl at 0 °C, extracted with EtOAc (3 x 25 mL), dried over 
Na2SO4, and concentrated in vacuo. The crude product was purified by silica gel flash 
chromatography with gradient elution using 0 -  40% EtOAc in hexanes to yield 11 (4.8 
g, 90%) as a colorless sticky solid; 1H NMR (300 MHz, CDCh) 5 2.93-3.09 (m, 2H), 
3.70 (s, 3H), 4.18 (t, J  = 6.9 Hz, 1H), 4.27-4.46 (m, 2H), 4.57-4.67 (m, 1H), 5.35 (d, 8.4
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Hz, 1H), 6.72 (d, J  = 8.4 Hz, 2H), 6.91 (d, J  = 8.4 Hz, 2H), 7.25-7.43 (m, 4H), 7.51-7.57 
(m, 2H), 7.71-7.78 (m, 2H). The 1H NMR matched the published data.109
N-9-Fluorenylmethoxycarbonyl-4-((trifluoromethane- 
sulfonyl)oxy)-L-phenylalanine Methyl Ester (12)
Trifluoromethanesulfonic anhydride (1.9 mL, 11.3 mmol) was added dropwise to 
an ice-cold solution of 11 (4.1 g, 9.82 mmol) and DIPEA (8 .6  mL, 49.4 mmol) in DCM 
(20 mL). Stirring was continued at 0 °C for 2.5 h. The resulting mixture was diluted 
with H2O (30 mL) and DCM (50 mL) and washed sequentially with 10% NaHCO3 (25 
mL), H2O (30 mL), 10% citric acid (2 x 30 mL), and H2O (30 mL). The organic layer 
was dried over Na2SO4 and concentrated in vacuo. The crude product was purified by 
silica gel flash chromatography using an elution gradient of 0 -  30% EtOAc in hexanes to 
give 12 (3.0 g, 5.46 mmol, 56%) as a white solid; Rf 0.43 (hexanes:EtOAc 4:1); 1H NMR 
(300 MHz, CDCh) 5 3.07 (dd, J  = 6.0, 13.8 Hz, 1H), 3.16 (dd, J  = 6.0, 14.1 Hz, 1H), 3.70 
(s, 3H), 4.19 (t, J  = 6 .6  Hz, 1H ), 4.38 (dd, 6.3, 10.5 Hz, 1H), 4.48 (dd, 6.9, 10.8 Hz, 1H), 
4.64 (dd, J  = 6.0, 13.8 Hz, 1H), 5.27 (d, J  = 7.8 Hz, 1H), 7.12 (d, J  = 8.7 Hz, 2H), 7.17 
(d, J  = 8.7 Hz, 2H), 7.30 (t, J  = 7.5 Hz, 2H), 7.40 (t, J  = 7.5 Hz, 2H), 7.55 (d, J  = 7.5 Hz, 
2H), 7.76 (d, J  = 7.5 Hz, 2H); 13C NMR (75 MHz, CDCh) 5 37.8, 47.4, 52.7, 54.8, 67.0,
120.2, 120.3, 121.6, 125.1, 125.2, 127.3, 128.0, 131.3, 136.7, 141.6, 143.8, 143.9, 148.8,
155.6, 171.6; 19F NMR (282 MHz, CDCh, TFA) 5 73.8; MS-ESI m/z 572.1 [M + Na]+, 
HRMS-ESI TOF m/z [M + Na]+ calcd for C^H^NOyNaSFs 572.0967, found 572.0970. 
The 1H NMR matched the published data; however, the 13C NMR had a few differences 
in the aromatic region and no 19F NMR data were previously reported.110
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4-Vinyl-L-phenylalanine Methyl Ester (13)
Under a nitrogen atmosphere, tributyl(vinyl)tin (267 ^L, 0.92 mmol) was added to 
a solution of flame-dried LiCl (270 mg, 6.35 mmol), PdCl2(PPh3)2 (12.5 mg, 0.018 
mmol), and triflate 12 (0.5 g, 0.91 mmol) in DMF (8  mL). The yellow-orange solution 
was then warmed to 90 °C. After stirring for 23 h, the reaction mixture was poured into 
ice-cold H2O (15 mL) and extracted with EtOAc (2 x 10 mL). The combined organic 
extracts were sequentially washed with H2O (2 x 10 mL) and brine (2 x 10 mL), dried 
over Na2SO4, and concentrated in vacuo to give a yellow oil. This oil was partially 
purified by silica gel flash chromatography with gradient elution using 0 -  100% EtOAc 
in hexanes, followed by 10% MeOH in EtOAc. Impure 4-vinyl-L-phenylalanine methyl 
ester (13, 0.13 g, 0.63 mmol, 70%) was recovered from the MeOH fractions; Rf 0.55 
(EtOAc:MeOH 4:1); 1H NMR (500 MHz, CDCh) 5 2.83 (dd, J  = 8.0, 13.5 Hz, 1H), 3.05 
(dd, J  = 5.5, 13.5 Hz, 1H), 3.61-3.77 (m, 4H), 5.20 (d, J  = 11.0 Hz, 1H), 5.70 (d, J  = 17.5 
Hz, 1H), 6.67 (dd, J  = 18.0, 11.0 Hz, 1H), 7.13 (d, J  = 8.0 Hz, 2H), 7.33 (d, J  = 8.0 Hz, 
2H); MS-ESI m/z 206.1 [M + H]+, 228.1 [M + Na]+.
N-9-Fluorenylmethoxycarbonyl-4-vinyl-L-phenylalanine 
Methyl Ester (14)
In an attempt to better purify the vinyl amino acid, impure 13 (0.13 g, 0.63 mmol) 
was reprotected with Fmoc in a procedure similar to the synthesis of 11, using NaHCO3 
(0.16 g, 1.91 mmol) and #-(9-fluorenylmethoxycarbonyl)succinimide (0.26 g, 0.77 
mmol). Silica gel flash chromatography using an elution gradient of 0 -  20% EtOAc in 
hexanes afforded 14 (0.15 g, 0.35 mmol, 55%). Rf 0.22 (hexanes:EtOAc 4:1), 0.60 
(hexanes:EtOAc 3:2); 1H NMR (500 MHz, CDCh) 5 3.07 (dd, J  = 6.0, 13.5 Hz, 1H),
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3.12 (dd, J  = 6.0, 14.0 Hz, 1H) 3.72 (s, 3H), 4.20 (t, J  = 7.0 Hz, 1H), 4.34 (dd, J  = 6.5,
10.5 Hz, 1H), 4.42 (dd, J  = 7.0, 10.5 Hz, 1H), 4.65 (dd, J  = 5.5, 13.5 Hz, 1H), 5.19-5.26 
(m, 2H), 5.71 (d, J  = 18.0 Hz, 1H), 6.67 (dd, J  = 11.0, 17.5 Hz, 1H), 7.03 (d, J  = 7.5 Hz, 
2H), 7.27-7.33 (m, 4H), 7.39 (t, J  = 7.5 Hz, 2H), 7.55 (t, J  = 7.0 Hz, 2H), 7.75 (d, J  = 7.5 
Hz, 2H); 13C NMR (125 MHz, CDCh) 5 38.1, 47.4, 52.6, 54.9, 67.2, 114.0, 120.1, 120.2,
120.3, 124.9, 125.2, 125.3, 126.7, 127.2, 127.3, 127.8, 127.9, 129.7, 135.5, 136.6, 136.7,
141.5, 141.8, 143.9, 144.1, 155.7, 172.1; MS-ESI m/z 450.1 [M + Na]+, HRMS-ESI TOF 
m/z [M + Na]+ calcd for C27H25NO4N  450.1681, found 450.1688.
4-Vinyl-L-phenylalanine (15)
Protected vinyl amino acid 14 (0.13 g, 0.30 mmol) was dissolved in a 1:1 mixture 
of 1 N NaOH (5x mol excess)/THF and allowed to stir at rt for 42 h. The reaction 
mixture was washed with diethyl ether (3 x 20 mL) and the aqueous layer was 
subsequently lyophilized to yield an off-white solid (0.056 g, 0.29 mmol, 96%). Product
15 was dissolved in H2O and purified by C18 RP-HPLC using a linear elution gradient of 
100% H2O to 100% ACN in a total volume of 30 mL at a flow rate of 1.0 mL/min. 
Fractions with retention times 9-11 min were collected and lyophilized to afford a white 
solid; 1H NMR (300 MHz, D2O/NaOD, DSS) 5 2.92 (dd, J  = 7.8, 14.1 Hz, 1H), 3.06 (dd, 
J  = 5.7, 14.1 Hz, 1H), 3.64 (dd, J  = 5.7, 7.5 Hz, 1H), 5.28 (d, J  = 11.1 Hz, 1H), 5.83 (d, J  
= 17.7 Hz, 1H), 6.78 (dd, J  = 10.8, 17.7 Hz, 1H), 7.26 (d, J  = 8.4 Hz, 2H), 7.47 (d, J  = 8.4 
Hz, 2H); 13C NMR (75 MHz, D2O/NaOD, DSS) 5 39.2, 57.1, 114.1, 126.5, 129.9, 136.2,
136.5, 137.2, 179.9; UV (ACN:H2O 1:3) Xmax 202.6, 249.9 nm; MS-ESI m/z 214.1 [M + 
Na]+, 236.1 [M + 2Na+ - H+]+; HRMS-ESI TOF m/z [M + Na]+ calcd for CnHoNOzNa 
214.0844, found 214.0838.
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Expression of the T. maritime Tryptophan Synthase P-Subunit 
Bacterial Strains, Plasmids and Culture Conditions
tmTrpB, an E. coli BL21-(DE3)-RIPL strain containing the pET28a-tmTrpB1 
vector was obtained from Reinhard Sterner. tmTrpB1 encodes the P-subunit of 
tryptophan synthase from the hyperthermophilic bacterium Thermotoga maritime.111 
Expression strains were grown in liquid LB broth or on solid LB-agar medium at 37 °C. 
Kanamycin (35 p,g mL-1) and chloramphenicol (34 ^g mL-1) were used to select vector- 
containing E. coli strains.
Overproduction and Purification of Tryptophan Synthase
As advised by the Sterner lab, E. coli BL21-DE3-RIPL containing pET28a- 
tmTrpB1 was cultivated in 1 L LB broth containing kanamycin and chloramphenicol at 
37 °C with shaking at 225 rpm to an OD600 of 0.5 -  1.0. The culture was then cooled to 
20 °C and allowed to grow for 1 h. Overexpression of the P-subunit of tryptophan 
synthase was induced with IPTG to a final concentration of 0.5 mM. After inducing for 
18 h, cells were harvested by centrifugation (2,700 x g, 15 min, 4 °C). Pelleted cells 
were resuspended in 25 mL lysis buffer (100 mM K2HPO4, 300 mM KCl, 10 mM 
imidazole, 40 ^M PLP, pH 7.5) and sonicated (Branson Sonifier 350) for 4 x 30 sec at 4 
°C. The lysate was clarified by centrifugation (23,400 x g, 15 min, 4 °C). The resulting 
soluble lysate was heated to 75 °C for 20 min and again clarified by centrifugation 
(23,400 x g, 15 min, 4 °C). Purification of the recombinant protein was achieved through 
nickel affinity chromatography (GE Healthcare HisTrap HP) following the 
manufacturer’s instructions. Tryptophan synthase was eluted with elution buffer (100 
mM K2HPO4, 300 mM KCl, 1 M imidazole, pH 7.5) and pure protein was dialyzed 3 x
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against 4 L of 100 mM K2HPO4 buffer, pH 7.5. The protein was then divided into 1 mL 
portions, flash frozen with liquid nitrogen and stored at -80 °C until use.
Synthesis of Indole Analogues 
4-((Trifluoromethanesulfonyl)oxy)-indole (16)
Under a nitrogen atmosphere, trifluoromethanesulfonic anhydride (0.76 mL, 4.52 
mmol) was added dropwise to an ice-cold solution of 4-hydroxyindole (500 mg, 3.76 
mmol) and 2,6-lutidene (0.57 mL, 4.89 mmol) in DCM (5.5 mL). While stirring, the 
reaction was held at 0 °C for 1 h. The resulting yellow-brown mixture was poured into 
H2O (20 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL) and the 
combined organic fractions were washed with H2O (20 mL) and brine (20 mL). The 
organic layer was then dried over Na2SO4 and concentrated in vacuo. The crude product
16 was isolated as an oil and used without further purification; Rf 0.57 (hexanes:EtOAc 
3:2); 1H NMR (500 MHz, CDCh) 5 6.61-6.65 (m, 1H), 7.04 (d, J  = 13.0 Hz, 1H), 7.15 (t, 
J  = 13.0 Hz, 1H), 7.21 (dd, J  = 4.5 Hz, 5.5 Hz, 1H), 7.34 (dt, J  = 1.5 Hz, 14.0 Hz, 1H), 
8.58 (br, 1H); 19F NMR (470 MHz, CDCh) 5 73.7. The 1H NMR matched the published 
data; however, no 19F NMR data were previously reported.112
4-(»S-terf-Butylthio)-mdole (17)
Tris(dibenzylideneacetone)dipalladium(0 )-chloroform adduct (Pd2dba3-CHCl3, 
0.056 g, 0.055 mmol, 1.5 mol%) was first added to DMF (18.7 mL) under nitrogen. 1,1’- 
Bis(diphenylphosphino)ferrocene (DPPF, 0.138 g, 0.249 mmol, 6 .6  mol%) was then 
added to the purple solution and allowed to stir at rt for 10 min. A mixture of 
triethylamine (1.14 mL, 8.235 mmol) and triflate 16 (crude, assumed 3.76 mmol) in DMF
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(18.7 mL) was added dropwise and allowed to stir at rt for 10 min before the addition of 
2-methyl-2-propanethiol (0.464 mL, 4.11 mmol). After stirring at 75 °C for 18 h, the 
reaction mixture was diluted with EtOAc (50 mL) and H2O (20 mL), cooled in an ice 
bath and acidified to pH 2-3 with 50 mM citric acid. The aqueous phase was extracted 
with EtOAc (2 x 25 mL) and the combined organic layers were washed with H2O (2 x 25 
mL) and brine (2 x 25 mL) and dried over Na2SO4. The organic layer was concentrated 
by rotary evaporation to a red-brown oil and purified by silica gel flash chromatography 
with gradient elution using 0 -  20% EtOAc in hexanes to give 17 (0.60 g, 2.92 mmol, 
78%) as a yellow solid; Rf 0.45 (EtOAc:MeOH 4:1); 1H NMR (500 MHz, CDO3) 5 1.31 
(s, 9H), 6.80-6.83 (m, 1H), 7.14 (t, J  = 7.5 Hz, 1H), 7.22 (t, J  = 3.0 Hz, 1H), 7.31 (d, J  =
7.0 Hz, 1H), 7.39 (d, J  = 8.0 Hz, 1H), 8.20 (br, 1H); 13C (125 MHz, CDO3) 5 31.7, 47.4,
104.1, 112.1, 121.9, 124.5, 124.6, 130.6, 133.8, 135.9; GCMS m/z 205 [M]; HRMS-ESI 
TOF m/z [M + H]+ calcd for C12H 16NS 206.1003, found 206.1007.
4-Mercaptoindole (18)
Concentrated HCl (6  mL) was added to 17 (180 mg, 0.88 mmol) and the resulting 
tan solution with brown precipitate was heated at reflux overnight. After cooling to rt, 
the solution was diluted with MeOH (2 mL) and H2O (20 mL) and extracted with EtOAc 
(3 x 20 mL). The resulting organic layer was concentrated in vacuo and purified by silica 
gel flash chromatography with gradient elution using 0 -  40% EtOAc in hexanes to give 
18 as a brown oil (40 mg, 0.27 mmol, 31%); Rf 0.53 (Hex:EtOAc 3:2); 1H NMR (300 
MHz, CDO3) 5 4.02 (br, 1H), 6.62 (d, J  = 7.5 Hz, 1H), 7.15 (t, J  = 7.8 Hz, 1H), 7.26 (d, J  
= 5.7 Hz, 1H), 7.29-7.36 (m, 2H); 13C (75 MHz, CDO3) 5 109.1, 113.2, 119.4, 124.6,
125.6, 128.4, 141.3, 141.7.
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4-Vinylindole (19)
Under a nitrogen atmosphere, tributyl(vinyl)tin (0.922 mL, 3.18 mmol) was added 
to a solution of flame-dried LiCl (1.12 g, 26.36 mmol), PdCl2(PPh3)2 (52.7 mg, 0.075 
mmol), and triflate 16 (crude, assumed 3.76 mmol) in DMF (21 mL). The solution was 
then warmed to 80 °C. After stirring for 20 h, the reaction mixture was poured into ice- 
cold H2O (80 mL) and extracted with EtOAc (3 x 25 mL). The combined organic 
extracts were washed with brine (2 x 25 mL), dried over Na2SO4, and concentrated in 
vacuo to a brown oil. The crude product was purified by silica gel flash chromatography 
with gradient elution using 0 -  40% EtOAc in hexanes to give 19 as a light brown liquid 
(0.29 g, 2.03 mmol, 64%); Rf 0.85 (EtOAc:MeOH 3:2); 1H NMR (500 MHz, CDCl3) 5
5.43 (dd, J  = 2.0, 18.5 Hz, 1H), 5.97 (dd, J  = 2.0, 29.5 Hz, 1H), 6.76-6.81 (m, 1H), 7.11­
7.34 (m, 5H), 8.19 (br, 1H); 13C (125 MHz, CDCl3) 5 101.0, 110.8, 114.7, 117.4, 122.1,
124.7, 126.1, 130.1, 135.5, 136.3; MS-ESI m/z 144.1 [M + H]+. The 1H NMR matched 
the published data, however no 13C NMR data was previously reported.113
Synthesis of L-Tryptophan Analogues 
General Tryptophan Analogue Synthesis Method
Typically, indole analogue (160 mg) and L-serine (250 mg, 2.38 mmol) were 
added to 25 mL of Buffer TS (100 mM K2HPO4, pH 7.5, 180 mM KCl, 120 |iM PLP) 
containing 1 -  8 mg of tryptophan synthase. For most analogues (4-OH, 7-OH, 4-OMe, 
4-NH2, 4-Me, 7-Me, 4-Vinyl, DIT), the reactions were carried out under nitrogen. The 
reactions were heated to 80 °C and incubated 16 - 90 h. After incubation, the reaction 
mixture was cooled to rt and the enzyme was removed by filtration using an Amicon 
Ultra 10 kDa MWCO filter. After concentrating in vacuo, the resulting residue was
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purified by silica gel flash chromatography with gradient elution using 0 -  20 % H2O in 
ACN. All purified compounds were stored under N2 at -20 °C unless otherwise noted.
2-Methyl-L-tryptophan (20)
2-Methylindole (160 mg, 1.22 mmol) was incubated with 3.1 mg of tryptophan 
synthase as described above for 24 h. Column chromatography yielded 20 (140 mg, 0.64 
mmol, 53%) as a pink solid; Rf 0.37 (ACN:H2O 4:1); 1H NMR (500 MHz, D2O, DSS) 5 
2.40 (s, 3H), 3.20 (dd, J  = 8.5, 15.5 Hz 1H), 3.41 (dd, J  = 5.0, 15.5 Hz, 1H), 4.00 (dd, J  =
5.5, 8.5 Hz, 1H), 7.14 (dt, J  = 1.0, 8.0 Hz, 1H), 7.20 (dt, J  = 1.5, 7.5 Hz, 1H), 7.43 (d, J  =
8.0 Hz, 1H), 7.61 (d, J  = 7.5 Hz, 1H); UV (ACN:H2O 1:3) Xmax 221.5, 227.2 nm; MS-ESI 
m/z 241.1 [M + Na]+, 257.1 [M + K]+; HRMS-ESI TOF m/z [M + Na]+ calcd for 
C12H 14N2O2Na 241.0953, found 241.0964. The 1H NMR matched the literature.100
4-Amino-L-tryptophan (21)
4-Aminoindole (160 mg, 1.21 mmol) was incubated with 2 mg of tryptophan 
synthase as described above for 16 h. Column chromatography yielded 21 (220 mg, 1.00 
mmol, 83%) as a gray solid; Rf 0.34 (ACN:H2O 4:1); 1H NMR (500 MHz, D2O) 5 3.38 
(dd, J  = 8.0, 16.0 Hz, 1H), 3.62 (dd, J  = 5.0, 16.0 Hz, 1H), 4.02 (dd, J  = 5.0, 8.0 Hz, 1H), 
6.57 (t, J  = 4.5 Hz, 1H), 7.08-7.10 (m, 2H), 7.20 (s, 1H); UV (ACN:H2O 1:3) Xmax 221.5, 
272.4 nm; MS-ESI m/z 220.1 [M + Na]+, 242.2 [M + Na]+, 258.1 [M + K]+; HRMS-ESI 
TOF m/z [M + H]+ calcd for Cn H 14N3O2 220.1086, found 220.1078. The 1H NMR 
matched the literature, except the chemical shift of one aromatic proton.101
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4-Hydroxy-L-tryptophan (22)
4-Hydroxyindole (160 mg, 1.20 mmol) was incubated with 8 mg of tryptophan 
synthase as described above for 90 h. Column chromatography yielded 22 (200 mg, 0.91 
mmol, 76%) as light brown-gray crystals, which were stored under argon at -80 °C; Rf
0.42 (ACN:H2O 4:1); 1H NMR (300 MHz, D2O) 5 3.07 (dd, J  = 8.4, 15.0 Hz, 1H), 3.47 
(ddd, J  = 0.9, 4.5, 15.0 Hz, 1H), 3.95 (dd, 4.5, 8.1 Hz, 1H), 6.38 (dd, J  = 3.6, 4.8 Hz, 1H), 
6.89-6.91 (m, 2H), 6.97 (s, 1H); UV (ACN:H2O 1:3) Xmax 219.1, 265.3, 280.7, 290.3 nm; 
MS-ESI m/z 243.1 [M + Na]+; HRMS-ESI TOF m/z [M + H]+ calcd for CnH 13N2O3 
221.0926, found 221.0934. The 1H NMR matched the literature.114
4-Mercapto-L-tryptophan (23)
4-Mercaptoindole (18, 20 mg, 0.14 mmol) was incubated with 1 mg of tryptophan 
synthase in Buffer TS containing 20 mM 2-mercaptoethanol (PME) as described above 
for 24 h. Column chromatography yielded 23 as a light yellow solid; Rf 0.41 (ACN:H2O 
4:1); UV (ACN:H2O 1:3) Xmax 213.2, 271.2, 317.7 nm; MS-ESI m/z 237.1 [M + H]+,
259.1 [M + Na]+; HRMS-ESI TOF m/z [M + Na]+ calcd for CnH 12N2O2NaS 259.0517, 
found 259.0524.
4-Methoxy-L-tryptophan (24)
4-Methoxyindole (160 mg, 1.09 mmol) was incubated with 8 mg of tryptophan 
synthase as described above for 24 h. Column chromatography yielded 24 (120 mg, 0.51 
mmol, 47%) as a light yellow solid; Rf 0.44 (ACN:H2O 4:1); 1H NMR (500 MHz, D2O) 5 
3.23 (dd, J  = 8.5, 14.5 Hz 1H), 3.67 (dd, J  = 4.5, 14.5 Hz, 1H), 4.01 (s, 3H), 4.14 (dd, J  =
4.5, 8.5 Hz, 1H), 6.70 (d, J  = 7.0 Hz, 1H), 7.17 (d, J  = 8.0 Hz, 1H), 7.18 (s, 1H), 7.22 (t, J
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= 7.5 Hz); 13C NMR (125 MHz, D2O) 5 28.0, 55.5, 56.5, 100.1, 105.7, 107.7, 116.6,
123.3, 124.4, 138.3, 153.8, 174.8; UV (ACN:H2O 1:3) Xmax 217.9, 265.3, 279.6, 289.1 
nm; MS-ESI m/z 257.1 [M + Na]+, 273.1 [M + K]+; HRMS-ESI TOF m/z [M + H]+ calcd 
for C12H 14N2O3N  257.0902, found 257.0903. The 1H NMR matched the literature for 4- 
methoxy-D-tryptophan in DMSO-d6, with the exception of the a proton.115
4-Methyl-L-tryptophan (25)
4-Methylindole (160 mg, 1.22 mmol) was incubated with 7.5 mg of tryptophan 
synthase in Buffer TS containing 0.5 mL DMSO ([DMSO]final = 2 %) as described above 
for 89 h. Column chromatography yielded 25 (175 mg, 0.80 mmol, 6 6 %) as an off-white 
solid; Rf 0.65 (ACN:H2O 4:1); 1H NMR (300 MHz, D2O/NaOD) 5 2.19 (s, 3H), 2.44 (dd, 
J  = 8.1, 14.4 Hz, 1H), 2.83 (dd, J  = 5.4, 14.4 Hz, 1H), 2.96 (dd, J  = 5.7, 7.8 Hz, 1H), 6.38 
(d, J  = 7.5 Hz, 1H), 6.61 (t, J  = 7.8 Hz, 1H), 6.69 (s, 1H), 6 .8 6  (d, J  = 8.1 Hz, 1H); UV 
(ACN:H2O 1:3) Xmax 219.1, 270.0 nm; MS-ESI m/z 219.2 [M + H]+; HRMS-ESI TOF m/z 
[M + H]+ calcd for C12H 15N2O2 219.1134, found 219.1136. The 1H NMR matched the 
literature.100
4-Vinyl-L-tryptophan (26)
4-vinylindole (19, 160 mg, 1.12 mmol) was incubated with 2 mg of tryptophan 
synthase in a flask equipped with a reflux condenser as described above for 42 h. 
Column chromatography yielded 26 (180 mg, 0.78 mmol, 70%) as a yellow solid; Rf 0.41 
(ACN:H2O 4:1); 1H NMR (500 MHz, D2O/NaOD, DSS) 5 2.97 (dd, J  = 8.0, 14.5 Hz 1H), 
3.31 (dd, J  = 6.0, 14.5 Hz, 1H), 3.53 (dd, J  = 6.0, 8.0 Hz, 1H), 5.45 (dd, J  = 1.5, 11.0 Hz, 
1H), 5.80 (dd, J  = 1.5, 17.5 Hz, 1H), 7.20-7.24 (m, 3H), 7.33 (d, J  = 7.5 Hz, 1H), 7.45 (d,
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J  = 8.0 Hz, 1H), 7.56 (dd, J =  11.0, 17.5 Hz, 1H); 13C NMR (125 MHz, D2O/NaOD, 
DSS) 5 35.6, 60.2, 97.5, 114.0, 114.3, 118.5, 119.1, 124.7, 126.5, 128.4, 134.2, 138.1,
139.9, 185.5; UV (ACN:H2O 1:3) Xmax 219.1, 299.8 nm; MS-ESI m/z 231.1 [M + H]+,
253.1 [M + Na]+, 269.1 [M + K]+; HRMS-ESI TOF m/z [M + H]+ calcd for CbH 15N2O2 
231.1134, found 231.1135.
7-Hydroxy-L-tryptophan (27)
7-Hydroxyindole (160 mg, 1.20 mmol) was incubated with 8 mg of tryptophan 
synthase as described above for 90 h. Column chromatography yielded 27 (200 mg, 0.91 
mmol, 76%) as light gray crystals, which were stored under argon at -80 °C; Rf 0.42 
(ACN:H2O 4:1); 1H NMR (300 MHz, D2O) 5 3.23 (dd, J  = 7.8, 15.0 Hz, 1H), 3.63 (dd, J  
= 4.5, 15.0 Hz, 1H), 4.11 (dd, J  = 4.5, 8.1 Hz, 1H), 6.54 (dd, J  = 3.9, 4.5 Hz, 1H), 7.05 (s, 
1H), 7.07 (d, J  = 1.2 Hz, 1H), 7.13 (s, 1H); UV (ACN:H2O 1:3) Xmax 219.1, 265.3, 280.7,
290.3 nm; MS-ESI m/z 243.1 [M + Na]+; HRMS-ESI TOF m/z [M + H]+ calcd for 
C11H 13N2O3 221.0926, found 221.0922. The 1H NMR did not match the literature 
aromatic region, however it looked similar to 4-hydroxy-L-tryptophan, which would be 
expected.114
7-Methyl-L-tryptophan (28)
7-Methylindole (160 mg, 1.22 mmol) was incubated with 2.34 mg of tryptophan 
synthase in Buffer TS containing 0.5 mL DMSO ([DMSO]final = 2 %) as described above 
for 42 h. Column chromatography yielded 28 (230 mg, 1.05 mmol, 8 6%) as a white 
solid; Rf 0.47 (ACN:H2O 4:1); 1H NMR (500 MHz, D2O) 5 2.57 (s, 3H), 3.36 (dd, J  =
7.5, 15.0 Hz, 1H), 3.53 (d, J  = 15.0 Hz, 1H), 4.09-4.15 (m, 1H), 7.15-7.22 (m, 2H), 7.40
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(s, 1H), 7.64 (d, J =  7.5 Hz, 1H); UV (ACN:H2O 1:3) Xmax 217.9, 270.0, 276.0 nm; 
HRMS-ESI TOF m/z [M + H]+ calcd for C12HMN2O2Na 241.0953, found 241.0955. The 
1H NMR matched the literature.100
Dihydroiso-L-tryptophan (29)
Indoline (160 mg, 1.34 mmol) was incubated in the dark with 1 mg of tryptophan 
synthase in Buffer TS containing 0.5 mL DMSO ([DMSO]final = 2 %) as described above 
for 21 h. Column chromatography yielded 29 (240 mg, 1.16 mmol, 87%) as a cream 
colored solid; Rf 0.57 (ACN:H2O 4:1); 1H NMR (500 MHz, D2O) 5 3.04 (t, J  = 8.5 Hz, 
2H), 3.39 (dd, J  = 8.0, 16.5 Hz, 1H), 3.48 (dd, J  = 8.0, 16.5 Hz, 1H), 3.58 (dd, 5.0, 14.5 
Hz, 1H), 3.63 (dd, J  =7.5, 15.0 Hz, 1H), 4.07 (dd, J  = 4.5, 7.0 Hz, 1H), 6.74 (d, J  = 8.0 
Hz, 1H), 6 .8 6  (t, J  = 7.5 Hz, 1H), 7.22 (t, J  = 7.5 Hz, 1H), 7.27 (d, J  = 7.5 Hz, 1H); 13C 
NMR (125 MHz, D2O) 5 28.4, 51.3, 54.0, 54.6, 107.9, 119.3, 125.2, 127.7, 130.9, 152.3. 
UV (ACN:H2O 1:3) Xmax 205.0, 247.5, 293.8 nm; HRMS-ESI TOF m/z [M + H]+ calcd 
for C11H 15N2O2 207.1134, found 207.1148. The 1H NMR matched the literature, except a 
contamination singlet at 2.8 ppm; no 13C NMR data was previously reported.116
Results and Discussion 
Synthesis of Tyrosine Analogues
O-Dimethylallyl-L-tyrosine (7) was synthesized according to the procedure 
outlined by Pedras and coworkers for use as an authentic standard.68 Briefly, 
commercially available #-Boc-L-tyrosine was prenylated with dimethylallyl bromide (4). 
Simple amine deprotection by heating at 150 °C and purification by silica gel 
chromatography yielded pure 7.
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We began the synthesis of 4-mercapto-L-phenylalanine following the literature 
procedures for the chlorosulfonation of L-phenylalanine followed by a Sn/HCl reduction 
first reported by Escher and coworkers.90,91 Although we attempted the above synthesis 
numerous times, we were never able to obtain the tyrosine analogue. For our purposes, 
this synthesis also suffered from its lack of isolation and purification of the unprotected 
amino acid. Both groups used the crude reaction mixture in a variety of protection 
reactions for further use in peptide synthesis. After searching the literature and testing 
many other thiol syntheses, 117-125 we settled on a procedure that introduces a t-butyl 
protected thiol107 that can be deblocked under acidic conditions (Scheme 2.1) .126
The two-step synthesis of disulfide 9 involves a palladium catalyzed cross­
coupling reaction between the commercially available N-t-Boc-4-iodo-L-phenylalanine 
and t-butylthiol followed by the simultaneous deprotection of the Boc and ^-t-butyl 
protecting groups with concentrated HCl. Due to the oxidative nature of the deprotection 
reaction, we isolated the symmetrical disulfide of 4-mercapto-L-phenylalanine (9). This 
was an acceptable product as the disulfide was easily reduced with a reducing agent such 
as p-mercaptoethanol before addition to an enzymatic assay.
4-Vinyl-L-phenylalanine (15) can be synthesized from L-tyrosine by converting 
the phenolic moiety of tyrosine into a triflic ester which can then be substituted to a vinyl 
group through the Stille coupling.92 Due to the fact L-tyrosine t-butyl ester is 
commercially available, we decided to protect the amino acid moiety of L-tyrosine as Boc 
and t-butyl ester moieties, respectively, which allowed both protecting groups to be 
removed under the same conditions. After protection with Boc, triflic anhydride was 













tributyl(vinyl)tin92 to obtain #-^-Boc-4-vinyl-L-phenylalanine ^-butyl ester. Both the Boc 
and t-butyl ester protecting groups were removed in the presence of trifluoroacetic acid 
(TFA), but an unwanted side reaction also occurred. NMR analysis of the crude product 
showed that the vinyl peaks had disappeared. A literature search revealed that styrene 
polymerizes to polystyrene in the presence of TFA, 128 suggesting that the vinyl amino 
acid (a styrene derivative) had undergone polymerization.
In order to circumvent this issue, 15 was synthesized using protecting groups that 
can be removed under nonacidic conditions (Scheme 2.2). #-Fmoc-L-tyrosine methyl 
ester (11) was synthesized from L-tyrosine using literature methods and the phenol was 
converted to its triflate (12) under the same procedure as earlier described. Similar to 
above, the triflate 12  was then treated with tributyl(vinyl)tin to obtain the corresponding 
vinyl substituted L-tyrosine derivative (13). Unfortunately, this reaction also deprotected 
the Fmoc protecting group to give the free amine, most likely due to diethylamine 
contamination in the DMF used as a solvent. The free amine was re-protected using 
Fmoc chemistry to form 14 to facilitate purification by silica gel chromatography. After 








































Synthesis of Tryptophan Analogues
Using the described synthetic pathways for 4-vinyl-L-phenylalanine (15) and 4- 
mercapto-L-phenylalanine as models (see above), we synthesized 4-vinylindole (19) and 
4-mercaptoindole (18) following similar procedures. First, commercially available 4- 
hydroxyindole was converted to its triflate (16).129 For 4-vinylindole (19), triflate ester 16 
was converted to a vinyl group by a Stille coupling. For 4-mercaptoindole (18), a 
palladium catalyzed cross-coupling reaction with triflate 16 and ^-butylthiol followed by 
acidic deprotection yielded 18. Both indole analogues were then used to biosynthetically 
produce tryptophan analogues (see below).
Tryptophan synthase was used to synthesize enantiomerically pure L-tryptophan 
analogues from a variety of indoles in one simple and convenient step (Scheme 2.3) .100,101 
Using both synthetic and commercially available indole analogues, we synthesized the 
following L-tryptophan analogues using the P-subunit of tryptophan synthase: 2-methyl- 
tryptophan (20), 4-aminotryptophan (21), 4-hydroxytryptophan (22), 4-mercapto- 
tryptophan (23), 4-methoxytrypotphan (24), 4-methyltryptophan (25), 4-vinyltryptophan 
(26), 7-hydroxytryptophan (27), 7-methyltryptophan (28), and dihydroisotryptophan (29). 
The incubations typically gave ~200 mg of purified product. However, if desired, the 
reactions can be easily scaled up to increase tryptophan production. Other indoles that 
were not substrates for tryptophan synthase include indene, 4-azaindole (although 
published) , 130 and 4-(S'-fert-butylthio)-indole (17). Overall, two L-tyrosine/phenylalanine 
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Figure 2.1. Amino acid analogues synthesized.
CHAPTER 3
SIRD: BIOCHEMICAL CHARACTERIZATION AND 
AROMATIC SUBSTRATE PROMISCUITY
Introduction
Phytopathogenic fungi produce toxic secondary metabolites that provide selective 
advantages against other microorganisms. Epipolythiodioxopiperazines (ETPs) constitute 
one class of fungal secondary metabolite toxins. The sulfur-bridged dioxopiperazine ring 
is constructed from a cyclic dipeptide and is known to contain one, three, or four sulfur 
atoms.18 Well-known examples include gliotoxin and sirodesmin PL (Figure 1.1).
The first known genes responsible for the biosynthesis of sirodesmin PL were 
reported in 2004. Found in the pathogenic organism, Leptosphaeria maculans, the 
sirodesmin PL gene cluster spans a 68 kilobase region encoding enzymes including a 
two-module nonribosomal peptide synthetase, a thioredoxin reductase, and a 
prenyltransferase.64 The prenyltransferase gene, named sirD, was found to be a 
homologue of a DMATS from Neotyphodium coenophialum. Given the other members 
of the gene cluster and sirodesmin PL’s structure, SirD was hypothesized to prenylate the 
tyrosyl group of either free L-tyrosine or the cyclic dipeptide cyclo-L-Ser-L-Tyr (c-SY) 
(Scheme 1.3). Pedras and Yu recently completed an isotopic feeding experiment, 
utilizing tritium-labeled biosynthetic intermediates to determine incorporation into 
sirodesmin PL. L-Tyrosine and O-prenyl-L-tyrosine were efficiently incorporated into 
phomamide and sirodesmin PL, while was not.68 This suggested that the SirD-mediated 
prenylation of L-tyrosine is the first committed step in sirodesmin PL biosynthesis.
A BLAST69 search reveals that SirD is a member of the aromatic 
prenyltransferase/DMATS superfamily. 7-DMATS from A. fumigatus, 35% identity, is 
the closest relative to SirD studied to-date. Alignments with other relevant DMATS 
report the following sequence identities: 31% with FgaPT2 from A. fumigatus, 27% with
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4-DMATS from C. purpurea, and 27% with CTrpPT from A. oryzae DSM1147. A 
putative SirD from Sirodesmium diversum, 87% identity, is the nearest known relative of 
L. maculans SirD, however the C-terminus is truncated by 165 residues compared to L. 
maculans SirD.
The mechanism proposed for prenylation by DMATSs is a dissociative 
electrophilic alkylation of the indole ring by DMAPP where cleavage of the carbon- 
oxygen bond in DMAPP gives a dimethylallyl cation-PPi ion pair, with subsequent 
alkylation of the indole moiety, followed by loss of a proton to give the prenylated 
product.80,131 Due to the dissociative electrophilic nature of these enzymes, many
81,132,133aromatic prenyltransferases demonstrate relaxed aromatic substrate specificity. Of
particular interest to this chapter are the indole prenyltransferases 7-DMATS and 
CTrpPT. 7-DMATS from A. fumigatus was cloned, expressed, and reported to prenylate 
the C7 position of tryptophan’s indole ring in a normal orientation.76 7-DMATS 
displayed the ability to prenylate free L- and D-tryptophan (15.5% relative activity to L- 
tryptophan), as well as the linear (10.9%) and cyclic (1.8%) L-Trp-L-Gly dipeptide. 7- 
DMATS showed no prenylation product when incubated with L-tyrosine.76 CTrpPT from 
Aspergillus oryzae DSM1147 was shown to prenylate two different sites on the indole 
ring of certain L-tryptophan-containing cyclic dipeptides.77 This enzyme, which shares an 
identity of 28% with 7-DMATS, catalyzes either normal prenylation at C7 or reverse 
prenylation at N1. CTrpPT is the first enzyme known to simultaneously prenylate both 
the C7 and N1 positions of an indole ring.
Given the promiscuous nature of aromatic prenyltransferases, we hypothesized 
SirD may also accept and prenylate tyrosine, phenylalanine and tryptophan derivatives.
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In this chapter, we report the cloning, expression, purification and biochemical 
characterization of SirD, including the determination of its natural substrates and its 
ability to prenylate a variety of substituted aromatic amino acids. During the course of 
our investigations, two studies were published reporting a few of the experiments and 
results reported in this chapter.134,135 Where relevant, comparisons and contrasts between 
our data and the published results will be addressed.
Experim ental Procedures 
General
NMR experiments were recorded on an INOVA 600 NMR spectrometer equipped 
with a HCN cryogenic probe and spectra were processed with MestReNova 7.1. All 
chemical shifts and coupling constants are reported in parts per million (ppm) and hertz 
(Hz), respectively. 1H chemical shifts are referenced relative to the following peaks: 
DMSO-d6 at 2.50 ppm (center peak) or DSS at 0.00 ppm. 13C chemical shifts are 
referenced relative to the following peaks: DMSO-d6 at 39.51 (center peak) or DSS at 
0.00 ppm. 15N chemical shifts are referenced relative to liquid ammonia in D2O at 6 0.0 
ppm. HPLC was conducted on a Waters 2690 Separation Module equipped with a 
Microsorb MVtm C18 5 ^m column and a Waters 996 photodiode array detector. 
Normal phase thin layer chromatography (TLC) was carried out on silica gel 60 glass- 
backed plates (Merck). Reverse phase TLC was carried out on either C8 glass-backed 
plates (Silicycle) or C18 glass-backed plates with a concentrating zone (Merck). Mass 
spectrometry was performed by Dr. James Muller at the Chemistry Department Mass 




All compounds were obtained from Sigma-Aldrich unless otherwise noted. The 
following compounds were purchased from the companies indicated: L-tyrosine 
[14C(U)], DMAPP triammonium salt [1-14C], IPP triammonium salt [1-14C] (American 
Radiolabeled Chemicals, Inc.); and ampicillin (Roche). Deuterated solvents were 
purchased from Cambridge Isotope Laboratories, Inc. E. coli IDI-1 was provided by Dr. 
Jonathan Johnston. 2-Oxo-L-tryptophan was supplied by Dr. Raj Viswanathan.
Leptosphaeria maculans and Sirodesmium diversum sirD Gene 
Design and Cloning
The L. macalam sirD gene (NCBI GenBank: AY553235.1) was optimized for 
heterologous expression in E. coli and synthesized by Genscript. The gene (Figure 3.1) 
was engineered with 5’-BamHI and 3’-Hindlll endonuclease restriction sites, an TV- 
terminal histidine tag, and a thrombin cleavage site and placed in the pUC57 vector. The 
modified L. macalam sirD gene in pUC57 and the destination vector pET21a(+) were 
digested with BamHI and Hindlll endonucleases (New England Biolabs, Inc.) as per the 
manufacturer’s instructions. After purification by agarose gel electrophoresis, the sirD 
gene was ligated with T4 DNA Ligase (NEB) into the cut pET-21a(+) vector to produce
sirD
BamHI MGSS SSG linker 
linker
H linker Hindlll
Figure 3.1. The engineered sirD gene constructs synthesized by Genscript.
pLmSirD. pLmSirD was transformed into E. coli DH5a (Invitrogen) for plasmid 
isolation and DNA sequencing and into E. coli BL21 (DE3) (Stratagene) for expression. 
Both E. coli strains were grown in liquid LB broth or on solid LB-agar medium at 37 °C. 
Ampicillin (50 p,g mL-1) was used to select vector-containing E. coli DH5a and BL21 
(DE3) strains.
A putative S. diversum sirD gene (AY571972.1) was designed, optimized, 
synthesized and cloned as described above to produce pSdSirD.
Production and Purification of L. maculans SirD
The pLmSirD-BL21 (DE3) cultures were cultivated in 1 L of LB broth containing 
ampicillin (50 p,g mL-1) at 37 °C with shaking at 225 rpm until an OD600 of 0.6 was 
reached. The culture was induced with IPTG to a final concentration of 0.6 mM. After 5 
h, cells were harvested by centrifugation (4000 x g, 20 min, 4 °C). Pelleted cells were 
resuspended in lysis buffer (50 mM NaH2PO4, pH 8.0, containing 300 mM NaCl and 10 
mM imidazole) containing 1 mg mL-1 lysozyme and 10 ^g mL-1 RNase A. After 
incubation at 0 °C for 30 min, the cell suspension was sonicated for 6 x 10 s at 4 °C. The 
lysate was clarified by centrifugation (10,000 x g, 20 min, 4 °C). The recombinant 
protein was purified by nickel affinity chromatography (GE Healthcare HisTrap HP) 
following the manufacturer’s instructions. L. maculans SirD was eluted with a gradient 
of 0 -  100% of lysis buffer/elution buffer (50 mM NaH2PO4, pH 8.0, containing 300 mM 
NaCl and 500 mM imidazole). The purified protein was dialyzed 2 x against 4 L of 
dialysis buffer (20 mM Tris-HCl, pH 8.0, containing 1 mM PME), then 1 x against 4 L of 
dialysis buffer containing 20% glycerol. The protein concentration was measured using
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the Pierce® BCA Protein Assay Kit (Thermo Scientific), divided into 100 ^L portions, 
flash frozen with liquid nitrogen, and stored at -80 °C until use.
Production and Purification of S. diversum SirD
The pSdSirD-BL21 (DE3) cultures were cultivated and expressed as described 
above, but the expressed protein was insoluble. Therefore, the following insolubility 
troubleshooting procedures were tried: 1) protein denaturation/refolding and 2 ) 
coexpression with pGroES/EL.
1) After cell lysis, the pelleted insoluble cellular material was resuspended in urea 
lysis buffer (100 mM NaH2PO4, pH 8.0, containing 10 mM TrisHCl and 8 M urea) with 
shaking at 100 rpm for 30 min at rt. The suspension was centrifuged (10,000 x g, 20 min, 
rt) and the resulting lysate was shaken with 2.75 mL Ni-NTA slurry (Qiagen) for 60 min 
at rt. The lysate-resin was loaded onto a column, the flow-through was collected, and the 
resin was washed/eluted successively with 4 mL of urea buffer C (100 mM NaH2PO4, pH
6.3, containing 10 mM TrisHCl and 8 M urea), urea buffer D (100 mM NaH2PO4, pH 5.9, 
containing 10 mM TrisHCl and 8 M urea), and urea buffer E (100 mM NaH2PO4, pH 4.5, 
containing 10 mM TrisHCl and 8 M urea). Purified protein was successively dialyzed 
against 2 L each of urea dialysis buffer A (20 mM Tris-HCl, pH 8.0, containing 1 mM 
PME and 4 M urea), urea dialysis buffer B (20 mM Tris-HCl, pH 8.0, containing 1 mM 
PME, and 2 M urea), urea dialysis buffer C (20 mM Tris-HCl, pH 8.0, containing 1 mM 
PME and 1 M urea), and urea dialysis buffer D (20 mM Tris-HCl, pH 8.0, containing 1 
mM PME and 20% glycerol).
2) The plasmids pSdSirD and pGroESL were co-transformed into BL21 Star™ 
(DE3) cells (Stratagene) following the manufacturer’s instructions. Plasmid pGroESL, a
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construct containing the E. coli groE operon136 was obtained from Anthony Gatenby. 
The cultures were cultivated in 1 L of LB broth containing ampicillin (50 p,g mL-1) and 
chloramphenicol (34 p,g mL-1) at 37 °C with shaking at 225 rpm until an OD600 of 0.6 was 
reached. Protein expression was induced with IPTG to a final concentration of 0.5 mM 
and the culture was cultivated for 4 h. The cell lysis and protein purification procedures 
were the same as described for L. maculans SirD.
Crystallization Studies of L. maculans SirD
L. maculans SirD was expressed and purified as described above. Purified L. 
maculans SirD was incubated with 6 units (5 ^L) of thrombin (Novagen) at rt for 16 h. 
The reaction mixture was concentrated to 0.5 mL with a 10 kDa MWCO filter and 
injected onto a gel filtration column packed with HiLoad Superdex 200 (GE Life 
Sciences). Thrombin-digested L. maculans SirD was purified from thrombin, the cleaved 
^-terminal peptide, and other impurities by elution with 50 mM HEPES, pH 7.5, 
containing 150 mM NaCl and 1 mM PME. Fractions containing SirD were pooled and 
concentrated to 9.7 mg/mL. MgCl2 was added to a final concentration of 5 mM and the 
protein was set in crystallization trays. Crystals appeared after 9 days at rt and promising 
crystals were looped, placed in the corresponding buffer containing 30% glycerol, and 
flash frozen by plunging into liquid nitrogen. The following crystals/buffer conditions 
were mounted and irradiated by Mark Mabanglo in Dr. Chris Hill’s laboratory at the 
Department of Biochemistry, University of Utah: JENA D3, PACT H3a, PACT H3b, 
PACT H4. Additional crystallization conditions were tested (data not shown), however 
at best, the results were similar.
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Com putational S tructure Studies of L. maculans SirD
The secondary structure of L. maculans SirD was predicted from the amino acid 
sequence using the Advanced Protein Secondary Structure Prediction (APSSP) Server.137 
Each residue was assigned as a helix, strand, or coil along with a probability value for 
correct prediction. Residues predicted to be in a helix or strand of < 2 consecutive 
residues were ignored. Combining a primary sequence alignment138 with the secondary 
structure prediction for SirD and the secondary structure acquired from the crystal 
structure of FgaPT2 (4-DMATS from A. fumigatus),59 both the amino acid sequences and 
the secondary structures of L. maculans SirD and the known aPPa prenyltransferase 
FgaPT2 were compared.
Using MODELLER 9v7,139 a homology model of SirD was created based on the 
FgaPT2 crystal structure. In order to model tyrosine into the active site in place of 
tryptophan, the following changes were implemented: 1) deletion of the indole ring side 
chain from the tryptophan substrate in the FgaPT2 crystal structure while leaving the 
amino acid moiety intact, 2 ) construction of a phenol ring side chain and attachment to 
the remaining amino acid moiety, and 3) energy minimization of the SirD homology 
model with the new tyrosine substrate.
N atural Substrate Studies
The assay for determining the natural substrates of SirD was conducted in 37 mM 
Tris-HCl buffer, pH 7.4, containing 14.8 mM MgCl2, 1.1 mM DTT, 0.74 mg/mL BSA, 
148 mM KCl, 310 ^M 14C-IPP (2.4 mCi/mmol), 1.5 mM of the aromatic substrate, 5.5 
^M IDI-1, and 340 nM SirD in a total volume of 135 ^L. The negative control reactions 
were incubated in the absence of IDI-1. Each reaction mixture was incubated at 37 °C
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for 30 min. After incubation, 4 ^L of the assay mixture were spotted and developed by 
TLC. For normal phase TLC, a solvent system of 1:9 acetic acid/EtOH was used to 
develop the plate. The developed TLC plates were imaged on a storage phosphor screen 
(Molecular Dynamics) and scanned by a Typhoon 8600 Variable Mode Imager (GE 
Healthcare). The data was visualized and processed with ImageQuant 5.2.
Divalent Cation Studies
The assay was conducted in 50 mM Tris-HCl buffer, pH 8.0, containing 10 mM 
MgCl2, 0.1 mg/mL BSA, 10 mM KCl, 436 ^M 14C-IPP (3.4 mCi/mmol), 4 mM L- 
tyrosine, 7.5 ^M IDI-1, and 500 nM SirD in a total volume of 100 ^L. The negative 
control reaction was incubated in the absence of IDI-1. Each reaction mixture was 
incubated at 37 °C for 30 min. After incubation, a 3 ^L portion of assay mixture was 
spotted and developed by TLC. TLC development and data visualization was performed 
as described above.
O-Dimethylallyl-L-tyrosine Stability Studies
The HPLC assay used to determine the stability of O-dimethylallyl-L-tyrosine 
toward quenching conditions was performed on a C18 column with gradient elution using 
98:2 H2O/ACN to 90:10 in 5 min, to 50:50 in 20 min, to 2:98 in 5 min. The total elution 
volume was 30 mL at a flow rate of 1.0 mL/min. The eluant was monitored at 273.6 nm 
and product ratios were determined by peak integration. Five minutes before sample 
injection, 50 ^L of O-dimethylallyl-L-tyrosine (7) and L-tyrosine dissolved in H2O 
(unknown concentrations) were added to 50 uL of unbuffered H2O, 1.5 M trichloroacetic
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acid (TCA), or MeOH. After 5 min incubation at rt, each “quenched” mixture was 
injected for analysis by HPLC.
Therm al Stability Studies
The assay for determining thermal stability was conducted in 20 mM Tris-HCl 
buffer, pH 8.0, containing 1 mM 14C-L-tyrosine (4 mCi/mmol), 1 mM DMAPP, and 300 
(100 for 37 °C) nM SirD in a total volume of 50 ^L. The negative control was incubated 
in the absence of SirD for 2.5 h. Each reaction mixture was incubated at rt, 30 or 37 °C 
prior to initiation by the addition of DMAPP. For 37 °C, the pre-incubations were 0, 20, 
40, 60, 90 and 120 min and the reaction time was 30 min. For rt and 30 °C, the pre­
incubations were 0, 10, 20, 30, 60 and 90 min and the reaction times were 10 and 15 min 
for 30 °C and rt, respectively. The assay was quenched by plunging the sample into a 
boiling water bath for 15 s. A 10 uL portion was spotted on a C18 RP-TLC plate, which 
was developed with 25:75 H2O/MeOH. Data visualization and processing was performed 
as described above.
Promiscuity Studies
The assays for detecting the promiscuity of aromatic substrates were conducted in 
50 mM Tris-HCl buffer, pH 8.0, containing 10 mM MgCl2, 0.1 mg/mL BSA, 10 mM 
KCl, 1 mM 14C-IPP (0.44-1 mCi/mmol), 1-10 mM of aromatic substrate, ~2 ^M IDI-1, 
and 240-713 nM SirD in a total volume of 50 ^L. For thioanalogue assays, 20 mM PME 
was included. Typically, each reaction mixture was incubated at 30 °C for 1 h and 20 h. 
After incubation, a 10 ^L portion of the assay mixtures was spotted and developed by 
TLC. For normal phase TLC, a solvent system of 1:9 acetic acid/EtOH or 2:8 H2O/ACN
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was used to develop the plate. Reverse phase C18-TLC and data visualization/processing 
was performed as previously described.
Kinetic Studies
All kinetic assays were performed in a total volume of 100 ^L, incubated at 30 °C 
for 10 min unless otherwise noted, and quenched by heating at 100 °C for 30 s. After 
centrifugation, a 10 portion of the reaction mixture was spotted and developed by RP- 
TLC. For L-tyrosine/DMAPP assays, RP-C18 plates were used with a solvent system of 
25:75 H2O/MeOH. For assays with 4-mercapto-L-phenylalanine and tryptophan 
derivatives, RP-C8 plates were used with a solvent system of 4:6 25 mM 
NH4HCO3/MeOH. Visualization/processing of TLC plates was peformed as previously 
described. Background radioactivity was determined from incubations without the 
aromatic substrate. Each kinetic assay was performed in triplicate or quadruplicate.
For L-tyrosine, the assays were conducted in 20 mM Tris-HCl buffer, pH 8.0, 
containing 80 nM SirD, 1 mM DMAPP, 0.1 p,Ci of 14C-L-tyrosine, and total L-tyrosine 
concentrations of 0.04, 0.05, 0.07, 0.08, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35 and 0.4 mM. For 
DMAPP, the assay was conducted in 20 mM Tris-HCl buffer, pH 8.0, containing 50 nM 
SirD, 0.5 mM L-tyrosine, 0.05 p,Ci of 14C-L-tyrosine, and DMAPP concentrations of 0, 
0.04, 0.05, 0.06, 0.08, 0.1, 0.15, 0.2, 0.25, 0.3, 0.4 and 0.5 mM. For 4-mercapto-L- 
phenylalanine, the assay was conducted in 100 mM Tris-HCl buffer, pH 8.0, containing
10 mM PME, 2% v/v glycerol, 5 ^M SirD, 1 mM DMAPP, 0.1 ^Ci of 14C-DMAPP, and
4-mercapto-L-phenylalanine concentrations of 0.25, 0.5, 0.75, 1, 2.5, 5, 7.5 and 10 mM 
with 30 min incubations. For L-tryptophan, the assay was conducted in 100 mM Tris- 
HCl buffer, pH 8.0, containing 2% v/v glycerol, 5 ^M SirD, 1 mM DMAPP, 0.1 p,Ci of
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14C-DMAPP, and tryptophan concentrations of 0.1, 0.2, 0.3, 0.6, and 1 mM with 20 min 
incubations. For 4-methoxy and 7-methyltryptophan, concentrations were 0.3, 0.6, 1, 2, 3, 
4, 6 , and 10 mM with 30 min incubations.
Product Studies
Incubations with tyrosine were conducted in 50 mM Tris-HCl buffer, pH 8.0, 
containing 2 mM DMAPP, 5 mM L-tyrosine and 2.11 ^M SirD in a total volume of 3 
mL. The glycerol present in the dialysis buffer was removed by repetitive 
dialysis/centrifugation using a 10 kDa MWCO filter. The reaction mixture was incubated 
at 30 °C for 21 h. SirD was removed by centrifugation through a 10 kDa MWCO 
membrane and the products were purified by chromatography on a C18 RP-HPLC 
column at a flow rate of 1 mL/min with isocratic elution using ACN:H2O (25/75). 
Products were detected by monitoring the UV absorbance at 273.6 nm.
Incubations with thiotyrosine were identical to above with the following 
differences: 5 mM MgCl2, 20 mM PME, 5 mM DMAPP, 10 mM 4-mercapto-L- 
phenylalanine and 14.5 ^M SirD in a total volume of 5 mL. Products were detected by 
their absorbance at 254 nm.
Incubations with tryptophan derivatives were identical to above with the 
following differences: 10 mM MgCl2, 2.92 mM DMAPP, 20 mM tryptophan analogue, 5 
^M SirD in a total volume of 5 mL. No PME was included as no thiols were needed to 
be reduced. The reaction mixtures were incubated for 21-42 h and the products were 
detected at 225 nm, except for 4-vinyltryptophan (26), which was detected at 220 nm. 
Product ratios were calculated by integrating the area under each product peak visualized 
at 220 nm (4-vinyl/4-methoxy) or 225 nm (tryptophan/4-methyl/7-methyl).
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Structure of Prenylated A rom atic Products
After purification of the prenylated product(s), each product was lyophilized, 
dissolved in DMSO-d6 (D, 99.96%) or D2O (D, 99.96%) (Cambridge Isotope 
Laboratories, Inc.) and placed in a Norell 3 mm NMR tube (Sigma). Unless noted, the 
following NMR experiments were performed: 1D 1H, COSY 1H -1H, TOCSY 1H -1H, 
ROESY 1H -1H, HSQC or HMQC 1H-13C, HMBC 1H -13C, and HMBC 1H -15N. All 
spectra were processed with MestReNova 7.1.
O-Dimethylallyl-L-tyrosine (30)
1H NMR (500 MHz, D2O/NaOD, DSS) 5 1.74 (s, 3H), 1.78 (s, 3H), 2.77 (dd, J  =
7.0, 13.5 Hz, 1H), 2.92 (dd, J  = 5.5, 14.0 Hz, 1H), 3.44 (dd, J  = 5.5, 7.5 Hz, 1H), 4.59 (d, 
J  = 7.0 Hz, 2H), 5.50 (t, J  = 7.0 Hz, 1H), 6.96 (d, J  = 8.5 Hz, 2H), 7.19 (d, J  = 8.5 Hz, 
2H); 1H NMR (500 MHz, DMSO-d6) 5 1.69 (s, 3H), 1.73 (s, 3H), 2.77 (dd, J  = 8.0, 14.5 
Hz, 1H), 3.05 (dd, J  = 4.0, 14.5 Hz, 1H), 4.48 (d, J  = 6.5 Hz, 2H), 5.41 (t, J  = 7.0 Hz, 
1H), 6.83 (d, J  = 8.5 Hz, 2H), 7.15 (d, J  = 8.0 Hz, 2H); UV (ACN:H2O 1:3) Xmax 223.8, 
273.6 nm; HRMS-ESI TOF m/z [M + Na]+ calcd for C14H 19NO3N  272.1263, found 
272.1257.
S-Dimethylallyl-4-thio-L-phenylalanine (31)
1H NMR (600 MHz, DMSO-d6) 5 1.58 (s, 3H), 1.66 (s, 3H), 2.58-2.68 (m, 1H), 
2.99 (d, J  = 11.4 Hz, 1H), 3.24 (m, 2H), 3.55 (d, J  = 7.8 Hz, 2H), 5.24 (t, J  = 7.2 Hz, 1H),
7.14 (d, J  = 7.2 Hz, 2H), 7.19 (d, J  = 7.8 Hz, 2H); 13C NMR (150 MHz, DMSO-d6) 5
17.3, 25.1, 30.9, 32.1, 56.7, 119.2, 128.2, 129.5, 133.1, 135.5, 137.4; UV (ACN :H2O 1:3)
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Xmax 257.0 nm; HRMS-ESI TOF m/z [M + Na]+ calcd for C14H wNO2NaS 288.1034, 
found 288.1041.
N1-(3-M ethylbut-1-en-3-yl)-L-tryptophan (32, Reverse N-Di- 
methylallyl-L-tryptophan)
1H NMR (600 MHz, D2O) 5 1.62 (s, 6H), 3.06 (dd, J  = 7.8, 15.0 Hz, 1H), 3.24 
(dd, J  = 4.8, 15.0 Hz, 1H), 3.75 (t, J  = 6.6 Hz, 1H), 5.02 (d, J  = 17.4 Hz, 1H), 5.11 (d, J  =
10.8 Hz, 1H), 6.03 (dd, J  = 10.8, 17.4 Hz, 1H), 7.05 (t, J  = 7.2 Hz, 1H), 7.09 (t, J  = 7.8 
Hz, 1H), 7.33 (s, 1H), 7.54 (d, J  = 8.4 Hz, 1H), 7.60 (d, J  = 7.8 Hz, 1H); 13C NMR (150 
MHz, D2O) 5 29.6, 30.3, 57.9, 128.5; UV (ACN:H2O 1:3) Xmax 222.7, 284.3 nm; HRMS- 
ESI TOF m/z [M + Na]+ calcd for C16H20N2O2N  295.1422, found 295.1428.
7-(2-Methylbut-2-en-4-yl)-L-tryptophan (33, Normal 7-Di- 
methylallyl-L-tryptophan)
1H N M R  (600 MHz, D2O) 5 1.61 (s, 3H), 1.64 (s, 3H), 3.10 (dd, J  = 7.8, 15.0 Hz, 
1H), 3.29 (dd, J  = 4.8, 15.6 Hz, 1H), 3.47 (d, J  = 7.2 Hz, 2H), 3.83 (dd, J  = 4.8, 7.8 Hz, 
1H), 5.36 (d, J  = 7.8 Hz, 1H), 6.98 (d, J  = 6.6 Hz, 1H), 7.01 (t, J  = 7.2 Hz, 1H), 7.16 (s, 
1H), 7.45 (d, J  = 7.2 Hz, 1H); 13C NMR (150 MHz, D2O) 5 19.7, 27.4, 29.7, 31.8, 57.9,
111.3, 118.9, 122.3, 123.6, 123.8, 127.1, 128.1, 129.5, 137.8, 138.3; UV (ACN:H2O 1:3) 
Xmax 221.5, 277.2, 287.9 nm; HRMS-ESI TOF m/z [M + H]+ calcd for C16H21N 2O2 
273.1603, found 273.1609.
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N1-(3-Methylbut-1-en-3-yl)-4-methyl-L-tryptophan (34, Reverse 
N-Dimethylallyl-4-methyl-L-tryptophan)
1H NMR (600 MHz, D2O) 5 1.60 (s, 3H), 1.61 (s, 3H), 2.58 (s, 3H), 3.03 (dd, J  =
9.0, 15.6 Hz, 1H), 3.48 (dd, J  = 5.4, 15.6 Hz, 1H), 3.68 (dd, J  = 5.4, 9.0 Hz, 1H), 5.00 (d, 
J  = 17.4 Hz, 1H), 5.09 (d, J  = 10.8 Hz, 1H), 6.01 (dd, J  = 10.8, 18.0 Hz, 1H), 6.79 (d, J  = 
7.2 Hz, 1H), 6.96 (t, J  = 7.2 Hz, 1H), 7.30 (s, 1H), 7.38 (d, J  = 8.4 Hz, 1H); 13C NMR 
(150 MHz, D2O) 5 22.2, 29.8, 32.3, 59.6, 61.8, 110.7, 115.2, 116.1, 123.5, 123.8, 128.8,
129.3, 133.7, 138.3, 146.6, 179.5; 15N NMR (60.8 MHz, D2O) 5 27.9, 145.9; UV 
(ACN:H2O 1:3) Xmax 225.0, 285.5, 295.0 nm; HRMS-ESI TOF m/z [M + H]+ calcd for 
C17H23N2O2 287.1760, found 287.1762.
4-Methyl-7-(2-methylbut-2-en-4-yl)-L-tryptophan (35, Normal 
7-Dimethylallyl-4-methyl-L-tryptophan)
1H NMR (600 MHz, D2O) 5 1.61 (s, 3H), 1.63 (s, 3H), 2.56 (s, 3H), 3.06 (dd, J  =
10.8, 16.2 Hz, 1H), 3.47-3.51 (m, 2H), 3.53-3.59 (m, 1H), 3.74-3.79 (m, 1H), 5.33 (d, J  =
6.0 Hz, 1H), 6.75 (d, J  = 7.2 Hz, 1H), 6.86 (t, J  = 7.2 Hz, 1H), 7.14 (s, 1H); 13C NMR 
(150 MHz, D2O) 5 19.5, 21.7, 27.3, 31.4, 59.1, 94.6, 123.8, 123.9, 125.6, 127.4, 127.5,
131.0, 137.7, 138.3; UV (ACN:H2O 1:3) Xmax 222.7, 270.0, 290.3, 295.0 nm; HRMS-ESI 
TOF m/z [M + H]+ calcd for C17H23N2O2 287.1760, found 287.1763.
4-M ethoxy-7-(3-methylbut-1-en-3-yl)-L-tryptophan (36, Reverse 
7-Dimethylallyl-4-methoxy-L-tryptophan)
1H NMR (600 MHz, D2O) 5 1.35 (s, 6H), 3.02 (dd, J  = 8.4, 15.0 Hz, 1H), 3.48 
(dd, J  = 3.6, 15.0 Hz, 1H), 3.84 (s, 3H), 3.88 (dd, J  = 3.6, 7.8 Hz, 1H), 4.98 (d, J  = 17.4
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Hz, 1H), 5.03 (d, J  = 10.8 Hz, 1H), 6.00 (dd, J  = 10.8, 17.4 Hz, 1H), 6.55 (d, J  = 8.4 Hz, 
1H), 6.97 (s, 1H), 7.06 (d, J  = 7.8 Hz, 1H); 13C NMR (150 MHz, D2O) 5 29.4, 33.5, 42.0,
57.8, 102.2, 114.4, 119.6, 126.1, 127.8, 149.8; UV (ACN:H2O 1:3) Xmax 220.3, 266.5,
280.7, 291.5 nm; HRMS-ESI TOF m/z [M + Na]+ calcd for C1yH22N2O3Na 325.1528, 
found 325.1532.
4-M ethoxy-7-(2-methylbut-2-en-4-yl)-L-tryptophan (37, Normal 
7-Dimethylallyl-4-methoxy-L-tryptophan)
1H NMR (600 MHz, D2O) 5 1.59 (s, 3H), 1.60 (s, 3H), 3.02 (dd, J  =8.4, 15.0 Hz, 
1H), 3.35-3.37 (m, 2H), 3.42 (dd, J  = 4.2, 15.0 Hz, 1H), 3.80 (s, 3H), 3.85 (dd, J  = 4.8,
8.4 Hz, 1H), 5.30 (t, J  = 6.6 Hz, 1H), 6.47 (d, J  = 7.8 Hz, 1H), 6.84 (t, J  = 7.8 Hz, 1H),
7.00 (s, 1H); 13C NMR (150 MHz, D2O) 5 19.7, 27.5, 31.2, 31.5, 57.8, 59.2, 102.6, 119.3,
121.5, 124.0, 126.5, 137.5, 139.1, 154.7; UV (ACN:H2O 1:3) Xmax 220.3, 266.5, 281.9, 
291.5 nm; HRMS-ESI TOF m/z [M + Na]+ calcd for C1yH22N2O3Na 325.1528, found 
325.1532.
N1-(3-Methylbut-1-en-3-yl)-7-methyl-L-tryptophan (38, Reverse 
N-Dimethylallyl-7-methyl-L-tryptophan)
1H NMR (600 MHz, D2O) 5 1.64 (s, 6H), 2.54 (s, 3H), 2.97-3.04 (m, 1H), 3.17­
3.23 (m, 1H), 3.66-3.72 (m, 1H), 4.49 (d, J  = 17.4 Hz, 1H), 4.94 (d, J  = 10.8 Hz, 1H), 
6.30 (dd, J  = 10.8, 17.4 Hz, 1H), 6.96 (d, J  = 6.6 Hz, 1H), 7.00 (t, J  = 7.8 Hz, 1H), 7.43 
(s, 1H), 7.46 (d, J  = 7.8 Hz, 1H); 13C NMR (150 MHz, D2O) 5 26.6, 34.3, 35.1, 58.2,
62.5, 109.5, 114.7, 119.1, 122.5, 125.5, 128.5, 130.3, 133.3, 137.2, 150.0; UV (ACN:H2O
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1H NMR (600 MHz, D2O) 5 1.69 (s, 3H), 1.77 (s, 3H), 2.42 (s, 3H), 3.16 (dd, J  =
7.8, 15.0 Hz, 1H), 3.36 (dd, J  = 3.6, 15.0 Hz, 1H), 3.46 (d, J  = 7.2 Hz, 2H), 3.84 (dd, J  = 
3.6, 12.0 Hz, 1H), 5.32 (t, J  = 7.2 Hz, 1H), 7.03 (d, J  = 7.8 Hz, 1H), 7.23 (s, 1H), 7.48 (d, 
J  = 7.8 Hz, 1H); 13C NMR (150 MHz, D2O) 5 14.7, 19.7, 27.5, 33.8, 57.9, 118.4, 121.6,
125.8, 135.8; UV (ACN:H2O 1:3) Xmax 222.7, 271.2, 278.4, 295.0 nm; HRMS-ESI TOF 
m/z [M + Na]+ calcd for C17H22N 2O2N  309.1579, found 309.1576.
Timecourse Studies
The assay for time-dependent product formation was conducted in 50 mM Tris- 
HCl buffer, pH 8.0, containing 10 mM MgCl2, 2.92 mM DMAPP, 20 mM of tryptophan 
analogue, and 4.7 ^M SirD in a total volume of 4 mL. The reaction mixture was 
incubated at 30 °C. At 1, 2, 3, 5, 10, 15, 30, 60, 120, 240, 360, 480 and 1440 min, 200 
^L samples were taken and the enzyme was removed by centrifugation through a 10 kDa 
MWCO membrane. The filtrates were analyzed by C18 RP-HPLC as described above 
for product isolation. Products were detected and quantified at 225 nm.
R earrangem ent Studies
The assay for the detection of prenyl rearrangement was conducted in 50 mM 
Tris-HCl buffer, pH 8.0, containing 10 mM MgCl2, 4.7 ^M SirD, and an unknown 
concentration of 34 and 35 in a total volume of 0.5 mL. Additional assays included 2.92
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mM DMAPP or 2.92 mM PPi. The control reaction was incubated in the absence of 
SirD. The reaction mixture was incubated at 30 °C for 18 h. After protein removal by 10 
kDa MWCO filtering, the filtrates were analyzed by C18 RP-HPLC as described above. 
Products were detected and quantified at 225 nm.
Results and Discussion 
pLm SirD and pSdSirD Plasmid Engineering, Expression 
and Purification
Two plasmids were constructed for overexpression of SirD (Genscript). pLmSirD 
contained a sirD gene from Leptosphaeria maculans optimized for E. coli expression 
(Figure 3.2), while pSdSirD contained an optimized sirD gene from Sirodesmium 
diversum (Figure 3.3). The fidelity of both genes were confirmed by DNA sequencing 
(University of Utah DNA Sequencing Core Facility) and both genes encoded the NCBI 
reported protein sequences for L. maculans SirD (AAS92554.1) and S. diversum SirD 
(AAT69743.1).
L. maculans SirD and S. diversum SirD were overexpressed in E. coli BL21 
(DE3). SDS-PAGE of L. maculans SirD gave a strong band for a soluble protein at ~55 
kDa (Figure 3.4), in agreement with the calculated molecular weight of 54,501.8 Da. An 
electrospray mass spectrum of L. maculans SirD gave a molecular weight of 54611.4 Da. 
SDS-PAGE of the pellet from the induced S. diversum SirD culture showed a band at ~38 
kDa (data not shown). While in agreement with the calculated molecular weight of
35,617.4 Da, S. diversum SirD was insoluble. Two procedures were used in an attempt to 
solubilize the S. diversum SirD protein. First, after cell lysis, the insoluble cellular 
material was resuspended in a buffer containing 8 M urea, to unfold and solubilize the
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1 M G S S H H H H H H S S G L V P R G
1 GGATCCATGGGCAGCAGCCATCATCATCATCATCATAGCAGCGGCCTGGTGCCGCGTGGC
21 S H M Q T A R L F Q G N L N L A A A N I
61 AGCCATATGCAGACCGCGCGTCTGTTTCAGGGCAACCTGAACCTGGCGGCGGCGAACATT
41 R D Y E K K E Q R N L G V W L S L N Q W
121 CGTGATTATGAGAAGAAAGAACAGCGTAACCTGGGCGTGTGGCTGAGCCTGAACCAGTGG
61 L R L Y D E D T R F W W T T T A P M L G
181 CTGCGTCTGTATGATGAAGATACCCGTTTTTGGTGGACCACCACCGCGCCGATGCTGGGC
81 R M M E L I G Y D Q D A Q Q K H L L F Y
241 CGTATGATGGAACTGATTGGCTATGATCAGGATGCGCAGCAGAAACATCTGCTGTTTTAT
101 Y I Y V L P S L G R R P S P E G Y P T G
301 TATATTTATGTGCTGCCGAGCCTGGGCCGTCGTCCGAGCCCGGAAGGTTATCCGACCGGT
121 W N S F M T D D Y S P L E L S W D W G V
361 TGGAACAGCTTCATGACCGATGATTATAGCCCGCTGGAACTGAGCTGGGATTGGGGCGTG
141 A E G E S S V R F S I E P I G K Y A G T
421 GCGGAAGGCGAAAGCAGCGTGCGTTTTAGCATTGAACCGATTGGCAAATATGCGGGCACC
161 Q A D P L N Q K M V Y Q L V D G L R P A
481 CAGGCAGATCCACTGAACCAGAAAATGGTGTATCAGCTGGTTGATGGCCTGCGTCCGGCG
181 F H H T L D L T L F D V F S E A L T T S
541 TTTCATCATACCCTGGATCTGACCCTGTTTGATGTGTTTAGCGAAGCGCTGACCACCAGC
201 R E K F G T R K L S L E G R S Q Y F V A
601 CGTGAAAAATTTGGCACCCGTAAACTGAGCCTGGAAGGCCGTAGCCAGTATTTTGTGGCG
221 F D L D V G H P R L K A Y F M P G L K S
661 TTTGATCTGGATGTGGGCCATCCGCGTCTGAAAGCGTATTTTATGCCGGGCCTGAAAAGC
241 I E S N T P V S E L V V K A M D A C E L
721 ATTGAAAGCAACACCCCTGTGAGCGAACTGGTGGTGAAAGCGATGGATGCGTGCGAACTG
261 H F G S L F M Q A F R R L N S D L E A F
781 CATTTTGGCAGCCTGTTTATGCAGGCGTTTCGTCGTCTGAACAGCGATCTGGAAGCGTTT
281 S A T S Y H R P E I E I V G I D C V S P
841 AGCGCGACCAGCTATCATCGTCCGGAAATTGAAATTGTGGGCATTGATTGCGTGAGCCCG
301 V K S R A K I Y I R H R G T S F D S V C
9 01 GTGAAAAGCCGTGCGAAAATTTATATTCGTCATCGTGGCACCAGCTTTGATAGCGTGTGC
321 R M L S M G A K A P L D A A S V A S L R
961 CGTATGCTGAGCATGGGTGCAAAAGCACCGCTGGATGCAGCAAGCGTGGCGAGCCTGCGT
341 E L W A L V L G L P K D F P S D Q E L P
1021 GAACTGTGGGCACTGGTGCTGGGTCTGCCGAAAGATTTTCCGAGCGATCAGGAACTGCCG
361 S V P H R T S G V L Y Y F E I K P T S D
1081 AGCGTGCCGCATCGTACCAGCGGCGTGCTGTATTATTTTGAAATTAAACCGACCAGCGAT
381 A I V P K V Y I P V R H Y A S N D L S I
1141 GCGATTGTGCCGAAAGTGTATATTCCGGTGCGTCATTATGCGAGCAACGATCTGAGCATT
401 A Q G L A T Y F E R R G Q T V A A E N Y
1201 GCGCAGGGCCTGGCGACCTATTTTGAACGTCGTGGCCAGACCGTGGCGGCGGAAAACTAT
421 V D A L S D I F S H R S L D S G L G L H
1261 GTGGATGCGCTGAGCGATATTTTTAGCCATCGTAGCCTGGATAGCGGCCTGGGCCTGCAT
441 T Y I S C T F K K T G L S V T S Y F N P
1321 ACCTATATTAGCTGCACCTTTAAGAAAACCGGCCTGAGCGTGACCAGCTATTTTAACCCG
461 E I Y H P N R Y R Q -
1381 GAAATTTATCATCCGAACCGTTATCGTCAGTAAAAGCTT
Figure 3.2. L. maculans sirD engineered gene and encoded amino acid sequence.
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1 M G S S H H H H H H S S G L V P R G
1 GGATCCATGGGCAGCAGCCATCATCATCATCATCATAGCAGCGGCCTGGTGCCGCGTGGC
21 S H M Q T A R L F Q G N L N L A A A K P
61 AGCCATATGCAGACCGCGCGTCTGTTTCAGGGCAACCTGAACCTGGCGGCGGCGAAACCG
41 R E L E K N E Q G N L G V W L S L N Q W
121 CGTGAACTGGAAAAGAACGAACAGGGCAACCTGGGCGTGTGGCTGAGCCTGAACCAGTGG
61 L R L F D E D T R F W W V T T A P I L G
181 CTGCGTCTGTTTGATGAAGATACCCGTTTTTGGTGGGTGACCACCGCGCCGATTCTGGGC
81 R M M E L V G Y D Q D A Q Q K H L L F Y
2 41 CGTATGATGGAACTGGTGGGCTATGATCAGGATGCGCAGCAGAAACATCTGCTGTTTTAT
101 Y I Y V L P S L G R R P S P E G Y P T G
301 TATATTTATGTGCTGCCGAGCCTGGGCCGTCGTCCGAGCCCGGAAGGTTATCCGACCGGT
121 W N S F M T D D N S P L E L S W D W G I
361 TGGAACAGCTTCATGACCGATGATAACAGCCCGCTGGAACTGAGCTGGGATTGGGGCATT
141 A E G E S S V R F S I E P I G K Y A G T
421 GCGGAAGGCGAAAGCAGCGTGCGTTTTAGCATTGAACCGATTGGCAAATATGCGGGCACC
161 P A D P L N Q K M V F Q L V D G L R P A
481 CCGGCAGATCCACTGAACCAGAAAATGGTGTTTCAGCTGGTTGATGGCCTGCGTCCGGCG
181 F H H T L D L T V F D V F S E A L T T S
541 TTTCATCATACCCTGGATCTGACCGTGTTTGATGTGTTTAGCGAAGCGCTGACCACCAGC
201 R E K L D T R K I S V E G R S Q Y F V A
601 CGTGAAAAACTGGATACCCGTAAAATTAGCGTGGAAGGCCGTAGCCAGTATTTTGTGGCG
221 F D L D V G H P R L K A Y F M P G L K A
661 TTTGATCTGGATGTGGGCCATCCGCGTCTGAAAGCGTATTTTATGCCGGGCCTGAAAGCG
241 V E A N A S V F E L V V K A M D S C E V
721 GTGGAAGCGAACGCGAGCGTGTTTGAACTGGTGGTGAAAGCGATGGATAGCTGCGAAGTG
261 H F G P L F M Q A F R R F N S D L A T F
781 CATTTTGGCCCGCTGTTTATGCAGGCGTTTCGTCGTTTTAACAGCGATCTGGCGACCTTT
281 S A T S S D R P E V E I V G I D C V I P
841 AGCGCGACCAGCAGCGATCGTCCGGAAGTGGAAATTGTGGGCATTGATTGCGTGATTCCG
301 A K S R V -
901 GCGAAAAGCCGTGTGTAAAAGCTT
Figure 3.3. S. diversum sirD engineered gene and encoded amino acid sequence.
Figure 3.4. SDS-PAGE of pLmSirD expression in BL21 (DE3). Lane S, molecular 
weight standards; lane 1, pellet; lane 2, cell-free lysate; lane 3, HisTrap column 
flow-through; lanes 4 and 5, HisTrap column washes; lanes 6-10, HisTrap column 
elutions.
protein. The soluble portion was then purified under denaturing conditions to obtain 
purified, unfolded S. diversum SirD (Figure 3.5). Refolding was attempted by dialysis 
against decreasing concentrations of urea. It was not determined whether refolding was 
successful. Second, S. diversum SirD was coexpressed with the GroES/EL chaperone 
protein complex.136 SDS-PAGE analysis (data not shown) showed the overexpression of 
both the S. diversum SirD protein and the GroES/EL complex. However, while 
GroES/EL was found in the soluble lysate, a S. diversum SirD band was located in the 
pellet. A weak band was seen in the soluble washes; however, no corresponding bands 
were seen in the elution fractions suggesting no His6 tagged enzyme was present in the 
soluble lysate. Thus, S. diversum SirD was not solubilized.
Due to concerns about S. diversum’s folded state, along with the fact that soluble 
L. maculans SirD was in hand, S. diversum SirD was set aside. From this point on, L. 
maculans SirD is referred to as simply SirD.
Crystallization Studies
Heterologously expressed SirD was crystallized in a variety of buffer conditions 
with the help of Mark Mabanglo. SirD most commonly gave rod-shaped crystals, and on 
occasion gave large diamond-like crystals (Table 3.1). Four crystals were looped, 
mounted, and irradiated to collect preliminary data sets -  three rod-like crystals from 
PACT H3 and H4 and one large diamond crystal from JENA D3. The three PACT 
crystals did not diffract. It was initially thought the crystals were not properly aligned in 
the beam, however, after realignment, the result was unchanged. The JENA D3 crystal 
gave the diffraction pattern seen in Figure 3.6. A preliminary analysis indicated that the 
resolution was ~8  A. Other attempts at crystallization gave thin rods that did not diffract.
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kDa S 1 2 3 4 5 6 7 8 9 S
Figure 3.5. SDS-PAGE of pSdSirD expression in BL21 (DE3). Lane S, molecular 
weight standards; lane 1, cell-free lysate; lane 2, pellet; lane 3, urea lysate; lane 4, 
HisTrap column flow-through; lanes 5 and 6, HisTrap column washes; lanes 7-9, 
HisTrap column elutions.
Table 3.1. Crystallization conditions resulting in SirD crystal formation
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Well CrystalDescription Buffer PH Salt PEG
Index H3 rods (ppt.) 0.2 M Na malonate 7.0 - 20% 3350
Index H5 rods (ppt.) 0.1 M succinic acid 7.0 - 15% 3350
Index H7 rods (ppt.) 0.15 M DL-malic acid 7.0 - 20% 3350
PACT G8 irregular 0.1 M BTP 7.5 0.2 M Na sulfate 20% 3350
PACT G9 irregular (ppt.) 0.1 M BTP 7.5 0.2 M Na/K tartrate 20% 3350
PACT G10 long, thin rods 0.1 M BTP 7.5 0.2 M Na/K phosphate 20% 3350
PACT H3 rods 0.1 M BTP 8.5 0.2 M Na iodide 20% 3350
PACT H4 rods 0.1 M BTP 8.5 0.2 M K thiocyanate 20% 3350
JENA B6 irregular 0.1 M Na HEPES 7.5 0.2 M Na acetate 20% 3000
JENA D3 diamond 0.1 M Tris-HCl 8.5 0.5 M LiCl 8% 4000
JENA D9 diamond 0.1 M Na HEPES, 10% 2-propanol 7.5
0.2 M ammonium 
acetate 16% 400
JENA F7 rods (ppt.) 0.1 M Tris-HCl 8.5 0.5 M LiCl 28% 6000
JENA G2 rods (ppt.) 0.1 M Na HEPES 7.5 0.2 M Ca acetate 10% 8000
HAMPTON H10 rods 0.1 M Tris 7.0 - 20% 2000
HAMPTON H12 rods (ppt.) 0.1 M imidazole 8.0 0.2 M Ca acetate 20% 1000
Figure 3.6. Diffraction pattern obtained from the ~8 A SirD JENA D3 crystal.
Com putational S tructure Studies
The secondary structure of L. maculans SirD was predicted using software on the 
APSSP Server. Based on the computational prediction, SirD consists of 16 a-helices 
and13 P-sheets (Figure 3.7). SirD also contains a clear pattern of alternating a-helices 
and P-sheets. A comparison with the secondary structure of the published crystal 
structure FgaPT2 shows a strong parallel between the secondary structures of the two 
aromatic prenyltransferases. Each a-helix or P-sheet in the FgaPT2 structure has an 
overlapping matching region with the aligned SirD sequence and predicted structure. 
While there are some minor differences, mainly lengths of helices or sheets, the predicted 
structure of SirD correlates very well with FgaPT2’s known structure suggesting SirD is 
an aPPa prenyltransferase.
In order to visualize SirD, a homology model based on the FgaPT2 crystal 
structure was constructed (Figure 3.8). The overall structure consists of 12 major a- 
helices surrounding a 10 antiparallel P-sheet barrel. L-tyrosine and DMASPP are located 
at the center of the solvent-filled barrel. This tertiary structure correlates well with the 
predicted secondary structure. Examination of the active site revealed candidates 
important for binding and/or catalysis (Figure 3.9). Four positively charged residues 
(R106, K189, R262, K264) are located near the negatively charged diphosphate group in 
DMASPP. The oxygen atoms of the diphosphate moiety may also be involved in 
hydrogen bonding with the side chain hydroxyl groups of Y191, Y266, Y330, and Y345, 
thereby creating additional stabilization of the negative charges. Tyrosine is bound 
through ionic interactions between R349’s side chain and tyrosine’s carboxylic acid 
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LAVREPRI-LPPLNMLEEYIRSRGSKSTASPR— LVSCDLTSPAKSRIKIYLLEQMVSLE 270 
eeee^ eeeeeeeeeeeee' ee-
eeeeeeee' eeeeeeeeee'......eeeeeeee' —
SVCRMLSMGAKAPLDAASVASL---RELWALVLGLP— KDFPSDQ-ELPSVPHRTSGVLY 34 9
• • • • • • • • • • • • • •• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
AMEDLWTLGGRRR-DASTLEGLSLVRELWDLIQLSPGLKSYPAPYLPLGVIPDERLPLMA 32 9 
eeeeee' eeeeeeeeeeeeeeeee'
eeeeeeeeeeeeee' eee- eeeeeeee' 
YFEIKPTSDAIVPKVYIPVRHYASNDLSIAQGLATYFERRGQTVAAENYVDALSDIFSHR 409
• • • • • • • • • • • • • •  • • • •
NFTLHQNDPVPEPQVYFTT— FGMNDMAVADALTTFFERRGWSEMARTYETTLKSYYPHA 38 7
eeeeeeeeeeeeeee' eeeeeeeeeeeeee'
SirD SLDSGLGLHTYISCTFKKTGLSVTSYFN---------------------------------PE 439
• • • • • • • • •  • • •  • • • • • • •
DMATS DHDKLNYLHAYISFSYRDRTPYLSVYLQSFETGDWAVANLSESKVKCQDAACQPTSLPPD 4 4 7
SirD IYHPNRYR---Q 448
DMATS LSKTGVYYSGLH 4 59
Figure 3.7. A sequence alignment of L. maculans SirD and A. fumigatus FgaPT2 (4- 
DMATS) containing the predicted secondary structure of SirD and the secondary 
structure determined by FgaPT2’s crystal structure. Numbers denote the amino 
acid sequence position; colons (:) and periods (.) signify amino acid sequence 
identity and similarity, respectively; block arrows denote beta sheets; cursive e’s (e) 
denote alpha helices.
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Figure 3.8. Homology structure of SirD. (left) C artoon representation of SirD 
viewed from the side; (right) cartoon representation of SirD and its two natural 
substrates L-tyrosine and DMAPP viewed from the top. a-Helices, p-sheets, and 
flexible loops are shown in cyan, red and m agenta, respectively. Bound L-tyrosine 
and DMASPP are shown in stick representation.
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Figure 3.9. Active site of SirD. (left) Active site representation including residues 
positioned for ionic or hydrogen bond stabilization of the L-tyrosine and DMASPP 
substrates; (right) active site representation including the tyrosine “shield” 
positioned around the dimethylallyl moiety of DMAPP. Bound L-tyrosine and 
DMAPP are shown in stick representation. Active site residues are shown in line 
representation and labeled with residue name and num ber.
tyrosine’s amino moiety. This orientation positions tyrosine’s hydroxyl group in direct 
line with E91, a potential catalytic base. The distance between the hydroxyl oxygen in 
tyrosine and C1’ of DMASPP is 4.8 A, suggesting one or both of the substrates must 
undergo movement to reduce the distance between the atoms involved in the alkylation 
mechanism. Similar movements were proposed for other aromatic prenyltransferases 
including FgaPT259 and NphB.56 There is an abundance of tyrosine residues in the active 
site (Y191, Y266, Y330, Y345, Y400, Y415), many of which surround the allylic 
substrate. This tyrosine “shield” may protect the reactive carbocation intermediate from 
interacting with water or other potential reaction-blocking nucleophiles, possibly through 
n-cation stabilization. Together, these computational structure predictions strongly 
support SirD’s addition into the aPPa prenyltransferase family of enzymes.
N atural Substrates and Biochemical C haracterization
The natural substrates of SirD were determined using a coupled radio-assay. L- 
Tyrosine and the cyclic dipeptide c-SY were incubated with 14C-IPP in the presence of 
IDI-1 to convert 14C-IPP to 14C-DMAPP (Figure 3.10). Negative controls were incubated 
in the absence of IDI-1, confirming SirD’s inability to use IPP as a prenyl donor. The L- 
tyrosine reaction (lane 5) gave a new spot on the radio-TLC as compared to the L- 
tyrosine negative control (lane 4), while the c-SY reaction (lane 7) appeared unchanged 
compared to the c-SY negative control (lane 6). These data clearly indicate that the 
natural substrates of SirD are L-tyrosine and DMAPP, in agreement with previous 
biosynthetic pathway labeling experiments.64,68 An HPLC co-injection of incubation of 
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Figure 3.10. Radioautography TLC of the assay for the determination of SirD’s 
natural substrates. Lane 1 ,14C-IPP standard; lane 2 , 14C-L-tyrosine standard; lane 
3, lanes 1 and 2 co-spot; lane 4, L-tyrosine control; lane 5, L-tyrosine reaction; lane 
6, cyclo-L-serine-L-tyrosine control; lane 7, cyclo-L-serine-L-tyrosine reaction. 
Controls and reactions are run in the absence and presence of IDI-1, respectively.
product peak (data not shown), suggesting the enzymatic and synthetic prenylated 
products were identical.
To confirm O-prenylation, L-tyrosine was incubated with DMAPP and SirD and 
one product, 30, was formed. The *H NMR spectrum in D20  (Table 3.2) confirmed 
normal prenylation by the presence of proton signals for methylene protons at C l ’ (4.59 
ppm, d, J  = 7.0 Hz), the proton at C2’ (5.50 ppm, t, J  = 7.0 Hz), and methyl groups at 
1.74 and 1.78 ppm. An AB quartet for the aromatic protons at 6.96 and 7.19 ppm, each 
integrating to two protons, indicated that the aromatic ring was para-substituted. The 
downfield chemical shift (4.59 ppm) for the protons at C l ’ indicates that the 
dimethylallyl moiety is attached to oxygen. Thus, SirD catalyzes the normal O-
80















J J 2 n h 2
Position 5h, multi., J (D2O) 5h, multi., J (DMSO-d6) 5h, multi., J 5c
1 - - - 137.4
2 7.19, d, 8.5 7.15, d, 8.0 7.14, d, 7.2 129.5
3 6.96, d, 8.5 6.83, d, 8.5 7.19, d, 7.8 128.2
4 - - - 133.1
8 2.92, dd, 5.5, 14.0 3.05, dd, 4.0, 14.5 2.99, d, 11.4 32.1
2.77, dd, 7.0, 13.5 2.77, dd, 8.0, 14.5 2.58-2.68, m -
9 3.44, dd, 5.5, 7.5 shielded by H2O 3.24, m 56.7
10 - - - n.f.
1' 4.59, d, 7.0 4.48, d, 6.5 3.55, d, 7.8 30.9
2' 5.50, t, 7.0 5.41, t, 7.0 5.24, t, 7.2 119.2
3' - - - 135.5
4' 1.78, s 1.73, s 1.66, s 25.1
5' 1.74, s 1.69, s 1.58, s 17.3
prenylation of L-tyrosine. Furthermore, HRMS of the enzymatic product shows a peak at 
m/z 272.1257, corresponding to a monoprenylated sodium adduct of tyrosine.
Concomitant with our work, Kremer and coworkers reported that SirD is a 
tyrosine O-prenyltransferase.134 They established the structure of the product by 1H NMR 
spectroscopy, however, they used DMSO-d6 as the solvent instead of D2O. To verify our 
product was identical to the reported product, we re-performed NMR analysis using 
DMSO-d6 as the solvent. With the exception of the a  proton shielded by a moisture peak, 
the 1H NMR spectrum matched the literature spectrum in DMSO-d6.
We examined the dependence of the reactions catalyzed by SirD on Mg2+. TLC 
analysis showed spots for product in both the presence and absence of Mg2+ (data not 
shown). Thus, SirD does not require Mg2+. Other soluble aromatic prenyltransferases are 
independent of divalent cations.55,76,78
The thermal stability of SirD at rt, 30 and 37 °C was determined by pre­
incubation followed by an assay for activity (Figure 3.11). As expected, the enzyme was 
more stable at lower temperatures. After 20 min, SirD retains 90%, 72%, and 54% 
relative activities at rt, 30 and 37 °C, respectively. After 90 min, the respective activities 
decrease to 62%, 59%, and 22%.
Stability of O-Dimethylallyl-L-tyrosine under Acidic Conditions
The stability of O-dimethylallyl-L-tyrosine (7) was determined in unbuffered 
water, water at pH ~2, and in methanol using tyrosine as an internal standard. As a 
control, the compounds were incubated with unbuffered H 2O and the product ratios were 
determined to be 34% and 66% for tyrosine and 7, respectively. There was no change in 
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Figure 3.11. Thermal stability of SirD. After SirD incubation at room temperature 
(O ), 30 °C (O ) or 37 °C (A ) for designated lengths of time, enzymatic activities 
were determined relative to the 0 min pre-reaction incubation samples.
that no degradation of 7 had occurred. Conversely, incubation with 1.5 M trichloroacetic 
acid resulted in 61% and 39% of tyrosine and 7, respectively. This drastic change in 
product ratios indicates that 7 is not stable under acidic conditions. Therefore, acidic 
conditions should not be used, especially to quench enzyme kinetic experiments.
Kinetic Studies with L-Tyrosine and DMAPP
Michaelis-Menten kinetic parameters for SirD’s natural substrates L-tyrosine and 
DMAPP were determined. Rates (kcat) and Michaelis constants (KM) were determined 
from a nonlinear regression fit by GraFit 5.0.11. Vmax = 0.49 pmol min'1 m g'1, 
corresponding to a turnover number of 27 min'1, which compared well to the published 
value of 0.58 [j,mol min'1 mg'1.134 KM = 0.14 mM for L-tyrosine, also compared well with 
the previously reported values of 0.13 mM134 and 0.19 mM.135 Km = 0.040 mM for
DMAPP, ~ 4 times less than the reported value.134 This difference may arise due to our
exclusion of divalent cations. DMAPP was not tested in the presence of divalent cations, 
however, evidence of increased KMs for DMAPP was reported for 4-DMATS in the 
presence of divalent cations.84 Michaelis-Menten plots and kinetic parameters are 
summarized in Figure 3.12 and Table 3.3, respectively.
Promiscuity Studies
Commercially available analogues of tyrosine and tryptophan were tested as 
alternate substrates in the presence of DMAPP and SirD by the qualitative radio-TLC 
coupled assay outlined above. SirD accepted tyrosine and tryptophan analogues (Figure 
3.13). SirD prenylated tyrosine, 4-aminophenylalanine, and 3,4-dihydroxyphenylalanine; 
SirD did not prenylate the ortho and meta isomers of tyrosine. Thus, a prenyl acceptor 
para (C4) to the amino acid moiety is required for prenylation. SirD did not prenylate 
phenol, even in the presence of alanine and/or glycine, indicating the importance for the 
aromatic substrate to contain an amino acid moiety. This is undoubtedly due to the 
necessary ionic and polar interactions between the active site residues and the substrate’s 
amino acid moiety, thus binding and positioning the substrate in a catalytic manner. 
Given the sequence similarity between SirD and members of the DMATS superfamily, 
SirD prenylating tryptophan and tryptophan analogues was expected. Similar rates of 
turnover for tryptophan and 4-methyltryptophan suggested prenylation did not occur at 
C4 of the indole ring (similar to 4-DMATS and FgaPT2).
Two studies reported SirD’s capacity to accept and prenylate a variety of aromatic 
substrates including 4-aminophenylalanine, 3,4-dihydroxyphenylalanine, tryptophan and 
4-methyltryptophan.134,135 Using NMR, Li and coworkers identified normal prenylation at 
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Figure 3.12. Michaelis-Menten kinetic plots for select SirD substrates. Each graph 
plots substrate concentration vs. rate and illustrates individual data points and a 
nonlinear regression curve. A, L-tyrosine; B, DMAPP; C, 4-mercapto-L- 
phenylalanine; D, L-tryptophan; E, 4-methoxy- L-tryptophan; F, 7-methyl- L- 
tryptophan. All kinetic experiments were conducted at 30 °C.
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Table 3.3. Kinetic param eters for SirD substrates at 30 °C
Substrate Vmax (^mol min-1 mg-1) Km (mM) kcat (min-1) kcat / Km (min-1 mM-1)
l-TYR 0.49 ± 0.01 0.14 ± 0.01 27 ± 1 190
DMAPP 0.34 ± 0.02 0.04 ± 0.01 18 ± 1 450
l-TYR (repeat) 1.4 ± 0.1 0.30 ± 0.04 76 ± 6 260
4-SH-L-PHE (9) 0.030 ± 0.002 1.1 ± 0.2 1.6 ± 0.1 1.5
L-TRP 0.17 ± 0.01 0.37 ± 0.06 5.7 ± 0.1 15
4-OCH3-L-TRP (24) 0.033 ± 0.006 5.1 ± 2.0 0.77 ± 0.20 0.15





# |  -------  IPP/DMAPP




0 8 f t
1 2 3 4 5 6 7 8 9 10 11 12
Figure 3.13. Radioautography TLCs (A, normal phase; B, reverse phase) of 
substrate promiscuity assays for SirD. Lane 1, L-tyrosine negative control; lane 2, 
L-tyrosine positive control; lane 3, DL-o-tyrosine; lane 4, DL-»i-tyrosine; lane 5, O- 
methyl-L-tyrosine; lane 6, 4-amino-L-phenylalanine; lane 7, 3,4-dihydroxy-L- 
phenylalanine; lane 8, L-tryptophan; lane 9, 4-methyl-DL-tryptophan; lane 10, 
phenol + L-glycine + L-alanine; lane 11, 14C-L-tyrosine standard; lane 12, 14C-IPP 
standard. Each aromatic substrate was tested at a final concentration of 1 mM.
tryptophan.134 Thus, SirD was shown to prenylate oxygen, nitrogen, and carbon atoms on 
aromatic amino acids.
The analogues 4-mercapto-L-phenylalanine (9) and 4-vinyl-L-phenylalanine (15) 
were also tested as described above. Due to 9’s intrinsic insolubility in water, 9 was 
dissolved in DMSO or minimal NaOH prior to its addition to the assay. The appearance 
of an aromatic product spot after incubations of 1  h and 20  h confirmed the prenylation of 
4-mercapto-L-phenylalanine by SirD (Figure 3.14A). All assays containing 9 showed 
turnover, except the assay containing 20% v/v DMSO (lane 2c). To our knowledge, this 
is the first report of an aromatic prenyltransferase performing an S-prenylation. 
Conversely, no products appeared when 15 was incubated with DMAPP and SirD in the 
coupled assay or analyzed by HPLC (data not shown). The vinyl moiety is either too 
large for the active site, not properly positioned for prenylation, or the alkene is 
electronically unable to attack the dimethylallyl cation.
The following tryptophan analogues were tested as described above and found to 
be substrates of SirD: 4-amino (21), 4-hydroxy (22), 4-methoxy (24), 4-vinyl (26), 7- 
methyl (28), and dihydroisotryptophan (DIT, 29). Some substrates showed turnover at 
concentrations as low as 1 mM (26 and 28) while others only showed turnover at 
concentrations of 10 mM (21, 24, 29) (Figure 3.14). Because 7-DMATS is the closest 
relative to SirD and SirD was reported to prenylate C7 of tryptophan,134 the products of 
the 4-substituted analogues were hypothesized to be normal C7 prenylated. The 
prenylation site of the 7-methyl analogue 28 was of particular interest as the C7 position 
was blocked, preventing the assumed normal C7 prenylation. Other aromatic analogues 
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Figure 3.14. Radioautography TLCs of substrate promiscuity assays for SirD. 
Lanes 1, L-tyrosine positive control; lanes 2, 4-mercapto-L-phenylalanine in DMSO; 
lanes 3, 4-mercapto-L-phenylalanine in NaOH; lanes 4, 4-methoxy-L-tryptophan; 
lanes 5, 4-vinyl-L-trytophan; lanes 6, 4-amino-L-tryptophan; lanes 7, 7-methyl-L- 
tryptophan; lanes 8, dihydroiso-L-tryptophan; lanes 9, 4-hydroxy-L-tryptophan. 
Superscripts designate aromatic substrate concentrations: a, 2.5 mM; b, 5 mM; c, 10 
mM; no superscript, 1 mM.
tryptophan, 4-methylphenylalanine, 7-hydroxytryptophan (27), 4- and 7-hydroxyindoles 
and indene (Table 3.4, TLC data not shown). Unsurprisingly, non-aromatic amino acids 
including cysteine, serine, and threonine are not substrates for SirD.
Kinetic Studies with Tyrosine and Tryptophan Analogues
Michaelis-Menten kinetic parameters for 4-mercapto-L-phenylalanine, L- 
tryptophan, 7-methyl-L-tryptophan and 4-methoxy-L-tryptophan were determined (Figure 
3.12, Table 3.3). Rates (kcat) and Michaelis constants (KM) were determined as described 
above. Previously, we determined that KM for L-tyrosine was 0.14 mM. After the 
synthesis of 9, 24, and 28, we repeated the experiments with tyrosine and freshly 
expressed SirD. KM = 0.30 mM for L-tyrosine, while KM = 1.1 mM for thiotyrosine. kcat 
= 1.6 min-1 for thiotyrosine, substantially smaller than that of tyrosine (76 min-1). Thus, 
the catalytic efficiency (kcat/KM) for thiotyrosine was less than 1% of the normal reaction.
The increase in KM and the decrease in kcat of 9 compared with tyrosine indicate 
that replacing oxygen with sulfur decreases substrate binding and reduces the rate of the 
reaction. The pKa of thiotyrosine’s sulfhydryl provides a reasonable explanation. The 
pKa of tyrosine’s hydroxyl is ~10, causing the phenolic oxygen to be protonated in 
physiological conditions. As described above, tyrosine’s hydroxyl group was modeled to 
be in direct line with E91, a potential catalytic base. E91 is hypothesized to abstract the 
hydrogen from tyrosine’s hydroxyl, facilitating oxygen attack of the dimethylallyl cation. 
The pKa of thiotyrosine’s sulfhydryl is ~7, potentially causing the sulfur to be 
deprotonated in physiological conditions. A negatively charged sulfur atom positioned 




Table 3.4. A rom atic substrate analogues tested for turnover with SirD and 
corresponding product ratios
Compound [Compound] mM Reaction (y/n) Product Ratios (%)
L-Tyrosine* 1 y 100
DL-o-Tyrosine* 1 n -
D L -m -Tyrosine* 1 n -
O-Methyl-L-tyrosine 1 n -
4-Amino-L-phenylalanine* 1 y 100
3,4-Dihydroxy-L-phenylalanine* 1 y 100
4-Mercapto-L-phenylalanine (9) in DMSO 2.5, 5, 10 y, y, n 100
4-Mercapto-L-phenylalanine (9) in NaOH 2.5, 5, 10 y, y, y 100
4-Methyl-L-phenylalanine 1 n -
4-Vinyl-L-phenylalanine (15) 5, 10 n, n -
L-Tryptophan*a 1 y 7:93
4-Amino-L-tryptophan (21) 1, 10 n  y n.d.
4-Hydroxy-L-tryptophan (22) 2.5, 5, 10 y, y, y n.d.
4-Mercapto-L-tryptophan (23) 1 n -
4-Methoxy-L-tryptophanb (24) 2.5, 5, 10 n, n, y 8:92
4-Methyl-L-tryptophan*a (25) 1 y 79:21
4-Vinyl-L-tryptophanb (26) 1, 5, 10 y, y, y 52:48
7-Hydroxy-L-tryptophan (27) 2.5, 5, 10 n, n, n -
7-Methyl-L-tryptophan*a (28) 1,10 y, y 13:87
2-Methyl-L-tryptophan (20) 1 n -
Dihydroiso-L-tryptophan (29) 1, 10 n  y 100
2-Oxo-L-tryptophan 1 n -
4-Hydroxyindole 4 n -
7-Hydroxyindole 4 n -
Indene 10 n -
Phenol 10 n -
L-Alanine 10 n -
L-Glycine 10 n -
Phenol + L-Alanine + L-Glycine 1 (each) n -
L-Cysteine 10 n -
L-Serine 10 n -
L-Threonine 10 n -
Cyclo-L-Tyr-L-Ser* 1 n -
Aromatic substrates previously reported134,135 
aProduct ratios determined by peak integration at 225 nm 
bProduct ratios determined by peak integration at 220 nm 
n.d., not determined
KMTrp = 0.37 mM is comparable with the previously reported value,134 as well as 
the value for tyrosine. KM = 2.0 and 5.1 mM for the 7-methyl and 4-methoxy analogues, 
respectively, were substantially higher. kcat for the tryptophan analogues ranged between 
0.77 and 5.7 min-1, substantially smaller than kcat for tyrosine (76 min-1). The catalytic 
efficiency (kcat/KM) for tryptophan was 6% of the normal reaction, comparable with the 
reported relative yield of 8.1% . 134 The kcat/KM for the 7-methyl and 4-methoxy analogues 
were less than 1% of the normal reaction. The saturation limit of 4-methyltryptophan was 
not found (linear up to 10 mM, data not shown), preventing the determination of kcat and 
Km using Michaelis-Menten kinetics. The maximum solubility of 4-methyltryptophan 
for this study was 10 mM.
Product Studies 
4-M ercapto-L-phenylalanine (9)
Given that SirD can catalyze prenylations on oxygens, nitrogens, and carbons, 
prenylation at the para-sulfur atom of 9 by SirD seemed likely. To confirm our 
hypothesis, a large-scale incubation of 9 and DMAPP with SirD was completed. C18 
RP-HPLC was used to identify and purify the aromatic product 31 (10.3 min) (Figure 
3.15). Monoprenylation of 9 was confirmed using HRMS -  the sodium adduct of 
dimethylallyl thiotyrosine was found to have an m/z of 288.1041. We established the 
structure of 31 using a combination of 1H and 2D NMR spectroscopy (Table 3.2). 
Normal prenylation was confirmed by the presence of signals for the methylene protons 
at C1’ (3.55 ppm, d, J  = 7.8 Hz), the proton at C2’ (5.24 ppm, t, J  = 7.2 Hz), and the 
methyl groups at C3’ (1.66 and 1.58 ppm). An AB quartet for the aromatic protons at




Figure 3.15. HPLC chrom atogram  of 4-mercapto-L-phenylalanine and DMAPP 
incubation with SirD. Product form ation was monitored at 254 nm.
para-substituted. Thus, aromatic prenylation occurred at the sulfur atom. The HMBC 
spectrum revealed correlations between the dimethylallyl’s methylene protons and C2’ 
(119.2 ppm), C3’ (135.5 ppm), and the para carbon C4 (133.1 ppm). These data prove 
that SirD catalyzes a normal ^-prenylation of 4-mercapto-L-phenylalanine. Therefore, 
SirD catalyzes normal O-, N-, and ^-prenylations of tyrosine derivatives.
4-M ethyl-L-tryptophan (25)
SirD catalyzes prenylation on L-tryptophan and 4-methyl-DL-tryptophan. SirD 
was reported to normal prenylate the C7 position of tryptophan134 and tryptophan 
derivatives.135 The structure of 7-dimethylallyltryptophan was confirmed by 1H NMR 
spectroscopy,76,134 while the identity of 7-dimethylallyl-4-methyltryptophan was 
established by HPLC.135 Having 4-methyl-L-tryptophan (25) in hand and no 7- 
dimethylallyl-4-methyltryptophan NMR data in the literature, we decided to confirm C7 
prenylation of 25 by NMR spectroscopy.
Surprisingly, incubation with 25 and DMAPP with SirD gave two products, 34 
(18.8 min, 79%) and 35 (24.6 min, 21%) (Figure 3.16). HRMS analysis revealed that the 






Figure 3.16. HPLC chrom atogram  of 4-methyl-L-tryptophan and DMAPP 
incubation with SirD. Product form ation was monitored at 225 nm.
Since 7-dimethylallyl-4-methyltryptophan was reported to be the sole product 
from incubation of 4-methyltryptophan and DMAPP with SirD,135 we expected one of the 
products to be 7-prenylated. NMR analysis (Table 3.5) confirmed 35 was 7- prenylated 
due to the presence of aromatic proton signals at C2 (7.14 ppm, s), C5 (6.75 ppm, d, J  
=7.2 Hz), and C6 (6.86 ppm, d, J  = 7.2 Hz). Normal prenylation was confirmed by the 
presence of signals for the methylene protons at C1’ (3.47-3.51 ppm, m), the proton at C2 
(5.33 ppm, t, J  = 6.0 Hz), and the methyl groups at 1.61 and 1.63 ppm. The HMBC 
spectrum showed correlations between the methylene protons at C1’ and the C7 carbon 
of the indole ring (125.6 ppm). These data verify that SirD catalyzes a normal C- 
prenylation of 4-methyltryptophan at the C7 position of the indole ring.
In contrast to 35, the 1H NMR spectrum of 34 established that the indole ring 
contained a reverse dimethylallyl moiety with three characteristic vinyl signals at 6.01 
ppm (dd, J  = 10.8, 18.0 Hz), 5.09 ppm (d, J  = 10.8 Hz) and 5.00 ppm (d, J  = 17.4 Hz) for 
the protons at C2’ and C1’, respectively, and methyl groups at 1.61 and 1.60 ppm. The 
ROESY spectrum displayed a correlation between the methyl groups of the prenyl moiety 
and the proton at C2 (7.30 ppm). The presence of four aromatic protons at C2, C4 (6.79 
ppm), C5 (6.96 ppm), and C6 (7.38 ppm) indicated prenylation occurred at N1 of the 
indole ring. Together, these data prove 34 is reverse M-dimethylallyl-4-methyl-L- 
tryptophan.
L-Tryptophan
Given the surprising result that SirD catalyzes prenylations at two positions on the 
indole ring of 4-methyltryptophan, we decided to reinvestigate the reaction with L- 
tryptophan to verify one prenylation product or establish the presence of two prenylation
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1 13Table 3.5. H and C NM R data and structures of isolated enzymatic products from L-tryptophan and 4-methyl-L-tryptophan
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Position 5h, multi., J 5c 5h, multi., J 5c 5h, multi., J 5c 5h, multi., J 5c
1 - - exc. - - - exc. -
2 7.33, s 128.5 7.16, s 127.1 7.30, s 128.8 7.14, s 127.5
3 - n.f. - 111.3 - 110.7 - 94.6
3a - n.f. - 129.5 - 129.3 - 127.4
4 7.60, d, 7.8 n.f. 7.45, d, 7.2 118.9 - 133.7 - 131.0
5 7.05, t, 7.2 n.f. 7.01, t, 7.2 122.3 6.79, d, 7.2 123.5 6.75, d, 7.2 123.8
6 7.09, t, 7.8 n.f. 6.98, d, 6.6 123.6 6.96, t, 7.2 123.8 6.86, d, 7.2 123.8
7 7.54, d, 8.4 n.f. - 128.1 7.38, d, 8.4 115.2 - 125.6
7a - n.f. - 138.3 - 138.3 - 138.3
8 3.24, dd, 4.8, 15.0 30.3 3.29, dd, 4.8, 15.6 29.7 3.48, dd, 5.4, 15.6 32.3 3.53-3.59, m n.f.
3.06, dd, 7.8, 15.0 - 3.10, dd, 7.8, 15.0 - 3.03, dd, 9.0, 15.6 - 3.06, dd, 10.8, 16.2 -
9 3.75, t, 6.6 57.9 3.83, dd, 4.8, 7.8 57.9 3.68, dd, 5.4, 9.0 59.6 3.74-3.79, m 59.1
10 - n.f. - n.f. - 179.5 - n.f.
11 - - - - 2.58, s 22.2 2.56, s 21.7
1' 5.11, d, 10.8 n.f. 3.47, d, 7.2 31.8 5.09, d, 10.8 116.1 3.47-3.51, m 31.4
5.02, d, 17.4 - - - 5.00, d, 17.4 - - -
2 ’ 6.03, dd, 10.8, 17.4 n.f. 5.36, t, 7.8 123.8 6.01, dd, 10.8, 18.0 146.6 5.33, t, 6.0 123.9
3' - n.f. - 137.8 - 61.8 - 137.7
4' 1.62, s 29.6 1.61, s 27.4 1.61, s 29.8 1.61, s 27.3
5' 1.62, s 29.6 1.64, s 19.7 1.60, s 29.8 1.63, s 19.5
8h and SC in ppm; J  in Hz; n.f. = not found; exc. = exchanged 95
products. Incubation of tryptophan and DMAPP with SirD gave products 32 (12.7 min, 
7%) and 33 (15.3 min, 93%) (Figure 3.17). HRMS analysis confirmed both compounds 
were monoprenylated products.
NMR analysis (Table 3.5) revealed that compound 33 had a 1H NMR spectrum 
very similar to the reported data of 7-dimethylallyltryptophan.76 The HMBC spectrum 
showed a correlation between the methylene protons at C1’ (3.47 ppm, d, J  = 7.2 Hz) and 
C7 of the indole ring (128.1 ppm). Together, these data verified that 33 is normal 7- 
dimethylallyltryptophan.
Compound 32 was determined to contain a reverse dimethylallyl moiety as 
evidenced by signals of the three vinyl protons at 6.03 ppm (dd, J  = 10.8, 17.4 Hz), 5.11 
ppm (d, J  = 10.8 Hz) and 5.02 ppm (d, J  = 17.4 Hz), and the methyl groups at 1.62 ppm. 
Although the NMR sample was too dilute to collect relevant TOCSY, HMQC, or HMBC 
data, the ROESY spectrum showed a correlation between the proton at C2 (7.33 ppm, s) 
and the prenyl moiety’s methyl groups. The presence of 5 aromatic protons at C2, C4 
(7.60 ppm), C5 (7.05 ppm), C6 (7.09 ppm), and C7 (7.54 ppm) confirmed prenylation 
occurred at a position other than the available indole carbons, namely the indole nitrogen. 
Collectively, these data prove 32 is formed by reverse prenylation at the N1 position of 
tryptophan. Therefore, SirD catalyzes normal prenylation at C7 or reverse prenylation at 
N1 of tryptophan and 4-methyltryptophan.
Simultaneous prenylation was recently seen with CTrpPT, catalyzing both normal 
C7 and reverse N1 prenylations on tryptophan-containing cyclic dipeptides.77 An amino 




Figure 3.17. HPLC chromatogram of L-tryptophan and DMAPP incubation with 
SirD. Product formation was monitored at 225 nm.
oryzae DSM1147.140 This sequence similarity suggests SirD and CTrpPT share important 
aspects of both their active sites and reaction mechanisms.
One hypothesis for “simultaneous” prenylation is alkylation at one site, N1 or C7, 
followed by an aza-Claisen rearrangment to form the other product.89,141,142 To investigate 
this hypothesis, we performed a 24 h timecourse experiment by incubating L-tryptophan 
or 25 with DMAPP and SirD. At each time point, a quenched portion of assay mixture 
was analyzed by HPLC and the ratio of products was determined by integrating the area 
under each peak. Overall, we saw no evidence for an aza-Claisen rearrangement (Figure 
3.18). Significantly, the product ratios were present in expected amounts after only 1 min 
of incubation. In addition, incubation with 34 or 35 as a substrate did not yield any other 
products. SirD was unable to rearrange either product alone (Figure 3.19), or in the 
presence of DMAPP or inorganic pyrophosphate (data not shown). These experiments 
support a direct electrophilic alkylation mechanism, where the positioning of the indole 
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Figure 3.18. Timecourse of L-tryptophan (A) or 4-methyl-L-tryptophan (B) 
incubations with DMAPP and SirD. A, compounds 32 and 33 are depicted as A 
and O, respectively; B, compounds 34 and 35 are depicted as A and O, 
respectively. Product ratios were determined by peak integration at 225 nm. X- 











Figure 3.19. HPLC chromatogram of prenylated 4-methyl-L-tryptophan and 
DMAPP incubation with SirD. A, compound 34 standard; B, compound 34 
incubated with SirD; C, compound 35 standard; D, compound 35 incubated with 
SirD. All traces were monitored at 225 nm.
We suspected that Li and coworkers who previously reported single products for 
SirD incubations with L-tryptophan and 4-methyl-DL-tryptophan were unable to see the 
second product peaks due to their use of HPLC solvents containing 0.5% trifluoroacetic 
acid (TFA).134,135 HPLC analysis of incubations containing L-tryptophan or 25, DMAPP, 
and SirD, in the presence or absence of 0.5% TFA, indicated all products were lost under 
acidic conditions (data not shown). Therefore, as with kinetic studies, acidic conditions 
should not be used when analyzing and isolating prenylated aromatic amino acids. A 
recent report of the disassociation and rearrangement of a dimethylallyl moiety at 
position N 1 of tryptophan-containing cyclic dipeptides in the presence of trichloroacetic 
acid further supports this premise.143
7-Methyl-L-tryptophan (28)
Given the regiospecficity SirD displays by prenylating tryptophans at the N1 and 
C7 positions of the indole ring, we hypothesized a single prenylation product from 
enzymatic incubation with 7-methyltryptophan. The substitution of the hydrogen atom at 
C7 by a methyl group should block alkylation at that position, resulting only in reverse 
prenylation at N1. As described above, incubation of 28 and DMAPP with SirD gave 
products 38 (16.3 min, 13%) and 39 (19.6 min, 87%) (Figure 3.20). HRMS analysis 
indicated monoprenylation of the tryptophan analogue and the UV spectra suggested that 
the indole nuclei were intact.
The 1H NMR spectrum (Table 3.6) of 38 established that the indole ring contained 
a dimethylallyl moiety attached in reverse orientation as evidenced by signals for the 
three vinyl protons at 6.30 ppm (dd, J  = 10.8, 17.4 Hz), 4.94 ppm (d, J  = 10.8 Hz) and 










Figure 3.20. HPLC chromatogram of 7-methyl-L-tryptophan and DMAPP 
incubation with SirD. Product formation was monitored at 225 nm. Inset, identical 
trace with adjusted y-axis for product peak visualization.
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Position 5h, multi., J 5c 5h, multi., J 5c 5h, multi., J 5c 5h, multi., J 5c
1 exc. - exc. - - - exc. -
2 6.97, s 126.1 7.00, s 126.5 7.43, s 130.3 7.23,s n.f.
3 - n.f. - n.f. - 109.5 - n.f.
3a - 119.6 - 119.3 - 133.3 - n.f.
4 - n.f. - 154.7 7.46, d, 7.8 119.1 7.48, d, 7.8 118.4
5 6.55, d, 8.4 102.2 6.47, d, 7.8 102.6 7.00, t, 7.8 122.5 7.03, d, 7.8 n.f.
6 7.06, d, 7.8 n.f. 6.84, d, 7.8 n.f. 6.96, d, 6.6 128.5 - n.f.
7 - 127.8 - 121.5 - 125.5 - 121.6
7a - n.f. - 139.1 - 137.2 - n.f.
8 3.48, dd, 3.6, 15.0 33.5 3.42, dd, 4.2, 15.0 31.5 3.17-3.23, m 35.1 3.36, dd, 3.6, 15.0 n.f.
3.02, dd, 8.4, 15.0 - 3.02, dd, 8.4, 15.0 - 2.97-3.04, m - 3.16, dd, 7.8, 15.0 -
9 3.88, dd, 3.6, 7.8 n.f. 3.85, dd, 4.8, 8.4 59.2 3.66-3.72, m 58.2 3.84, dd, 3.6, 12.0 57.9
10 - n.f. - n.f. - n.f. - n.f.
11 3.84, s 57.8 3.80, s 57.8 2.54, s 26.6 2.42, s 14.7
1' 5.03, d, 10.8 114.4 3.35-3.37, m 31.2 4.94, d, 10.8 114.7 3.46, d, 7.2 33.8
4.98, d, 17.4 - - - 4.49, d, 17.4 - - -
2 ’ 6.00, dd, 10.8, 17.4 149.8 5.30, t, 6.6 124.0 6.30, dd, 10.8, 17.4 150.0 5.32, t, 7.2 125.8
3' - 42.0 - 137.5 - 62.5 - 135.8
4' 1.35, s 29.4 1.60, s 19.7 1.64, s 34.3 1.77, s 19.7
5' 1.35, s 29.4 1.59, s 27.5 1.64, s 34.3 1.69, s 27.5
8h and SC in ppm; J  in Hz; n.f. = not found; exc. = exchanged
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showed correlations between the dimethylallyl moiety methyl peaks and the proton at the 
C2 position of the indole ring (7.43 ppm). The presence of four aromatic protons at C2, 
C4 (7.46 ppm), C5 (7.00 ppm), and C6 (6.96 ppm) confirms prenylation occurred at the 
indole nitrogen. Together, these data confirm that SirD catalyzes the reverse prenylation 
at N1 of 7-methyltryptophan.
The 1H NMR spectrum of 39 had peaks for the protons at C1’ (3.46 ppm, d, 7.2 
Hz), C2’ (5.32 ppm, d, 7.2 Hz), and the methyl groups at C3’ (1.77 and 1.69 ppm) for 
normal prenylation. Signals for the aromatic protons at C2 (7.23, s) and two other 
coupled aromatic protons ((7.48 ppm, d, 7.8 Hz) and (7.03 ppm, d, 7.8 Hz)) indicated that 
prenylation occurred at either the 4 or 6 position on the indole ring. The HMBC spectrum 
showed a correlation between the methyl group at C7 (2.42 ppm) and C3’ of the 
dimethylallyl moiety (135.8 ppm). Although unambiguous structural determination was 
impossible from the available spectra, a comparison of the 1H NMR spectrum with 
published data for 4-dimethylallyl-7-methyltryptophan98 and 7-dimethylallyl-6- 
methyltryptophan75 suggests compound 39 is prenylated at the C6 position. 4- 
Dimethylallyl-7-methyltryptophan reports the protons at C5 (6.99 ppm) and C6 (6.89 
ppm). 7-Dimethylallyl-6-methyltryptophan reports the protons at C4 (7.41 ppm) and C5 
(6.86 ppm). The aromatic protons of compound 39 correspond well with the latter 
structure, and more importantly, do not match the chemical shifts of the possible C4- 
prenylation product. Collectively, these data prove SirD catalyzes the normal prenylation 
at the C6 position of 7-methyltryptophan.
The consistent reverse prenylation of indole’s nitrogen atom for tryptophan, 4- 
methyltryptophan, and 7-methyltrypophan suggests the binding orientation of these
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substrates in relation to the dimethylallyl substrate is similar. The C6 prenylation of 7- 
methyltryptophan, a substrate blocking one of the preferred prenylation sites, indicates 
SirD can bind DMAPP in different conformations. A similar prenylation “shift” was 
reported for IptA, a 6 -DMATS.75 Incubation of 6 -methyl-DL-tryptophan with DMAPP 
and IptA resulted in 7-dimethylallyl-6-methyl-DL-tryptophan. 6 -Chloro- and 6 -bromo- 
DL-tryptophan were not substrates.75 At this point, it is unknown whether SirD would 
accept 7-halogenated analogues.
4-Methoxy-L-tryptophan (24)
Incubation of 24 with DMAPP and SirD gave products 36 (16.1 min, 8%) and 37 
(20.8 min, 92%) (Figure 3.21). HRMS analysis indicated that the molecular ions of the 
compounds were 68 Da higher than the sodium adduct of 24, as expected for 
monoprenylation. The UV spectra for 36 and 37 suggested that the indole nuclei were 
intact.
The dimethylallyl moiety in compound 36 was attached in a reverse orientation as 
evidenced by the distinctive signals for the three vinyl protons at 6.00 ppm (dd, J  = 10.8,
17.4 Hz), 5.03 ppm (dd, J  = 10.8 Hz), and 4.98 ppm (dd, J  = 17.4 Hz), and two methyl
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Minutes
Figure 3.21. HPLC chromatogram of 4-methoxy-L-tryptophan and DMAPP 
incubation with SirD. Product formation was monitored at 225 nm.
groups at 1.35 ppm. The HMBC spectrum showed correlations between the methyl 
peaks of the prenyl moiety and C7 (127.8 ppm) in the indole ring. The ROESY spectrum 
showed correlations between the methyl peaks of the prenyl moiety and the aromatic 
proton at C6 (7.06 ppm), and between the methoxy substituent at C4 (57.8 ppm) and the 
proton at C5 (6.55 ppm). Together, these data confirm that 36 is formed by reverse 
prenylation at the C7 position of 4-methoxytryptophan.
Compound 37 contained a dimethylallyl moiety attached in a normal orientation 
as evidenced by the signals for the methylene protons at C1’ (3.35-3.37 ppm, m), the 
proton at C2’ (5.30 ppm, t, J  = 6.6 Hz), and the methyl groups at 1.60 and 1.59 ppm. 
Signals for the proton at C2 (7.00, s) and two other aromatic protons ((6.84 ppm, d, J  =
7.8 Hz) and (6.47 ppm, d, J  = 7.8 Hz)) indicated that prenylation had occurred at either 
the 5 or 7 position of the indole ring. The ROESY spectrum showed a weak correlation 
between the methylene protons of the prenyl moiety and the aromatic proton at C6 (6.84 
ppm). The HMBC spectrum showed correlations between the methylene protons of the 
prenyl moiety and C7 (121.5 ppm). Collectively, these data confirm that 37 is formed by 
a normal prenylation at the C7 position of 4-methoxytryptophan.
SirD prenylation of 4-methoxytryptophan was hypothesized to follow the 
prenylation pattern for tryptophan and 4-methyltryptophan. As expected, SirD prenylated 
compound 24 at the C7 position of the indole ring in a normal orientation. SirD also 
catalyzed a reverse prenylation at C7; SirD did not reverse prenylate N1 of 4- 
methoxytryptophan. Overall, these experiments demonstrate that SirD catalyzes normal 
or reverse prenylation of tryptophan and tryptophan analogues at three distinct sites on 
the indole ring, N1, C6 , and C7, depending on the substituent (Figure 3.22).
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Figure 3.22. Tryptophan prenylation sites and orientations catalyzed by SirD.
The indole ring in tryptophan is susceptible to electrophilic alkylation at N1, at 
C2, C5, and C7 by direct conjugation with N1 through the benzene ring, and at C3, C4, 
and C6 by conjugation with N1 through the C2-C3 double bond. The methyl and 
methoxy substituents introduced at C4 are both electron-donating relative to hydrogen. 
For tryptophan, alkylation is mostly at C7, with a small amount of N1 alkylation present. 
For the methyl substituent (o+ = 0.31),144 alkylation is mostly at N1, along with a smaller 
amount of C7 alkylation. The more powerful electron-donating methoxy group (o+ = 
0.78) directs alkylation exclusively to C7. It is hypothesized that prenylation sites and 
orientations are determined through a combination of steric and electronic factors.
Investigation into the prenylation of 4-hydroxy-L-tryptophan (22) by SirD would 
help uncover the dominating factor. Being electron-rich yet smaller than 24, the 
prenylation product(s) of compound 22  would contribute significantly to this story. 
Unfortunately, compound 22  is quite sensitive to oxygen; thus a more sophisticated 
approach must be used to prevent oxidation of it or its prenylated derivatives.
4-Vinyl-L-tryptophan (26) and Dihydroiso-L-tryptophan (29)
Incubation of 26 with DMAPP and SirD yielded products 40 (38.0 min, 52%) and 








Figure 3.23. HPLC chromatogram of 4-vinyl-L-tryptophan and DMAPP incubation 
with SirD. Product formation was monitored at 220 nm. Inset, identical trace with 
adjusted y-axis for product peak visualization.
223.8, 307.0 nm and 219.1, 302.2 nm) very similar to that of the substrate (26). Analysis 
by NMR spectroscopy and MS was not performed, however prenylation is proposed to 
occur at the N1 and C7 positions of the indole ring. Characterization of the prenylated 
products would further clarify the prenylation of tryptophan analogues by SirD.
DIT (29) provides an interesting substrate analogue as it contains an indoline ring 
with an amino acid moiety attached on the ring’s nitrogen atom. As the amino acid 
moiety is important for catalysis (Table 3.4), the connectivity of the bicyclic ring to the 
amino acid moiety may allow new sites to be positioned for prenylation. The 2,3- 
dihydropyrrole ring with a tertiary amine also prevents prenylation from occurring at the 
N1, C2 and C3 positions of the indoline ring. Compound 29 was incubated with DMAPP 
and SirD and one product (42, 11.3 min) was formed (Figure 3.24). UV analysis of 42 
indicated the indoline ring of DIT (Xmax = 205.0, 247.5, 293.8 nm) had changed to what 
appeared to be an indole ring (Xmax = 219.1, 267.7 nm). HRMS analysis revealed that the 
molecular ion of compound 42 was 68 D higher than DIT indicating the monoprenylation 
of 29. The 1H NMR spectrum (see Appendix B NMR 81) also indicated normal 
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Figure 3.24. HPLC chromatogram of DIT and DMAPP incubation with SirD. 
Product formation was monitored at 220 nm. Inset, identical trace with adjusted y- 
axis for product peak visualization.
Hz), the proton at C2’ (5.36 ppm, J  = 7.8 Hz), and the methyl groups at C3’ (1.64 and 
1.61 ppm). The presence of four aromatic peaks in a different coupling pattern than DIT 
indicates that prenylation occurred on the benzene ring. The presence of an aromatic 
singlet at 7.15 ppm suggests prenylation occurred at C5 or C6 . It is unclear, however, 
what the fourth aromatic peak corresponds to. An intact indole ring, as implied by the 
UV spectrum, may place the aromatic singlet at a different position. Although at this 
point, the prenylation site is undetermined, the ability of SirD to prenylate a tryptophan 
analogue as unique as DIT illustrates its exceptional promiscuity ability.
Overall, the O-, N-, and ^-prenylation of tyrosine and its analogues, and the N- 
and C-prenylation of tryptophan analogues by SirD, strongly supports an electrophilic 
alkylation mechanism where substrate orientation within the active site and substituent 
electronic effects determine the position and type of prenylation. The promiscuity of 
SirD provides an intriguing argument for the evolution of aromatic prenyltransferases 
from a common ancestor.
CHAPTER 4
4-DMATS: MULTISITE PRENYLATION OF
4-SUBSTITUTED TRYPTOPHANS
Introduction
Prenylated indole alkaloids constitute a large family of chemically diverse 
biologically active natural products.22-24 Biosynthetically, the carbon skeletons of these 
compounds are constructed from prenyl diphosphates and tryptophan or derivatives of 
tryptophan. Well-known examples include the ergot alkaloids, the brevianamides, 
epiamauromine, and verruculogen (Figure 1.1). Collectively a family of enzymes, the 
dimethylallyl tryptophan synthases (DMATS), catalyze alkylation of the indole ring in 
tryptophan or tryptophan-containing dipeptides at positions N1, C2, C3, C4, C5, C6, or 
C7 by dimethylallyl diphosphate (DMAPP) to give the different naturally occurring
63 70 76carbon skeletons. ’ - The dimethylallyl moiety can be attached at C1’ (“normal” 
prenylation) or C3’ (“reverse” prenylation), further increasing structural diversity. For
70 77 71 78wild type DMATSs both normal and reverse prenylation is seen at N1 ’ and C2. ’ 
Only reverse prenylation is seen at C3 in either the a- or P-configuration by the DMATSs 
AnaPT72 or CdpC3PT,73 respectively. Only normal prenylation is seen at C4,63,78 C5,74 
and C6.75 7-DMATS catalyzes normal prenylation at C7 of L-tryptophan76 and MpnD 
catalyzes reverse prenylation at C7 of an indolactam.79
4-DMATS catalyzes the normal prenylation of tryptophan at C4 by DMAPP as 
the first committed step in ergot alkaloid biosynthesis.30 The enzyme was the first indole 
prenyltransferase to be purified, characterized, and later available from expression clones 
and has been studied from Clavicepspurpurea62,63,80 and Aspergillusfumigatus.59,78,81,82
4-DMATS (FgaPT2) from A. fumigatus consists of a 10-stranded antiparallel P-barrel 
surrounded by a-helices.59 This “ABBA PT” fold is only seen for five other 
prenyltransferases - FtmPT161 and CdpNPT,60 normal C2 and reverse C3 indole
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prenyltransferases, respectively; NphB (formerly Orf2) ,56 CloQ ,57 and EpzP ,87 non­
indole aromatic prenyltransferases. BLAST alignments with 4-DMATS from C. 
purpurea and other DMATSs report the following sequence identities: 56% with FgaPT2 
from A. fumigatus, 35% with FtmPT1 from A. fumigatus, 35% with CdpC3PT from 
Neosartorya fischeri, 31% with CdpNPT from A. fumigatus, 47% with 5-DMATS from 
A. clavatus, 23% with IptA from Streptomyces sp. SN-593, and 28% with 7-DMATS 
from A. fumigatus69
The mechanism proposed for prenylation by DMATSs is a dissociative 
electrophilic alkylation of the indole ring by DMAPP where cleavage of the carbon- 
oxygen bond in DMAPP gives a dimethylallyl cation-PPi ion pair, with subsequent 
alkylation of the indole moiety, followed by loss of a proton to give the prenylated 
product.80,131 In the case of 4-DMATS, regiospecific alkylation of C4 of the indole ring 
by C1’ of the allylic cation generates an arenium intermediate, which rearomatizes by 
deprotonation at C4 to produce dimethylallyl tryptophan (DMAT). The crystal structure 
of FgaPT2 from A. fumigatus in complex with tryptophan and dimethylallyl S- 
thiolodiphosphate, a nonhydrolyzable DMAPP analogue,88 revealed two active site amino 
acids thought to be important for catalysis.59 A hydrogen bond between Glu89 and the 
indole N-H likely increases the electron density in the indole ring. Lys174 is situated near 
C4 and is a likely candidate for removing the C4 proton during rearomatization. 
Recently, a K174A mutant of FgaPT2 gave a C3 reverse-prenylated 
hexahydropyrroloindole as the major product in addition to a small amount of 4- 
DMAT .89 The authors suggested a new mechanism where the initial alkylation is a 
reverse prenylation at C3 of the indole ring, followed by a Cope rearrangement to give
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the normal C4 prenylated arenium intermediate and deprotonation facilitated by Lys174 
to produce 4-DMAT.
4-Methyltryptophan has been used as a competitive dead-end analogue of 
tryptophan in kinetic studies of 4-DMATS.83 The substitution of the hydrogen atom at the 
C4 by a methyl group should block alkylation at that position. Previously in the Poulter 
group, 4-methyl-DL-tryptophan was utilized as a competitive substrate inhibitor with 4- 
DMATS from C. purpurea8  During these inhibition studies, a consistently high 
background of activity was found. It was subsequently discovered that 4- 
methyltryptophan is an alternate substrate for 4-DMATS and produces four distinct 
products. In this chapter, we report studies with 4-methyltryptophan and other 
tryptophan analogues that provide insights about the mechanism of the reaction.
Experimental Procedures 
General
NMR experiments were recorded on an INOVA 600 NMR spectrometer equipped 
with a HCN cryogenic probe and spectra were processed with MestReNova 7.1. All 
chemical shifts and coupling constants are reported in parts per million (ppm) and hertz 
(Hz), respectively. 1H chemical shifts are referenced relative to DSS at 0.00 ppm. 13C 
chemical shifts are referenced relative to DSS at 0.00 ppm. HPLC was conducted on a 
Water 2690 Separation Module equipped with a Microsorb MVtm C18 5 ^m column and 
a Waters 996 photodiode array detector. Normal phase thin layer chromatography (TLC) 
was carried out on silica gel 60 glass-backed plates (Merck). Reverse phase TLC was 
carried out on either C8 glass-backed plates (Silicycle) or C18 glass-backed plates with a
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concentrating zone (Merck). Mass spectrometry was performed by Dr. James Muller at 
the Chemistry Department Mass Spectrometry Laboratory, University of Utah.
M aterials
All compounds were obtained from Sigma-Aldrich unless otherwise noted. The 
following compounds were purchased from the companies indicated: chloramphenicol 
(MP Biomedicals); DMAPP triammonium salt [1-14C], IPP triammonium salt [1-14C] 
(American Radiolabeled Chemicals, Inc.); and ampicillin (Roche). Deuterated solvents 
were purchased from Cambridge Isotope Laboratories, Inc. E. coli IDI-1 and pHDMAT 
were provided by Dr. Jonathan Johnston. 2-Oxo-L-tryptophan and compounds 0393-1 
and 0393-2, the two diastereomers of reverse C3-prenyl-2-oxo-L-tryptophan, were 
supplied by Dr. Raj Viswanathan.
Bacterial Strains, Plasmids and C ulture Conditions
Plasmid pHDMAT is a pET28a construct containing the C. purpurea dmaW, 
which encodes 4-DMATS. Plasmid pGroESL is a construct containing the E. coli groE 
operon136 and was obtained from Anthony Gatenby. The expression strain E. coli BL21 
Star™ (DE3) was obtained from Stratagene. Expression strains were grown in liquid LB 
broth or on solid LB-agar medium at 37 °C. Kanamycin (35 p,g/mL) and 
chloramphenicol (34 ^g/mL) were used to select vector-containing E. coli strains.
Production and Purification of 4-DMATS
A production strain for soluble 4-DMATS was constructed by cotransforming E. 
coli BL21 Star™ (DE3) with pHDMAT and pGroESL according to the manufacturer’s 
instructions. E. coli BL21 Star™ (DE3)/pHDMAT/pGroESL was incubated in 1 L of LB
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medium containing 35 ^g/mL kanamycin and 34 ^g/mL chloramphenicol at 37 °C with 
shaking at 225 rpm until an OD600 of 0.6 was reached. The culture was then cooled to 20 
°C and protein expression was induced with IPTG to a final concentration of 0.4 mM. 
After 18 h, cells were harvested by centrifugation (4,000 x g, 20 min, 4 °C). Pelleted 
cells were resuspended in lysis buffer (50 mM NaH2PO4, pH 8.0, containing 300 mM 
NaCl, 10 mM imidazole, 1 mg/mL of lysozyme and 10 p,g/mL of RNase A). After 
incubation at 0 °C for 30 min, the cell suspension was sonicated for 6 x 10 s at 4 °C. The 
lysate was clarified by centrifugation (10,000 x g, 20 min, 4 °C). 4-DMATS was purified 
by nickel affinity chromatography (GE Healthcare HisTrap HP) using a 0 -  100% 
gradient elution of lysis buffer/elution buffer (50 mM NaH2PO4, pH 8.0, containing 300 
mM NaCl and 500 mM imidazole). The purified protein was dialyzed against 2 x 4 L of 
dialysis buffer (20 mM Tris-HCl, pH 8.0, containing 1 mM PME), and then against 4 L 
of dialysis buffer containing 20% glycerol. The protein was flash frozen with liquid 
nitrogen and stored at -80 °C until use.
Promiscuity Studies
The assays for detecting the promiscuity of aromatic substrates were conducted in 
50 mM Tris-HCl, pH 8.0, containing 10 mM MgCl2, 0.1 mg/mL BSA, 10 mM KCl, 1 
mM 14C-IPP (0.44-1 mCi/mmol), 1-10 mM aromatic substrate, ~2 ^M IDI-1, and 0.65­
9.2 ^M 4-DMATS in a total volume of 50 ^L. For thioanalogue assays, 20 mM PME 
was included to reduce unwanted disulfides. Typically, each reaction mixture was 
incubated at 30 °C for 1 h and 20 h. After incubation, a 10 ^L portion of assay mixture 
was spotted and developed by TLC. For normal phase TLC, a solvent system of 1:9 
acetic acid/EtOH or 2:8 H2O/ACN was used to develop the plates. Reverse phase C18-
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TLC was performed as described in Chapter 3. The developed TLC plates were then 
imaged on a storage phosphor screen (Molecular Dynamics), scanned by a Typhoon 8600 
Variable Mode Imager (GE Healthcare), and the data were visualized and processed with 
ImageQuant 5.2.
Kinetic Studies
All kinetic assays were conducted in 50 mM Tris-HCl buffer, pH 8.0, containing 
4 mM MgCl2 and 50 ^M 14C-DMAPP (10 p,Ci/p,mol), in a total volume of 100 ^L. Each 
reaction was incubated at 30 °C and quenched by heating at 100 °C for 30 s. After 
centrifugation, 10 ^L of reaction mixture were spotted and developed by RP-C8 TLC 
using a solvent system of 4:6 25 mM NH4HCO3/methanol. TLC data 
visualization/processing was peformed as previously described. Background radioactivity 
was determined from incubations without the tryptophan substrate. Each kinetic assay 
was performed in duplicate or triplicate. For L-tryptophan, the assay contained 50 nM 4- 
DMATS and L-tryptophan concentrations of 3, 10, 20, 30 and 60 ^M, with a 5 min 
incubation. For the tryptophan analgoues, the assays contained 500 nM 4-DMATS with 
20 min incubations. For 4-methyltryptophan, final concentrations were 30, 100, 300 and 
600 ^M; for 4-methoxytryptophan, 30, 100, 300, 600, 1000 and 3000 ^M; and for 4- 
aminotryptophan, 3, 10, 20, 30, 60, and 100 ^M.
Product Studies
Incubations were in 50 mM Tris-HCl buffer, pH 8.0, containing 10 mM MgCl2,
8.8 mM DMAPP, 20 mM tryptophan analogue and 15 ^M 4-DMATS in a total volume 
of 5 mL. Glycerol present in the storage buffer was removed by repeated
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dialysis/centrifugation using an Amicon Ultra 10 kDa MWCO filter. The assay mixture 
was incubated at 30 °C for 18-42 h. 4-DMATS was removed by 10 kDa MWCO 
filtration, samples were concentrated by lyophilization, and the products were purified by 
C18 RP-HPLC at a flow rate of 1 mL/min with isocratic elution using ACN:H2O (25/75). 
Products were detected with simultaneous monitoring at 206, 225 and 254 nm. Product 
ratios were calculated by integrating the area under each product peak visualized at 214 
nm (4-methyl/4-methoxy) or 225 nm (4-amino/DIT).
Structure of 4-Substituted-dimethylallyltryptophan Products
After purification of the prenylated product(s), each product was lyophilized, 
dissolved in D2O (D, 99.9%), lyophilized again, dissolved in D2O (D, 99.96%) and 
placed in a Norell 3 mm NMR tube (Sigma). Unless otherwise noted, the following NMR 
experiments were performed: 1D 1H, COSY 1H -1H, TOCSY 1H -1H, ROESY 1H -1H, 




1H NMR (600 MHz, D2O) 5 0.85 (s, 3H), 0.93 (s, 3H), 2.29 (s, 3H), 2.34 (dd, J  =
8.4, 13.8 Hz, 1H), 2.72 (dd, J  = 7.8, 13.8 Hz, 1H), 3.49 (t, J  = 7.8 Hz, 1H), 4.94 (dd, J  =
0.6, 17.4 Hz, 1H), 4.95 (dd, J  = 0.6, 10.2 Hz, 1H), 5.06 (s, 1H), 5.85 (dd, J  = 10.8, 17.4 
Hz, 1H), 6.48 (d, J  = 7.8 Hz, 1H), 6.61 (d, J  = 7.8 Hz, 1H), 7.00 (t, J  = 7.8 Hz, 1H); 13C 
NMR (150 MHz, D2O) 5 23.1, 25.7, 26.1, 38.0, 44.7, 63.5, 68.1, 83.3, 110.8, 116.2, 
125.8, 130.9, 131.5, 138.9, 147.6, 152.7, 179.5; UV (ACN :H2O 1:3) Xmax 209.7, 242.8,
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1H NMR (600 MHz, D2O) 5 1.46 (s, 3H), 1.47 (s, 3H), 2.00 (dd, J  = 8.4, 12.6 Hz, 
1H), 2.22 (s, 3H), 2.34 (dd, J  = 8.4, 15.0 Hz, 1H), 2.51 (dd, J  = 6 .6 , 12.6 Hz, 1H), 2.55 
(dd, J  = 6 .6 , 15.0 Hz, 1H), 3.40 (m, 1H), 4.77 (t, J  = 7.2, 1H), 4.84 (s, 1H), 6.45 (d, J  =
7.8 Hz, 1H), 6.57 (d, J  = 7.8 Hz, 1H), 6.94 (t, J  = 7.8 Hz, 1H); 13C NMR (150 MHz, 
D2O) 5 19.8, 20.0, 27.4, 37.4, 44.2, 61.1, 63.4, 84.2, 110.5, 121.7, 124.5, 130.8, 133.7,
137.7, 138.6, 152.2; UV (ACN:H2O 1:3) Xmax 206.2, 239.2, 289.1, 293.8 nm; HRMS-ESI 
TOF m/z [M + H]+ calcd for C17H23N2O2 287.1760, found 287.1755.
N1-(2-Methylbut-2-en-4-yl)-4-methyl-L-tryptophan (46, Normal 
N-Dimethylallyl-4-methyl-L-tryptophan)
1H NMR (600 MHz, D2O) 5 1.60 (s, 3H), 1.70 (s, 3H), 2.58 (s, 3H), 2.98 (dd, J  = 
9.0, 15.0 Hz, 1H), 3.42 (dd, J  = 4.8, 15.0 Hz, 1H), 3.61 (dd, J  = 4.8, 9.0 Hz, 1H), 4.60 (d, 
J  = 6 .6 , 2H), 5.24 (t, J  = 6.6  Hz, 1H), 6.80 (d, J  = 7.2 Hz, 1H), 7.03 (dd, J  = 7.2, 8.4 Hz, 
1H), 7.07, (s, 1H), 7.19 (d, J  = 8.4 Hz, 1H); 13C NMR (150 MHz, D2O) 5 19.8, 22.2, 
27.2, 32.4, 46.3, 59.6, 110.7, 112.0, 121.9, 123.3, 124.4, 128.2, 130.6, 133.8, 138.9, 
140.4; UV (ACN:H2O 1:3) Xmax 225.0, 276.0, 290.3 nm; HRMS-ESI TOF m/z [M + H]+ 




1H NMR (600 MHz, D2O) 5 1.60 (s, 3H), 1.67 (s, 3H), 3.06 (dd, J  = 9.0, 15.0 Hz, 
1H), 3.35 (d, J  = 7.2 Hz, 2H), 3.41-3.44 (m, 1H), 3.79 (s, 3H), 3.87 (dd, J  = 4.8, 9.0 Hz, 
1H), 5.25 (t, J  = 7.2 Hz, 1H), 6.98 (d, J  = 8.4 Hz, 1H), 7.10 (s, 1H), 7.15 (d, J  = 8.4 Hz, 
1H); 13C NMR (150 MHz, D2O) 5 19.8, 27.5, 29.7, 65.1, 111.7, 126.2, 126.8, 127.8, 
136.3; UV (ACN:H2O 1:3) Xmax 222.7, 270.0 nm; HRMS-ESI TOF m/z [M + Na]+ calcd 
for C17H22N2O3N  325.1528, found 325.1530.
5-(2-Methylbut-2-en-4-yl)-4-amino-L-tryptophan (51, Normal
5-Dimethylallyl-4-amino-L-tryptophan)
1H N M R  (600 MHz, D2O) 5 1.61 (s, 3H), 1.66 (s, 3H), 3.17 (dd, J  = 8.4, 15.6 Hz, 
1H), 3.24 (d, J  = 7.2 Hz, 2H), 3.42-3.47 (m, 1H), 3.77-3.82 (m, 1H), 5.19 (t, J  = 7.2 Hz, 
1H), 6.87 (d, J  = 8.4 Hz, 1H), 6.89 (d, J  = 8.4 Hz, 1H), 7.02 (s, 1H); 13C NMR (150 MHz, 
D2O) 5 19.6, 27.4, 31.0, 31.9, 58.7, 107.0, 109.9, 120.0, 125.0, 127.0, 127.3, 136.8,
138.4, 139.4; UV (ACN:H2O 1:3) Xmax 225.0, 271.2, 292.7 nm; HRMS-ESI TOF m/z [M 
+ H]+ calcd for C16H22N3O2 288.1712, found 288.1715.
7-(2-Methylbut-2-en-4-yl)-4-amino-L-tryptophan (52, Normal 
7-Dimethylallyl-4-amino-L-tryptophan)
1H N M R  (600 MHz, D2O) 5 1.61 (s, 3H), 1.62 (s, 3H), 3.15 (dd, J  = 7.2, 15.0 Hz, 
1H), 3.35 (d, J  = 7.8, 2H), 3.34-3.40 (m, 1H), 3.68-3.72 (m, 1H), 5.31 (t, J  = 7.8 Hz, 1H), 
6.36 (d, J  = 7.2 Hz, 1H), 6.75 (d, J  = 7.2 Hz, 1H), 7.05 (s, 1H); 13C NMR (150 MHz, 
D2O) 5 19.4, 27.3, 31.2, 31.4, 58.9, 110.1, 111.3, 119.9, 120.3, 124.1, 124.2, 126.6,
118
137.3, 138.9, 139.9; UV (ACN:H2O 1:3) Xmax 223.8, 273.6 nm; HRMS-ESI TOF m/z [M 
+ H]+ calcd for C16H22N3O2 288.1712, found 288.1717.
Rearrangement Studies
The assay for the detection of prenyl rearrangement was conducted in 50 mM 
Tris-HCl, pH 8.0, containing 210 nM 4-DMATS and 5 mM of compound 0393-1 or 
0393-2 in a total volume of 0.5 mL. Additional assays included 2 mM DMAPP or 2 mM 
PPi. The control reaction was incubated in the presence of 2 mM DMAPP and 2 mM PPi 
and in absence of 4-DMATS. The assay mixture was incubated at 30 °C for 18 h. 4- 
DMATS was removed by 10 kDa MWCO filtration and the filtrates were analyzed by 
HPLC as described above. The detection of aromatic products was carried out at 254 nm.
Results and Discussion 
pHDMAT/pGroESL Cloning, Expression and Purification
As established by Wang and Poulter, soluble 4-DMATS from C. purpurea was 
obtained through co-expression with the chaperone protein complex GroEL/ES.84 Co­
transformation of the pHDMAT (His-tagged 4-DMATS) and pGroELS (GroE operon) 
plasmids and subsequent heterologous overexpression gave soluble 4-DMATS. 
Purification was achieved through nickel-affinity chromatography and SDS-PAGE gave 
a band at ~55 kDa (Figure 4.1), near the calculated weight of 54,021 Da.
Promiscuity Studies
Commercially available and synthetic substrate analogues o f aromatic amino 
acids were tested as alternate substrates in the presence of DMAPP and 4-DMATS by the 
qualitative radio-TLC coupled assay outlined in Chapter 3 (Figure 4.2). 4-DMATS
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Figure 4.1. SDS-PAGE of pHDMAT/pGroESL co-expression in BL21 (DE3). Lane
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Figure 4.2. Radioautography TLCs of substrate promiscuity assays for 4-DMATS. 
Lanes 1, L-tryptophan positive control; lanes 2, 4-amino-L-tryptophan; lanes 3, 
dihydroiso-L-tryptophan; lanes 4, 4-vinyl-L-tryptophan; lane 5, 4-hydroxy-L- 
trytophan; lane 6, 7-hydroxy-L-tryptophan; lane 7, 4-hydroxyindole; lane 8, 7- 
hydroxyindole; lane 9, 2-methyl-L-tryptophan; lane 10, 4-mercapto-L-tryptophan; 
lane 11, 2-oxo-L-tryptophan. Superscripts designate aromatic substrate 
concentrations: a, 5 mM; b, 10 mM; no superscript, 1 mM.
accepted tryptophan analogues, including analogues containing substituents at the 4 
position of the indole ring. The following tryptophan analogues were found to be 
substrates of 4-DMATS: 4-amino (21), 4-hydroxy (22), 4-mercapto (23), 4-methoxy (24), 
4-methyl (25), 4-vinyl (26), 7-hydroxy (27), 2-methyl (20), 2-oxotryptophan, and 
dihydroisotryptophan (DIT, 29). Some substrates showed turnover at concentrations as 
low as 1 mM (21 and 29) while others only showed turnover at concentrations of 10 mM 
(24 and 25) (Figure 4.2). The products of the analogues not substituted at position C4 of 
the indole ring were hypothesized to be normal C4 prenylated. The 4-substituted 
analogues were hypothesized to be normal prenylated at the heteroatom of compounds 
21, 22, and 23 or another available position on the indole ring for compounds 24, 25 and 
26. 4-DMATS may prenylate 4-substituted analogues at the C5 position in a normal 
orientation. This prenylation shift was shown by SirD prenylating 7-methyltryptophan at 
the C6 position (Chapter 3). Other aromatic analogues determined not to be substrates 
for 4-DMATS include L-tyrosine, 4-vinyl-L-phenylalanine (15), 4- and 7-hydroxyindoles 
and indene (Table 4.1, TLC data not shown). Similar to SirD, the inability of 4-DMATS 
to prenylate indole analogues such as 4- and 7-hydroxyindole indicates the importance 
for the aromatic substrate to contain an amino acid moiety.
Kinetic Studies
Michaelis-Menten kinetic parameters for tryptophan and its 4-substituted 
analogues were determined (Figure 4.3, Table 4.2). Rates (kcat) and Michaelis constants 
(Km) were determined from a nonlinear regression fit by GraFit 5.0.11. KM = 20 ^M for 
L-tryptophan, which compared well with the previously reported value.80 Km = 17 ^M for 
4-aminotryptophan was comparable to the normal substrate, while those for the 4-methyl-
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Table 4.1. Aromatic substrate analogues tested for turnover with 4-DMATS and the 
corresponding product ratios
Com pound [Compound] m M Reaction (y/n) P roduct Ratios (% )
L-Tryptophan 1 y 100
4-Amino-L-tryptophana (21) 1, 10 y , y 82:18
4-Hydroxy-L-tryptophan (22) 2.5, 5, 10 y, y , y 100
4-Mercapto-L-tryptophan (23) 1 y n.d.
4-Methoxy-L-tryptophanb (24) 2.5, 5, 10 n, n, y 5:7:71:17
4-Methyl-L-tryptophanb (25) 1, 10 n  y 44:5:7:44
4-Vinyl-L-tryptophan (26) 1, 5, 10 n  y , y n.d.
7-Hydroxy-L-tryptophan (27) 2.5, 5, 10 y , y , y n.d.
2-Methyl-L-tryptophan (20) 1 y n.d.
Dihydroiso-L-tryptophan (29) 1, 10 y , y 36:64
2-Oxo-L-tryptophan 1 y 100
4-Hydroxyindole 4 n -
7-Hydroxyindole 4 n -
Indene 10 n -
L-Tyrosine 1 n -
4-Vinyl-L-phenylalanine (15) 5, 10 n, n -
aProduct ratios determined by peak integration at 225 nm 




























Figure 4.3. Michaelis-Menten kinetic plots for select 4-DMATS substrates. Each 
graph plots substrate concentration vs. rate and illustrates individual data points 
and a nonlinear regression curve. A, L-tryptophan; B, 4-amino-L-tryptophan; C, 4- 
methoxy-L-tryptophan; D, 4-methyl-L-tryptophan. All kinetic experiments were 
conducted at 30 °C.
Table 4.2. Kinetic parameters for 4-DMATS substrates at 30 °C
Substrate Vmax (ftmol min 1 mg'1) Km OiM) kcat (  ^ ) kcat / KM (s'1 M"1)
l-TRP 65 ± 7 20 ± 5 60 ± 6 3.1 x 106
4-NH2-L-TRP (21) 0.45 ±0.03 17 ± 3 0.42 ±0.02 2.5 x 104
4 -OCH3-L-TRP (24) 1.4 ± 0.1 250 ± 42 1.3 ± 0.1 5.1 x 103
4 -CH3-L-TRP (25) 0.82 ±0.04 89 ± 16 0.75 ±0.04 8.5 x 103
and 4-methoxy analogues, 89 and 250 ^M, respectively, were substantially higher. kcat 
for the tryptophan analogues ranged between 0.42 and 1.3 s-1, substantially smaller than 
kcat = 60 s-1 for tryptophan. The catalytic efficiencies (kcat / KM) for the analogues were 
less than 1% of the normal reaction.
Product Studies
Previously in the Poulter group, racemic 4-methyltryptophan was used as a 
substrate with C. purpurea 4-DMATS.84 However, in a study of the A. fumigatus enzyme 
(FgaPT2) D-tryptophan was also a substrate, although at a rate of only 1.8% that of the 
L-enantiomer.78 Thus, we decided to use enantiomerically pure 4-methyl-L-tryptophan 
(25) in our study. The substrate was synthesized as described in Chapter 2. The same 
procedure was used to synthesize all tryptophan analogues used in this chapter.
4-M ethyltryptophan (25)
Incubation of 25 and DMAPP with 4-DMATS gave four products (Figure 4.4). 
The UV spectra of compounds 43 (11.4 min, 44%) and 44 (15.1 min, 5%) had peaks at
209.7, 242.8, 293.8 nm and 206.2, 239.2, 289.1, 293.8 nm, respectively, suggesting that 
the indole chromophore (Xmax ~ 278 nm) had been disrupted to give an indoline-like 
structure.145 Compounds 45 (24.6 min, 7%) and 46 (26.9 min, 44%) had peaks at 223.8, 
272.4 nm and 225.0, 276.0, 290.3 nm, respectively, suggesting that they contained intact 
indole chromophores. Chromatography of the reaction mixture from 25 on a C18 RP- 
HPLC column with an acidic solvent system (1% TFA) resulted in complete loss of 43 
while the ratios for compounds 44, 45 and 46 did not change (data not shown). HRMS 
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Figure 4.4. HPLC chromatogram of 4-methyl-L-tryptophan and DMAPP incubation 
with 4-DMATS. Product formation was monitored at 254 nm. Inset, identical trace 
with adjusted y-axis for product peak visualization.
corresponding peaks for 25 or its sodium adduct, indicating the addition of one isoprene 
unit.
The structures of the products were determined from their 1H and 13C NMR 
spectra (Table 4.3). The dimethylallyl moiety in compound 43 was attached in a reverse 
orientation as evidenced by the distinctive signals for the three vinyl protons at 5.85 ppm 
(dd, J  = 10.8, 17.4 Hz), 4.95 ppm (dd, J  = 0.6, 10.2 Hz), and 4.94 ppm (dd, J  = 0.6, 17.4 
Hz), and two methyl groups at 0.93 and 0.85 ppm. The HMBC spectrum showed 
correlations between the methyl peaks of the prenyl moiety and C3’ (44.7 ppm) of the 
isoprene unit and C3 (68.1 ppm) in the indoline moiety. Aromatic protons at C5 (6.61 
ppm), C6 (7.00 ppm), and C7 (6.48 ppm) support prenylation at C3 of the indole ring. In 
addition, the peak for the proton at C2 (5.06 ppm) is near reported values for C2 diamine 
protons in tricyclic C3-prenylated tryptophan derivatives.60,89 Collectively, these data 
confirm that 43 is formed by a reverse prenylation at the C3 position of 4- 
methyltryptophan, followed by cyclization to give a hexahydropyrroloindole (HHPI) 
structure.
1 13Table 4.3. H and C NMR data and structures of isolated enzymatic products from 4-methyl and 4-methoxy-L-tryptophan
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4' 3 2'  ^ jT ^ 2
6 T ^ H i
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Position 5h, multi., J 5c 5h, multi., J 5c 5h, multi., J 5c 5h, multi., J 5c
1 exc. - exc. - - - exc. -
2 5.06, s 83.3 4.84, s 84.2 7.07, s 130.6 7.10, s 127.8
3 - 68.1 - 61.1 - 112.0 - n.f.
3a - 138.9 - 137.7 - 128.2 - n.f.
4 - 130.9 - 133.7 - 133.8 - n.f.
5 6.61, d, 7.8 125.8 6.57, d, 7.8 124.5 6.80, d, 7.2 123.3 - n.f.
6 7.00, t, 7.8 131.5 6.94, t, 7.8 130.8 7.03, dd, 7.2, 8.4 124.4 6.98, d, 8.4 126.8
7 6.48, d, 7.8 110.8 6.45, d, 7.8 110.5 7.19, d, 8.4 110.7 7.15, d, 8.4 111.7
7a - 152.7 - 152.2 - 138.9 - n.f.
8 2.72, dd, 7.8, 13.8 38.0 2.51, dd, 6.6, 12.6 44.2 3.42, dd, 4.8, 15.0 32.4 3.41-3.44, m n.f.
2.34, dd, 8.4, 13.8 - 2.00, dd, 8.4, 12.6 - 2.98, dd, 9.0, 15.0 - 3.06, dd, 9.0, 15.0 -
9 3.49, t, 7.8 63.5 3.40, m 63.4 3.61, dd, 4.8, 9.0 59.6 3.87, dd, 4.8, 9.0 n.f.
10 - 179.5 - n.f. - n.f. - n.f.
11 2.29, s 23.1 2.22, s 20.0 2.58, s 22.2 3.79, s 65.1
1' 4.95, dd, 0.6, 10.2 116.2 2.55, dd, 6.6, 15.0 37.4 4.60, d, 6.6 46.3 3.35, d, 7.2 29.7
4.94, dd, 0.6, 17.4 - 2.34, dd, 8.4, 15.0 - - - - -
2 ’ 5.85, dd, 10.8, 17.4 147.6 4.77, t, 7.2 121.7 5.24, t, 6.6 121.9 5.25, t, 7.2 126.2
3' - 44.7 - 138.6 - 140.4 - 136.3
4' 0.93, s 26.1 1.47, s 19.8 1.70, s 19.8 1.67, s 19.8
5' 0.85, s 25.7 1.46, s 27.4 1.60, s 27.2 1.60, s 27.5
8h and SC in ppm; J  in Hz; n.f. = not found; exc. = exchanged
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Compound 44 also contains an HHPI moiety formed by normal prenylation at C3 
of 4-methyltryptophan. Normal prenylation was confirmed by the presence of proton 
signals for methylene protons at C1’ (2.34 (dd, J  = 8.4, 15.0 Hz) and 2.55 ppm (dd, J  = 
6.6, 15.0 Hz)), the proton at C2’ (4.77 ppm, app t, J ~  7.2 Hz), and the methyl groups at 
1.47 and 1.46 ppm. Cross peaks were also seen between a proton at C1’ (2.34 ppm) and 
C3 (61.1 ppm) and between the proton at C2 (4.84 ppm) and C1’ (37.4 ppm) in the 
HMBC spectrum. In addition, signals were seen for the aromatic protons at C5 (6.57 
ppm), C6 (6.94 ppm), and C7 (6.45 ppm). Thus, 4-DMATS catalyzes the normal and 
reverse prenylation at the C3 of 4-methyltryptophan. Very recently, FtmPT1 from A. 
fumigatus was seen to catalyze a normal prenylation at the C3 position of cyclic 
dipeptides.146
The 1H spectrum of 46 had peaks for the protons at C1’ (4.60 ppm, d, J  = 6.6 Hz) 
and C2’ (5.24 ppm, t, J  = 6.6 Hz) and the methyl groups at C3’ (1.70 and 1.60 ppm) for 
normal prenylation. Signals for aromatic protons at C5 (6.80 ppm), C6 (7.03 ppm), and 
C7 (7.19 ppm) indicated that prenylation had occurred in the pyrrole ring. The chemical 
shifts of C1’ (46.3 ppm) and the directly attached protons (4.60 ppm), along with cross 
peaks between the C1’ protons and C2 (130.6 ppm) in the HMBC spectrum indicate that 
normal prenylation occurred at the N1 position on the indole ring. The UV spectrum and 
the resonance at 7.07 ppm for the proton at C2 indicated that the indole ring was intact. 
This agreed with previous experimental data from our laboratory. A negative ion fast 
atom bombardment mass spectroscopy spectrum of fully exchanged compound 46 in 
deuterated glycerol and D2O verified indole ring nitrogen substitution.84 Unfortunately, 
we were unable to obtain sufficient quantities of 45 to establish its structure, although as
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mentioned earlier, the indole ring appeared to be intact. Co-injection experiments with 
45 and two products isolated and characterized in Chapter 3, normal 7-dimethylallyl-4- 
methyl-L-tryptophan (35) and reverse #-dimethylallyl-4-methyl-L-tryptophan (34), 
excluded these structures as candidates for 45 (Figure 4.5).
4-M ethoxytryptophan (24)
As described for 4-methyltryptophan, incubation of 24 with 4-DMATS gave 
products 47 (11.8 min, 5%), 48 (13.3 min, 7%), 49 (17.5 min, 71%), and 50 (21.4 min, 
17%) (Figure 4.6). HRMS analysis indicated that the molecular ions of the compounds 
were 68 Da higher than 24 and its sodium adduct as expected for monoprenylation. The 
UV spectra for 47 and 48 suggested that the indole moiety had been disrupted, while 
those for 49 and 50 indicated that the indole nucleus was intact.
The 1H NMR spectrum (Table 4.3) of 49 had peaks for the protons at C1’ (3.35 
ppm, d, J  = 7.2 Hz) and C2’ (5.25 ppm, t, J  = 7.2 Hz) and the methyl groups at C3’ (1.67 
and 1.60 ppm) for normal prenylation. Signals for the proton at C2 (7.10, s) and two other 
aromatic protons ((7.15 ppm, d, J  = 8.4 Hz) and (6.98 ppm, d, J  = 8.4 Hz)) indicated that 
prenylation had occurred at either the 5 or 7 position of the indole ring. Although we 
were unable to unambiguously determine the prenylation site from these data, we 
previously isolated and characterized normal 7-dimethylallyl-4-methoxy-L-tryptophan 
(37, Chapter 3). A comparison of UV spectra and NMR chemical shifts for both 
compounds confirm they are distinct products implying 49 is prenylated at C5. Thus, 4- 
DMATS catalyzes a normal prenylation at C5 of 4-methoxytryptophan.
Given the elution and UV profiles for compounds 47 -  50 were similar to those of 









Figure 4.5. HPLC chromatograms of prenylated 4-methyltryptophan product co­
injection. A, compound 45; B, compounds 34 and 35 standard; C, co-injection of 






Figure 4.6. HPLC chromatogram of 4-methoxy-L-tryptophan and DMAPP 
incubation with 4-DMATS. Product formation was monitored at 254 nm. Inset, 
identical trace with adjusted y-axis for product peak visualization.
and reverse prenylated at C3 and 50 is a normal prenylated indole, most likely at N1 or 
C7 (see next section).
4-Aminotryptophan (21)
As described for compounds 24 and 25, incubation of 21 with 4-DMATS gave 
products 51 (10.2 min, 82%) and 52 (14.2 min, 18%) (Figure 4.7). HRMS analysis 
indicated monoprenylation of 4-aminotryptophan. The UV spectra for 51 and 52 
suggested that the indole nucleus was intact.
NMR analysis (Table 4.4) revealed the dimethylallyl moiety in compound 51 was 
attached in a normal orientation as evidenced by the distinctive signals for the methylene 
protons at C1’ (3.24 ppm, d, J  = 7.2), the proton at C2’ (5.19 ppm, t, J  = 7.2 Hz), and the 
methyl groups at 1.66 and 1.61 ppm. Signals for the proton at C2 (7.02, s) and two other 
aromatic protons ((6.89 ppm, d, J  = 8.4 Hz) and (6.87 ppm, d, J  = 8.4 Hz)) indicated that 
prenylation had occurred at either the 5 or 7 position of the indole ring. The ROESY 
spectrum showed correlations between the methylene protons of the prenyl moiety and 
the aromatic proton at C6 (6.87 ppm). The HMBC spectrum showed correlations 
between the methylene protons of the prenyl moiety and C3a (120.0 ppm), C4 (138.4 
ppm), and C6 (127.0 ppm). Collectively, these data confirm that 51 is formed by a 
normal prenylation at the C5 position of 4-aminotryptophan.
Compound 52 also contains normal prenylation as confirmed by the presence of 
proton signals for methylene protons at C1’ (3.35, d, J  = 7.8), the proton at C2’ (5.31 
ppm, t, J  = 7.8), and the methyl groups at 1.62 and 1.61 ppm. Similar to compound 51, 
signals for the proton at C2 (7.05, s) and two other aromatic protons ((6.75 ppm, d, J  =
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Figure 4.7. HPLC chromatogram of 4-amino-L-tryptophan and DMAPP incubation 
with 4-DMATS. Product formation was monitored at 225 nm.
21 51
1 13Table 4.4. H and C NMR data and structures of isolated enzymatic products from 4-amino and 2-oxo-L-tryptophan
Structure/
Compound
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56
Position 5h, multi., J 5c 5h, multi., J 5c 5h, multi., J 5c
1 exc. - exc. - exc. -
2 7.02, s 127.3 7.05, s 126.6 - n.f.
3 - 109.9 - 111.3 exc. n.f.
3a - 120.0 - 119.9 - 120.8
4 - 138.4 - 139.9 6.71, d, 8.4 121.2
5 - n.f. 6.36, d, 7.2 110.1 7.16, d, 8.4 138.5
6 6.87, d, 8.4 127.0 6.75, d, 7.2 124.1 - 133.1
7 6.89, d, 8.4 107.0 - 120.3 7.52, s 132.5
7a - 139.4 - 138.9 - 150.9
8 3.42-3.47, m 31.0 3.34-3.40, m 31.4 3.30, dd, 6.6, 11.4 34.6
3.17, dd, 8.4, 15.6 - 3.15, dd, 7.2, 15.0 - 3.42-3.47, m -
9 3.77-3.82, m 58.7 3.68-3.72, m 58.9 3.87, dd, 4.2, 6.6 53.9
10 - n.f. - n.f. - n.f.
11 exc. - exc. - - -
1' 3.24, d, 7.2 31.9 3.35, d, 7.8 31.2 3.16, d, 7.8 35.1
2’ 5.19, t, 7.2 125.0 5.31, t, 7.8 124.2 5.26, t, 7.8 125.8
3' - 136.8 - 137.3 - 136.8
4' 1.66, s 19.6 1.62, s 19.4 1.61, s 19.5
5' 1.61, s 27.4 1.61, s 27.3 1.61, s 27.4
8h and SC in ppm; J  in Hz; n.f. = not found; exc. = exchanged 134
the 5 or 7 position of the indole ring. The COSY spectrum showed correlations between 
the methylene protons of the prenyl moiety and the aromatic proton at C6 (6.75 ppm). 
The HMBC spectrum showed correlations between the methylene protons of the prenyl 
moiety and C7 (120.3 ppm) and C7a (138.9 ppm), as well as a correlation between the 
aromatic proton at C6 and C1’ (31.2 ppm). Collectively, these data confirm that 52 is 
formed by a normal prenylation at the C7 position of 4-aminotryptophan. Interestingly, 
the amino group in 4-aminotryptophan is not alkylated. Thus, 4-DMATS catalyzes the 
normal prenylation at C5 and C7 of 4-aminotryptophan. These experiments demonstrate 
that 4-DMATS catalyzes normal or reverse prenylation of tryptophan and C4-substituted 
analogue at five distinct sites on the indole ring, N1, C3, C4, C5, and C7, depending on 
the substituent (Figure 4.8).
The indole ring in tryptophan is susceptible to electrophilic alkylation at N1, at 
C2, C5, and C7 by direct conjugation with N1 through the benzene ring, and at C3, C4, 
and C6 by conjugation with N1 through the C2-C3 double bond. When C4 is blocked, 4- 
DMATS catalyzes alkylation at all of the activated positions, except weakly activated C6, 
depending on the electron-donating properties of the blocking substituent. In addition, 
both normal and reverse prenylation is seen at C3 for 4-methyltryptophan. Alkylation of 
the indole ring at sites separated by several angstroms and by normal and reverse 
alkylation of C3 indicates that 4-DMATS can bind DMAPP in different conformations. 
The high regioselectivity for C4 alkylation with the normal substrates suggests that 
binding and catalysis of a single conformation has been optimized for synthesis of 4- 




Figure 4.8. Prenylation sites and orientations catalyzed by 4-DMATS.
The methyl, methoxy, and amino substituents introduced at C4 are all electron- 
donating relative to hydrogen. For the methyl substituent (o+ = 0.31),144 alkylation is 
mostly at C3, giving normal and reverse prenylated indolines, along with a smaller 
amount of the N1 alkylated indole. The methoxy group (o+ = 0.78) directs alkylation 
predominantly to C5 giving only trace amounts of putative indolines. The amino group 
(o+ = 1.3) directs alkylations exclusively to C5 and C7. Thus, when C4 is blocked by a 
relatively weak electron donating substituent, the dimethylallyl cation alkylates C3 to 
generate normal and reverse prenylated iminium intermediates, which cyclize to the 
corresponding indolines. The more powerful electron-donating methoxy and amino 
groups direct alkylation to the ortho (C5) and para  (C7) carbons, positions further 
activated by N1. Interestingly, the amino group in 4-aminotryptophan is not alkylated.
4-Hydroxy-L-tryptophan (22) and Dihydroiso-L-tryptophan (29)
In addition to electronic effects, the size differences between a hydrogen and 
methyl, methoxy, and amino substituents may cause steric clashing between the aromatic 
amino acid and active site residues causing reorientation of the active site molecules. The
prenylation pattern of 4-hydroxy-L-tryptophan (22) by 4-DMATS, an electron-donating 
yet smaller substrate than 24, would help confirm the dominating factor.
Incubation of 22 with DMAPP and 4-DMATS yielded product 53 (13.5 min) 
(Figure 4.9). UV analysis of 53 (Xmax = 222.7, 259.4, 287.9, 295.0 nm) indicated the 
indole ring was still intact. During overnight reactions and purification of compound 53, 
it was evident the product was oxidizing to an unknown product. Attempts to prevent 
product oxidation (reactions performed under nitrogen/argon) and thus 53 loss were 
unsuccessful; therefore analysis by NMR spectroscopy and MS was not performed. It is 
hypothesized that prenylation does not occur on the substituent oxygen, but rather a 
position on the indole ring such as C5 or C7, as is seen with 4-aminotryptophan. 
However, the lack of two distinct products raises the question as to whether 22 is 
prenylated at the C5 or C7 position of the indole ring.
As stated previously (Chapter 3), DIT (29) provides an interesting substrate 
analogue as it contains an indoline ring with an amino acid moiety attached on the ring’s 
nitrogen atom. As with SirD, because the amino acid moiety is important for catalysis 
the connectivity of the bicyclic ring to the amino acid moiety may allow new sites to be
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Figure 4.9. HPLC chrom atogram  of 4-hydroxy-L-tryptophan and DMAPP 
incubation with 4-DMATS. Product form ation was m onitored at 225 nm.
positioned for prenylation. The 2,3-dihydropyrrole ring with a tertiary amine also 
prevents prenylation from occurring at the N1, C2 and C3 positions of the indoline ring. 
The disruption of the pyrrole ring’s aromaticity also eliminates the activation of the C4 
and C6 carbons.
Incubation of 4-DMATS with compound 29 and DMAPP gave products 54 (11.1 
min, 36%) and 55 (26.4 min, 64%) (Figure 4.10). Similar to the SirD reaction with 29, 
UV analysis of 54 indicated the indoline ring of DIT had changed (Xmax = 220.1, 268.9 
nm). UV analysis of the product 55 revealed the indoline ring of DIT had not changed 
(Xmax = 205.0, 249.9, 298.6 nm), signifying prenylation occurred on the benzene ring of 
DIT and no other modifications had occurred at the five-membered 2,3-dihydropyrrole 
ring. Although the prenylation sites are undetermined, the ability of 4-DMATS to 
prenylate DIT illustrates its exceptional promiscuity.
2-Oxo-L-tryptophan
Recently, Luk and coworkers reported that the K174A mutant of A. fumigatus 4- 
DMATS catalyzes reverse prenylation of C3.89 A crystal structure of FgaPT2 and kinetic 
studies indicate that K174 is an important base, which facilitates removal of the C4 
hydrogen during the electrophilic aromatic substitution reaction.59 They suggested the 
reaction catalyzed by the wild-type enzyme proceeds in two steps, reverse alkylation at 
C3 followed by a Cope rearrangement and deprotonation to form the normal C4 
prenylation product.89 To investigate this claim, two diastereomers of reverse C3 prenyl- 
2-oxo-L-tryptophan (0393-1 and 0393-2) were incubated with wild type 4-DMATS to 




Figure 4.10. HPLC chromatogram of dihydroiso-L-tryptophan and DMAPP 
incubation with 4-DMATS. Product formation was monitored at 225 nm. Inset, 
identical trace with adjusted y-axis for product peak visualization.
2-oxo derivatives were available for use as the reverse C3 prenyl-L-tryptophan 
derivatives were unstable.147
Compounds 0393-1 and 0393-2 were individually incubated overnight in the 
presence and absence of 4-DMATS. HPLC analysis indicated no changes to the elution 
profile occurred when enzyme was introduced to the incubation (Figure 4.11). 
Furthermore, incubations with 4-DMATS and DMAPP or inorganic pyrophosphate 
yielded no changes to the chromatograms (data not shown). These results prove that 4- 
DMATS neither rearranges nor prenylates 0393-1 or 0393-2. The 2-oxo modification of 
the tryptophan side chain may prevent 4-DMATS from binding the modified substrate. 
To test 2-oxotryptophan as an alternate substrate, 2-oxo-L-tryptophan was incubated with 
DMAPP and 4-DMATS. One product (56, 10.5 min) was formed (Figure 4.12) and UV 
analysis revealed a spectrum (Xmax = 229.8, 255.8, 373.8 nm) similar to that of the 
substrate (Xmax = 223.8, 254.6, 362.2 nm).
Analysis by MS was inconclusive, however prenylation was unmistakable when 










Figure 4.11. HPLC chromatograms of prenylated 2-oxo-L-tryptophan incubations 
with 4-DMATS. A, compound 0393-1 control; B, compound 0393-1 incubated with 
4-DMATS; C, compound 0393-2 control; D, compound 0393-2 incubated with 4- 
DMATS. All traces were monitored at 225 nm.
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Figure 4.12. HPLC chromatogram of 2-oxo-L-tryptophan and DMAPP incubation 
with 4-DMATS. Product formation was monitored at 225 nm.
attached in a normal orientation as evidenced by the distinctive signals for the methylene 
protons at C1’ (3.16 ppm, d, J  = 7.8), the proton at C2’ (5.26 ppm, t, J  = 7.8 Hz), and two 
methyl groups at 1.61 ppm. Signals for three aromatic protons, one a downfield singlet 
(7.52, s) and two coupled doublets ((7.16 ppm, d, J  = 7.8 Hz) and (6.71 ppm, d, J  = 7.8 
Hz)) indicated that prenylation had occurred at either the 5 or 6 position of the indole 
ring. Therefore, an aromatic singlet must be placed at C4 or C7. Since the proton at C7 is 
in close proximity to the ring nitrogen, its deshielded nature should push the chemical 
shift downfield. This suggests prenylation occurred at the C6 position. Analysis of 
compound 56 by 2D NMR spectroscopy was ambiguous when determining prenylation 
site. Together, 4-DMATS’ ability to accept 2-oxotryptophan and catalyze prenylation at 
a position other than C4 with its inability to rearrange the reverse C3 prenyl-2-oxo-L- 
tryptophan derivatives supports a direct electrophilic aromatic substitution mechanism. 
The lack of rearrangement from C3 to C4, and in view of the multiplicity of products we 
observe when C4 is blocked, including normal and reverse alkylation at C3, a Cope 
rearrangement to move the dimethylallyl moiety from C3 to C4 seems to be an
unnecessary embellishment. Most likely, alkylation at C3 by the K174A mutant is a 
result of a decrease in the rate of alkylation at C4, which allows electrophilic attack at C3 
to compete.
Overall, our results provide strong evidence for a dissociative electrophilic 
alkylation of the indole nucleus by C1’, and in one instance C3’, of the dimethylallyl 
cation generated by heterolysis of DMAPP. 4-Dimethylallyltryptophan is the only 
product of the normal reaction catalyzed by 4-DMATS. When alkylation at C4 is 
blocked, the enzyme no longer catalyzes a regioselective reaction, but instead produces a 
variety of products characteristic of alkylation of the nucleophilic positions (N1, C3, C5, 
and C7) on the indole ring and electrophilic attack by the dimethylallyl cation. In 
addition, we saw only a three-fold variation in kcat for the methyl, methoxy, and amino 
tryptophans, which is most readily explained by formation of the dimethylallyl cation as 
the rate-limiting step, followed by alkylation of the indole nucleus. These results are 
consistent with previous studies with 7-methyl and 7-methoxy derivatives of tryptophan. 
In this case, tryptophan and the 7-substituted analogues are alkylated at C4 with only a 
two-fold variation in kcat.80
Conclusion
The work presented in this dissertation describes the synthesis of aromatic amino 
acid analogues, the biochemical characterization of a new aromatic amino acid 
prenyltransferase SirD, and the promiscuous nature and multisite prenylation capabilities 
of SirD and 4-DMATS.
Two tyrosine/phenylalanine and ten tryptophan derivatives were synthesized 
using a combination of synthetic and biosynthetic methods. Notably, tryptophan
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synthase was utilized to synthesize enantiomerically pure L-tryptophan analogues from a 
variety of substituted indoles. The dimethylallyltyrosine synthase SirD was cloned, 
heterologously expressed, and biochemically characterized with its natural substrates L- 
tyrosine and DMAPP. Using a secondary structure predictor and homology modeler, 
SirD was presented as the newest member of the aPPa aromatic prenyltransferase family. 
SirD and the dimethylallyltryptophan synthase 4-DMATS were tested for substrate 
promiscuity. SirD was found to catalyze O-, N-, and ^-prenylations of tyrosine 
derivatives. SirD was also determined to catalyze normal prenylations at the C6 and C7 
positions and reverse prenylations at the N1 and C7 positions of the indole ring of 
tryptophan derivatives. 4-DMATS was found to prenylate 4-substituted tryptophans at 
four different positions on the indole ring with normal or reverse prenylation at one of the 
sites. Normal prenylation occurred at positions N1, C3, C5 and C7 while reverse 
prenylation occurred at C3. With natural prenylation occurring at C4, 4-DMATS was 
shown to prenylate five of the seven sites for alkylation of the indole nucleus by the 
DMATS superfamily, providing logical rationale for the evolution of members of the 
superfamily from a common ancestor.
In conclusion, the ability of the aromatic amino acid prenyltransferases SirD and 
4-DMATS to catalyze both normal and reverse prenylations on six of the seven available 
positions of the indole ring (C2 the exception) supports a dissociative electrophilic 
alkylation mechanism where orientation of the substrates within the active site and 
substituent electronic effects determine the position and type of prenylation. Although 
many substrates, reactions, and products were studied, much is left unfinished. Several 
analogues were shown to be substrates yet their products were not determined.
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Establishing these prenylation products will undoubtedly increase our understanding of 
prenyltransferase promiscuity. Understandably, crystal structures with complexed 
substituted tryptophans and/or substrate docking studies would also be valuable additions 






Table S.1. HRMS data of synthesized compounds
Compound Chemical Formula Calculated Found Deviation (ppm)
9 Ci8H2lN2O4S2 393.0943 (M + H)+ 393.0945 0.5
12 C26H22NO7NaSF3 572.0967 (M + Na)+ 572.0970 0.5
14 C27H25NO4Na 450.1681 (M + Na)+ 450.1688 1.6
15 C11H13NO2Na 214.0838 (M + Na)+ 214.0838 -2.8
17 C12H16N2S 206.1003 (M + H)+ 206.1007 1.9
20 C12HMN2O2Na 241.0953 (M + Na)+ 241.0964 4.6
21 C11H14N3O2 220.1086 (M + H)+ 220.1078 -3.6
22 C11H13N2O3 221.0926 (M + H)+ 221.0934 3.6
23 C11H12N2O2NaS 259.0517 (M + Na)+ 259.0524 2.7
24 C12H14N2O3Na 257.0902 (M + Na)+ 257.0903 0.4
25 C12H15N2O2 219.1134 (M + H)+ 219.1136 0.9
26 C13H15N2O2 231.1134 (M + H)+ 231.1135 0.4
27 C11H13N2O3 221.0926 (M + H)+ 221.0922 -1.8
28 C12H14N2O2Na 241.0953 (M + Na)+ 241.0955 0.8
29 C11H15N2O2 207.1134 (M + H)+ 207.1148 6.8
30 C14H19NO3Na 272.1263 (M + Na)+ 272.1257 -2.2
31 C14H19NO2NaS 288.1034 (M + Na)+ 288.1041 2.4
32 C16H2oN2O2Na 295.1422 (M + Na)+ 295.1428 2.0
33 C16H21N2O2 273.1603 (M + H)+ 273.1609 2.2
34 C17H23N2O2 287.1760 (M + H)+ 287.1762 0.7
35 C17H23N2O2 287.1760 (M + H)+ 287.1763 1.0
36 C17H22N2O3Na 325.1528 (M + Na)+ 325.1532 1.2
37 C17H22N2O3Na 325.1528 (M + Na)+ 325.1532 1.2
38 C17H22N2O2Na 309.1579 (M + Na)+ 309.1579 0.0
39 C17H22N2O2Na 309.1579 (M + Na)+ 309.1576 -1.0
42 C16H22N2O2Na 297.1579 (M + Na)+ 297.1586 2.4
43 C17H22N2O2Na 309.1579 (M + Na)+ 309.1581 0.6
44 C17H22N2O2 287.1760 (M + H)+ 287.1755 -1.7
45 C17H22N2O2Na 309.1579 (M + Na)+ 309.1594 4.9
46 C17H22N2O2 287.1760 (M + H)+ 287.1760 0.0
47 CnH22N2O3Na 325.1528 (M + Na)+ 325.1539 3.4
48 C17H22N2O3Na 325.1528 (M + Na)+ 325.1524 -1.2
49 C17H22N2O3Na 325.1528 (M + Na)+ 325.1530 0.6
50 C17H22N2O3Na 325.1528 (M + Na)+ 325.1534 1.8
51 C16H22N3O2 288.1712 (M + H)+ 288.1715 1.0
52 C16H22N3O2 288.1712 (M + H)+ 288.1717 1.7
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NMR 1. 300 MHz NMR spectrum of compound 8  in CDCI3.
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NMR 2. 75 MHz 13C NMR spectrum of compound 8 in CDCI3.
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NMR 3. 500 MHz *H NMR spectrum of compound 9 in DMSO-d6.
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NMR 4. 125 MHz 13C NMR spectrum of compound 9 in DMSO-d6.
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NMR 5. 300 MHz JH NMR spectrum of compound 12 in CDCI3.
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NMR 6 . 75 MHz 13C NMR spectrum of compound 12 in CDCI3.
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NMR 7. 282 MHz 19F NMR spectrum of compound 12 in DMSO-d6.
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NMR 8 . 500 MHz JH NMR spectrum of compound 13 in CDCI3.
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NMR 9. 500 MHz JH NMR spectrum of compound 14 in CDCI3.
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NMR 10. 125 MHz 13C NMR spectrum of compound 14 in CDCI3.
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NMR 11. 300 MHz JH NMR spectrum of compound 15 in D2O with DSS.
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NMR 12. 75 MHz 13C NMR spectrum of compound 15 in D2O.
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NMR 13. 500 MHz JH NMR spectrum of compound 16 in CDCI3.
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NMR 15. 500 MHz JH NMR spectrum of compound 17 in CDCI3.
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NMR 20. 125 MHz 13C NMR spectrum of compound 19 in CDCI3.
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NMR 22. 125 MHz 13C NMR spectrum of compound 26 in D2O.
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NMR 23. 300 MHz *H NMR spectrum of compound 27 in D2O.
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NMR 24. 500 MHz *H NMR spectrum of compound 29 in D2O.
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NMR 25. 125 MHz 13C NMR spectrum of compound 29 in D2O.
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NMR 30. 1H-1H TOCSY NMR spectrum of compound 31 in DMSO-d6.
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NMR 32. 1H-13C HSQC NMR spectrum of compound 31 in DMSO-d6.
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NMR 38. 1H-13C HMQC NMR spectrum of compound 32 in D2O.
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NMR 39. 1H-13C HMBC NMR spectrum of compound 32 in D2O.
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NMR 40. 600 MHz *H NMR spectrum of compound 33 in D2O.
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NMR 44. 1H-13C HMQC NMR spectrum of compound 33 in D2O.
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NMR 45. 1H-13C HMBC NMR spectrum of compound 33 in D2O.
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NMR 46. 600 MHz *H NMR spectrum of compound 34 in D2O.
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NMR 51. 1H-13C HMBC NMR spectrum of compound 34 in D2O.
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NMR 58. 600 MHz *H NMR spectrum of compound 36 in D2O.
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NMR 65. 1H-1H COSY NMR spectrum of compound 37 in D2O.
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NMR 6 6 . 1H-1H TOCSY NMR spectrum of compound 37 in D2O.
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H-13C HMQC NMR spectrum of compound 37 in D2O.
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!QSY NMR spectrum of compound 38 in D2O.
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NMR 74. 1H-13C HMBC NMR spectrum of compound 38 in D2O.
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NMR 81. 600 MHz *H NMR spectrum of compound 42 in D2O.
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NMR 82. 600 MHz *H NMR spectrum of compound 43 in D2O.
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NMR 8 6 . 1H-13C HSQC NMR spectrum of compound 43 in D2O.
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NMR 90. 1H-1H TOCSY NMR spectrum of compound 44 in D2O.
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NMR 93. 1H-13C HMBC NMR spectrum of compound 44 in D2O.
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NMR 94. 600 MHz *H NMR spectrum of compound 46 in D2O.
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H- C HMBC NMR spectrum of compound 46 in D2O.
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NMR 100. 600 MHz JH NMR spectrum of compound 49 in D2O.
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NMR 106. 600 MHz *H NMR spectrum of compound 51 in D2O.
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NMR 108. 1H-1H TOCSY NMR spectrum of compound 51 in D2O.
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NMR 112. 600 MHz H NMR spectrum of compound 52 in D2O.
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1H-13C HMBC NMR spectrum of compound 52 in D2O.
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NMR 119. 1H-1H COSY NMR spectrum of compound 56 in D2O.
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